WO2011009084A2 - Benzimidazole analogues for the treatment or prevention of flavivirus infections - Google Patents

Benzimidazole analogues for the treatment or prevention of flavivirus infections Download PDF

Info

Publication number
WO2011009084A2
WO2011009084A2 PCT/US2010/042340 US2010042340W WO2011009084A2 WO 2011009084 A2 WO2011009084 A2 WO 2011009084A2 US 2010042340 W US2010042340 W US 2010042340W WO 2011009084 A2 WO2011009084 A2 WO 2011009084A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
substituted
unsubstituted
independently
membered
Prior art date
Application number
PCT/US2010/042340
Other languages
French (fr)
Other versions
WO2011009084A3 (en
Inventor
James A. Henderson
John Maxwell
Louis Vaillancourt
Mark Morris
Jr. Ronald Grey
Simon Giroux
Laval Chan Chun Kong
Sanjoy Kumar Das
Bingcan Liu
Carl Poisson
Caroline Cadilhac
Monica Bubenik
T. Jagadeeswar Reddy
Guy Falardeau
Constantin Yannopoulos
Jian Wang
Oswy Z. Pereira
Youssef L. Bennani
Albert C. Pierce
Govinda Rao Bhisetti
Kevin M. Cottrell
Valerie Marone
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to CA2767887A priority Critical patent/CA2767887A1/en
Priority to JP2012520823A priority patent/JP2012533569A/en
Priority to CN2010800415480A priority patent/CN102656160A/en
Priority to EP10734877A priority patent/EP2454254A2/en
Priority to MX2012000695A priority patent/MX2012000695A/en
Priority to AU2010274001A priority patent/AU2010274001A1/en
Priority to IN999DEN2012 priority patent/IN2012DN00999A/en
Publication of WO2011009084A2 publication Critical patent/WO2011009084A2/en
Publication of WO2011009084A3 publication Critical patent/WO2011009084A3/en
Priority to IL217503A priority patent/IL217503A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel compounds and a method for the treatment or prevention of Flavivirus infections using novel compounds.
  • Hepatitis is a disease occurring throughout the world. It is generally of viral nature, although there are other causes known. Viral hepatitis is by far the most common form of hepatitis. Nearly 750,000 Americans are affected by hepatitis each year, and out of those, more than 150,000 are infected with the hepatitis C virus ("HCV").
  • HCV hepatitis C virus
  • HCV is a positive-stranded RNA virus belonging to the Flaviviridae family and has close relationship to the pestiviruses that include hog cholera virus and bovine viral diarrhea virus (BVDV). HCV is believed to replicate through the production of a complementary negative- strand RNA template. Due to the lack of efficient culture replication system for the virus, HCV particles were isolated from pooled human plasma and shown, by electron microscopy, to have a diameter of about 50-60 nm.
  • the HCV genome is a single-stranded, positive-sense RNA of about 9,600 bp coding for a polyprotein of 3009-3030 amino-acids, which is cleaved co and post- translationally into mature viral proteins (core, E1 , E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). It is believed that the structural glycoproteins, E1 and E2, are embedded into a viral lipid envelope and form stable heterodimers. It is also believed that the structural core protein interacts with the viral RNA genome to form the nucleocapsid.
  • the nonstructural proteins designated NS2 to NS5 include proteins with enzymatic functions involved in virus replication and protein processing including a polymerase, protease and helicase.
  • the main source of contamination with HCV is blood.
  • the magnitude of the HCV infection as a health problem is illustrated by the prevalence among high-risk groups. For example, 60% to 90% of hemophiliacs and more than 80% of intravenous drug abusers in western countries are chronically infected with HCV. For intravenous drug abusers, the prevalence varies from about 28% to 70% depending on the population studied.
  • the proportion of new HCV infections associated with post-transfusion has been markedly reduced lately due to advances in diagnostic tools used to screen blood donors.
  • Combination of pegylated interferon plus ribavirin is the treatment of choice for chronic HCV infection. This treatment does not provide sustained viral response
  • the present invention is directed to compounds desribed herein, e.g., compounds represented by formulas (I), (II), (III), (IV), (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) described herein.
  • the present invention is directed to a method treating or preventing a Hepatitis C viral infection in a human comprising administering to the human a therapeutically effective amount of a compound described herein.
  • the present invention is directed to a
  • composition comprising at least one compound described herein and at least one pharmaceutically acceptable carrier or excipients.
  • the present invention is also directed to the use of a compound described herein for treating or preventing a Hepatitis C viral infection in a human.
  • the present invention provides a compound of formula (I):
  • A is C 2-4 alkenyl, C 2-5 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, or 4-12 membered heterocycle, 5-12 membered heteroaryl;
  • B and B' are each independently a 4-7 membered heterocycle
  • R 1 and R 1 ' are each independently H, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl;
  • R 2 and R 2 ' are each independently H, halogen, C 1-6 alkyl, or C 1-6 aIkOXy;
  • X and Y are each independently
  • R 3 and R 3 ' are each independently H, C 1-12 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted or substitute
  • R 4 is H, C 1-6 alkyl, or halogenated C 1-6 alkyl, or can be merged with R 3 or R 3 ' to form a 3-12 membered heterocycle;
  • R 5 and R 5 ' are each independently H, halogen, C 1-4 alkyl, hydroxyl, C 1-4 alkoxy, or C 1-4 halogenated alkyl;
  • Flaviviridae viral infection in a patient comprising administering to the patient a therapeutically effective amount of a compound, composition or combination of the invention.
  • a pharmaceutical composition comprising at least one compound of the invention and at least one pharmaceutically acceptable carrier or excipient.
  • a combination comprising a compound of the invention and one or more additional agents chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agent, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • compounds of the present invention comprise those wherein the following embodiments are present, either independently or in combination.
  • the compounds of the present invention are represented by formula or pharmaceutically acceptable salts thereof; In accordance with a further embodiment the compounds of the present invention are represented by formula (IV):
  • R 7 and R 7 ' are each independently C 1- ⁇ alkyl, C 2-8 alkenyl, C 2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl; and
  • A is phenyl, thiophene, pyridine, pyrimidine, or triazole.
  • A is phenyl, or thiophene. According to a further embodiment, A is phenyl.
  • B and B' in formulas (I) are each independently a pyrrolidine or a piperidine.
  • B in formulas (I) is a pyrrolidine.
  • B in formulas (I) is a piperidine.
  • B' in formulas (I) is a pyrrolidine.
  • B' in formulas (I) is a piperidine.
  • X is According to a further embodiment, X is
  • X is a bond
  • Y is
  • Y is
  • Y is
  • Y is
  • Y is a bond.
  • m and/or n are each independently 0, 1 , 2, or 3.
  • m and/or n are each independently 0,
  • n and/or n are each independently 0, or 1.
  • n and/or n are each independently 2. According to a further embodiment, m and/or n are each independently 1. According to a further embodiment, m and/or n are each independently 0.
  • p is 0, 1 , 2, or 3. According to a further embodiment, p is 0, 1 , or 2.
  • p is 0 or 1. According to a further embodiment, p is 0. According to a further embodiment, p is 1.
  • p is 2.
  • R 1 and R 1 ' are each independently H.
  • q and r are each independently 0, 1 , or 2.
  • q and r are each independently 0, or 1 . According to a further embodiment, q and r are each independently 1. According to a further embodiment, q and r are each independently 0.
  • R 2 and R 2 ' are each independently H or Halogen.
  • R 2 and R 2 ' are each independently H or fluoro.
  • R 2 and R 2 are each independently fluoro. According to a further embodiment, R 2 and R 2 ', are each independently H.
  • R 5 and R 5 ' are each independently H, Halogen, methyl, ethyl, t-butoxy-, or hydroxyl. According to a further embodiment, R 5 and R 5 ' are each independently H or Halogen.
  • R 5 and R 5 ' are each independently H or fluoro.
  • R 5 and R 5 ' are fluoro.
  • R 5 and R 5 ' are fluoro and m, and n, are 2.
  • R 5 and R 5 ' are each independently H.
  • R 6 is halogen, C 1-3 alkyl, hydroxyl, cyano, benzyloxy, or C 1-3 alkoxy. According to a further embodiment, R 6 is chloro, fluoro, methyl, hydroxyl, benzyloxy, cyano, or methoxy.
  • R 6 is fluoro, methyl, or methoxy, and p is 2.
  • R 6 is H.
  • R 3 and R 3 ' are each independently, C 1-8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , C 7-8 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-8 membered heterocycle-alkyl which is unsubstitute
  • R 3 and R 3 ' are each independently, C 1- 6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , C 7-8 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 6-8 membered heterocycle-alkyl which is unsubstitute
  • R 3 and R 3 ' are each independently, C 1 .
  • R 10 6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12 .
  • R 3 and R 3 ' are each independently phenyl which is unsubstituted or substituted one or more times by R 11 .
  • R 3 and R 3 ' are each independently benzyl which is unsubstituted or substituted one or more times by R 11 .
  • R 3 and R 3 ' are each independently benzyl.
  • R 3 and R 3 ' are each independently, C 1 . n alkyl which is unsubstituted or substituted one or more times by R 10 .
  • R 3 and R 3 ' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2- methylbutyl, 3-methylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH 2 )-, which in each case is unsubstituted or substituted one or more times by R 10 .
  • R 3 and R 3 ' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2- methylbutyl, 3-methylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH 2 )-.
  • R 3 and R 3 ' are each independently tert-butyl.
  • R 3 and R 3 ' are each independently H.
  • R 3 and R 3 ' are each independently 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 .
  • R 3 and R 3 ' are each independently tetrahydyrofuranyl.
  • R 3 and R 3 ' are each independently 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12 .
  • R a ,R b , and R d are each independently H, C 1-6 alkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • R a is C 1 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and R b , and R d are each independently H or methyl.
  • R a -R b are each independently H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • R a -R b are each independently H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • R a -R b are each independently H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • R a -R b are each independently H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • R 10 is halogen
  • R a C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein R a ,R b , and R d are each independently H, C 1 . 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • R 11 is halogen, -0R a , -NR a R b , hydroxyl, cyano, C 1-6 alkyl, wherein R a -R b are each independently H, C 1-3 alkyl.
  • R 11 is halogen, hydroxyl, cyano, or - NH 2 .
  • R 11 is halogen.
  • R a and R c are each independtly H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and R b , and R d .are each independently H or methyl.
  • R 3 C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein R 3 , R b , and R d are each independently H, C 1- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • C 1-6 alkyl C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • R 12 is halogen, -OR 3 , oxo, -NR 3 R b , -
  • R 12 is halogen, -0R a , oxo, -NR a R b , hydroxyl, cyano, C 1-6 alkyl, wherein R a -R b are each independently H, C 1-3 alkyl. According to a further embodiment, R 12 is halogen.
  • R 7 and R 7 ' in formula (IV), are each independently phenyl.
  • R 7 and R 7 ' in formula (IV), are each independently benzyl.
  • R 7 and R 7 ' in formula (IV) are each independently, C 1-6 alkyl. According to a further embodiment, R 7 and R 7 ' in formula (IV), are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. According to a further embodiment, R 7 and R 7 ' in formula (IV), are each independently methyl.
  • R 7 and R 7 ' in formula (IV), are each independently ethyl.
  • R 7 and R 7 ' in formula (IV), are each independently propyl.
  • R 7 and R 7 ' in formula (IV) are each independently isopropyl. According to a further embodiment, R 7 and R 7 ' in formula (IV), are each independently butyl. According to a further embodiment, R 7 and R 7 ' in formula (IV), are each independently tert-butyl.
  • R 7 and R 7 ' in formula (IV), are each independently cyclopropyl.
  • R 7 and R 7 ' in formula (IV), are each independently cyclobutyl.
  • R 7 and R 7 ' in formula (IV), are each independently cyclopentyl.
  • R 7 and R 7 ' in formula (IV), are each independently cyclohexyl.
  • the compounds of the present invention are selected from the compounds of the invention, wherein:
  • R 1 and R 1 ' are H
  • R 2 and R 2 ' are each independently H, or halogen; q and r are each independently 0, or 1.
  • X and Y are each independently — , or a bond
  • R 3 and R 3 ' are each independently H, C 1-12 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted or substitute
  • R 5 and R 5 ' are each independently H, or halogen;
  • n are each independently 0, 1 , or 2; p is O, 1 , or 2;
  • R 1 and R 1 ' are H
  • R 2 and R 2 ' are each independently H, or halogen; q and r are each independently 0, or 1.
  • X and Y are each independently — , or a bond
  • R 3 and R 3 ' are each independently H, C 1-12 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted or substitute
  • R 5 and R 5 ' are each independently H, or halogen;
  • the compounds of the present invention are selected from the compounds of the invention wherein: R 1 and R 1 ' are H;
  • R 2 and R 2 ' are each independently H, or halogen; q and r are each independently 0, or 1 ;
  • X and Y are each independently , or a bond
  • R 3 and R 3 ' are each independently H, C 1-12 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6 - ⁇ aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 ,
  • R 4 is H, C 1-6 alkyl, or halogenated C 1-6 alkyl, or can be merged with R 3 or R 3 ' to form a 3-12 membered heterocycle;
  • R 5 and R 5 ' are each independently H, or halogen
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • the compounds of the present invention are selected from the compounds of the invention, wherein: R 1 and R 1 ' are H;
  • R 2 and R 2 ' are each independently H, or halogen; q and r are each independently 0, or 1 ;
  • X and Y are each independently or a bond
  • R 3 and R 3 ' are each independently, C 1-8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , C 7-8 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or
  • R 5 and R 5 ' are each independently H, or halogen;
  • the compounds of the present invention are selected from the compounds of the invention, wherein:
  • R 1 and R 1 ' are H
  • R 2 and R 2 ' are each independently H, or halogen; q and r are each independently 0, or 1 ;
  • R 3 and R 3 ' are each independently H, C 1-12 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted or substitute
  • R 4 is H, C 1-6 alkyl, or halogenated C 1-6 alkyl, or can be merged with R 3 or R 3 ' to form a 3-12 membered heterocycle;
  • R 5 and R 5 ' are each independently H, or halogen;
  • NR b SO 2 NR a R b C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, or C 1 .*, halogenated alkyl, wherein R a -R d are each independently H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, or C 7-16 aralkyl; m, and n, are each independently 0, 1 , or 2; p is O, 1 , or 2;
  • the compounds of the present invention are selected from the compounds of formula (IV), wherein:
  • R 1 and R 1 ' are H
  • R 2 and R 2 ' are each independently H or Halogen
  • q and r are each independently 0, or 1.
  • R 5 and R 5 ' are each independently H or Halogen
  • R 6 is halogen, C 1-3 alkyl, hydroxyl, cyano, benzyloxy, or C 1-3 alkoxy; m, and n, are each independently 0, 1 , or 2; p is 0, 1 , or 2;
  • R 7 and R 7 ' are each independently C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl; and
  • the compounds of the present invention are selected from the compounds of formula (IV), wherein:
  • R 1 and R 1 ' are H
  • R 2 and R 2 ' are H
  • R 5 and R 5 ' are H
  • R 6 is halogen, C 1-3 alkyl, hydroxyl, cyano, benzyloxy, or C 1-3 alkoxy;
  • P is 0, 1 , or 2.
  • R 7 and R 7 ' are each independently C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl; and
  • the compounds of the present invention are selected from the compounds of formula (IV), wherein:
  • R 1 and R 1 ' are each H;
  • R 2 and R 2 ' are each H; R 5 and R 5 ' are each H;
  • R 6 is halogen, C 1-3 alkyl, hydroxyl, cyano, benzyloxy, or C 1-3 alkoxy; p is 0, 1 , or 2.
  • R 7 and R 7 ' are each independently C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl; and
  • p is 0, 1 or 2.
  • p is 0 or 1.
  • p 0.
  • p is 2.
  • R 4 and R 4 ' are H.
  • R 1 is halogen, C 1-3 alkyl, hydroxyl, cyano, Or C 1-3 alkoxy. In one embodiment in the compounds of the present invention R 1 is chloro, fluoro, methyl, hydroxyl, cyano, or methoxy.
  • R 1 is H.
  • R 3 , R b , and R d are each independently are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • R 11 is halogen, -OR a , -NR a R b , hydroxyl, cyano, C 1-6 alkyl, wherein R a -R b are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, CM 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, CM 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • R 12 is halogen, -OR a , oxo, -NR a R b , hydroxyl, cyano, d -6 alkyl, wherein R a -R b are are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7- i 6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
  • each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one or more times by halogen, -OR a .
  • R a' -R d > are each independently H, C 1-12 alkyl.
  • each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by halogen.
  • each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by fluoro.
  • a compound of the present invention further comprising administering at least one additional agent.
  • said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site
  • a pharmaceutical formulation comprising at least one compound of the present invention and at least one pharmaceutically acceptable carrier or excipient.
  • a compound of the present invention for treating an Hepatitis C viral infection in a human.
  • the use of a compound of the present invention further comprising administering at least one additional agent.
  • said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site
  • a pharmaceutical formulation comprising at least one compound of the present invention and at least one pharmaceutically acceptable carrier or excipient.
  • the compounds of the invention are selected from:
  • the present invention provides a compound described in the following embodiments.
  • the compounds of the present invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • each A is independently C 6-14 aryl, 4-12 membered heterocycle, C 3 .i 0 cycloalkyl, or
  • B and B' are each independently absent, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl;
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7- 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • R 3 and R 3 ' are each independently H, C 1-18 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted or substitute
  • X and Y are each independently
  • R 4 is H, C 1-6 alkyl, or halogenated C 1-6 alkyl
  • R 5 and R 5 ' are each independently halogen, -C(O)NR a R b , -(CH 2 )i-6 ⁇ H, C 1- ⁇ alkyl, C 1-6 halogenated alkyl, or C 6-14 aryl; wherein two occurrence of R 4 can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a
  • R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein two occurrence of R 4 ' can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein R a -R b are each independently H, C 1-12 alkyl,
  • R 6 and R 6 ' are each independently H, C 1-6 alkyl, -(CH 2 J 1-6 OH, C 2-6 alkenyl, or C 2-6 alkynyl;
  • n and n, combined are 1 , 2, 3 or 4;
  • p 0, 1 , 2, 3 or 4;
  • q' 0, 1 or 2;
  • the compounds of the present invention is represented by formula (NIA'):
  • B and B' are each independently absent or -(C ⁇ C)-;
  • R 5 and R 5 ' are each independently halogen, -C(O)NR a R b, -(CH 2 )i- 6 ⁇ H, C 1-6 alkyl, C 1-6 halogenated alkyl, C 6-14 aryl, or C 1-6 alkoxy; wherein two occurrence of R 4 can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein two occurrence of R 4 ' can be taken together with the atoms to which they are attached to form a C 1- 6 alkenyl which is unsubstituted or substituted one or more
  • R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein R a -R b are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
  • the compounds of the present invention are represented by formula (NIB):
  • each A is independently C 6-14 aryl, 4-12 membered heterocycle, C 3-10 cycloalkyl, or 5-12 membered heteroaryl;
  • B and B' are each independently absent, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl;
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7- 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • R 2' and R 2 are each independently halogen, CM 0 alkyl, C 1-6 halogenated
  • R 3 and R 3 ' are each independently H, CM 8 alkyl which is unsubstituted or
  • R 10 substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is
  • R 10 unsubstituted or substituted one or more times by R 10
  • C 6-14 aryl which is unsubstituted or substituted one or more times by R 11
  • C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11
  • 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 ,
  • X and Y are each independently
  • R 4 is H, C 1 - 6 alkyl, or halogenated d_ 6 alky
  • R 5 and R 5 ' are each independently halogen, -NR 3 R b , -C(0)NR 3 R b, -(CH 2 ) 1-6 OH, C 1-6 alkyl, C 1-6 halogenated alkyl, hydroxyl, C 6-14 aryl, or C 1-6 alkoxy; wherein two occurrence of R 4 can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein two occurrence of R 4 ' can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycl
  • R 6 and R 6 ' are each independently H, C 1-6 alkyl, -(CH 2 )i- 6 OH, C 2-6 alkenyl, or C 2-6 alkynyl;
  • n 1 , 2, 3 or 4;
  • p 0, 1 , 2, 3 or 4;
  • q' 0, 1 or 2;
  • q and r are each independently 0, 1 , 2, 3 or 4;
  • heteroaralkyl 3-12 membered heterocycle, or 4-18 membered
  • R 7 and R 7 ' are each independently C ⁇ alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by
  • R 12 or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12 ;
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl,
  • n and n combined are 0, 1 , 2, 3 or 4; and the remainder of the variables are as described above for formula (NIA).
  • the compounds of the present invention are represented by formula (VA):
  • the compounds of the present invention are represented by formula (VII) :
  • R 7 and R 7 ' are each independently C ⁇ alkyl which is unsubstituted or substituted one or more times by R 10 , C 2- s alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2- s alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R
  • R a -R d are each independently H, d. ⁇ alkyl, C 2-12 alkenyl, c 2-12 alkynyl, C 6-12 aryl, C 7 - 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • the compounds of the present invention are represented by formla (VIII):
  • C and C are each independently a 4-7 membered heterocycle
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7- 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • X and Y are each independently
  • R 3 and R 3 ' are each independently H, C 1 ⁇ 8 alkyl which is unsubstituted or
  • R 10 substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is
  • R 10 unsubstituted or substituted one or more times by R 10 , C 6 .
  • u aryl which is unsubstituted or substituted one or more times by R 11
  • C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12 ;
  • R 4 is H, C 1-6 alkyl, or halogenated C 1-6 alkyl, or can be merged with R 3 or R 3 ' to form a 3-12 membered heterocycle;
  • R 5 and R 5 ' are each independently halogen, -NR a R b , -C(O)NR a R bj -(CH 2 )i- 6 OH, C 1-6 alkyl, C 1-6 halogenated alkyl, hydroxyl, C 6 .-
  • R 6 and R 6 ' are each independently H, C 1-6 alkyl, -(CH 2 )i- 6 OH, C 2-6 alkenyl, or C 2-6 alkynyl;
  • n are each independently 0, 1 , 2, 3 or 4;
  • q and r are each independently 0, 1 , 2, or 3;
  • heteroaralkyl 3-12 membered heterocycle, or 4-18 membered
  • D is a 5-7 cycloalkyl which is unsubstituted or substituted by (Ri) t i, a 5-7 membered heterocycle which is unsubstituted or substituted by (R 1 J 11 or a 5-7 membered heteroaryl which is unsubstituted or substituted by (R 1 ) I1 ; p is 0, 1 , 2, 3 or 4; and
  • R 7 and R 7 ' are each independently C 1-8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12
  • VA and (V) is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, thienopyrroly
  • (IVA), (VA) and (V) is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, thienopyrrolyl, qui
  • each A in formula (INA), (NIA'), (NB), (IVA), (VA) and (V), is independently selected from the group consisting of:
  • each A in formula (NIA), (NIA'), (NB), (IVA), (VA) and (V), is:
  • each A in formula (NIA), (HIA'), (NB), (IVA), (VA) and (V) is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl,
  • NB is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, quinolinyl, or triazolyl, each of which is substituted with (R 1 J p .
  • each A in formula (NIA), (NIA'), (NB), (IVA), (VA) and (V), is independently selected from the group consisting of:
  • each A in formula (NIA), (HIA'), (NB), (IVA), (VA) and (V), is independently selected from the group consisting of:
  • each A in formula (NIA), (HIA'), (NB), (IVA), (VA), (V), (VIII), (IX), (X) and (Xl), is independently selected from the group consisting of:
  • each A in formula (NIA), (HIA'), (NB), (IVA), (VA) and (V), is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (R 1 J p .
  • B and B' in formulas (INA), (NIA'), (NB), (IVA), (VA) and (V), are independently absent, C 1-6 alkyl or C 2-6 alkynyl; and the remainder of the variables are as described in formula (NIA), (NIA'), (NB), (IVA), (VA) and (V) or any embodiments in the 1 st embodiment described above.
  • B and B' in formulas (INA), (NIA'), (NB),
  • (IVA), (VA) and (V) are independently absent, -(CH 2 J 2- or -(C ⁇ C)-; and the remainder of the variables are as described in formula (NIA), (NIA'), (NB), (IVA), (VA) and (V) or in any embodiments in the 1 st embodiment described above.
  • B and B' in formulas (INA), (NIA'), (NB), (IVA), (VA) and (V), are independently absent or -(C ⁇ C)-; and the remainder of the variables are as described in formula (INA), (NIA'), (NB), (IVA), (VA) and (V) or in any embodiments in the 1 st embodiment described above..
  • NIA (NIA), (NIA'), (NB), (IVA), (VA) and (V), is selected from the group consisting of:
  • t1 + t2 p; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5 th embodiment described above.
  • NIA in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), is selected from the group consisting of:
  • NIA (NIA), (NIA'), (NB), (IVA), (VA) and (V), is selected from the group consisting of:
  • t1 + t2 p; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5 th embodiment described above.
  • NIA (NIA), (NIA'), (NB), (IVA), (VA) and (V), is selected from the group consisting of:
  • t1 + t2 p; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5 th embodiment described above.
  • t1 + t2 p; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5 th embodiment described above.
  • t1 + t2 p; and the remainder of the variables are as described above in formulas formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5 th embodiment described above.
  • VA VA and (V), is ; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5 th embodiment described above.
  • NIA NIA
  • NIA' NIA
  • NB NIA
  • IVA IVAA
  • VA VA
  • V V
  • A1 b the remainder of the variables are as described above in formulas formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5 th embodiment described above.
  • NIA NIA
  • NIA' NIA
  • NB NIA
  • IVA IVAA
  • VA VA
  • V V
  • A1c 1 st to 5 th embodiment
  • R 1 in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), is chloro, fluoro, bromo, methyl, ethyl, propyl, butyl, -CH 2 OH, difluoromethyl, trifluoromethyl, hydroxyl, cyano, or methoxy; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), or in the 1 st to 12 th embodiment described above.
  • each R 2 ' in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), is independently fluoro or methyl.
  • q in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) is 0.
  • each R 2 in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), is independently fluoro or methyl.
  • r in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) is 0.
  • R 6 and R 6 ' in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), are H or methyl; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), or in the 1 st to 16 th
  • R 5 and R 5 ' in formulas (INA), (INA'), (IVA) and (VA), (NB), (VIII), (IX), (X) and (Xl), are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH 2 OH, -NR a N b , t-butoxy-, or hydroxyl or two R 5 groups together with the atoms
  • R 5 and R 5 ' in formulas (INA), (INA'), (IVA) and (VA), are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH 2 OH, -NR a N b , or t-butoxy-,; or two R 5 groups together with the atoms to which
  • R 5 and R 5 ' in formulas (INA), (INA'), (NB), (IVA), (VA), (VIII), (IX), (X) and (Xl), and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (VIII), (IX), (X) and (Xl), or in the 1 st to 17 th embodiment described above.
  • m and n in formulas (NIA), (NIA'), (NB), (IVA), (VIII) and (IX), are 1 or 2; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VIII) and (IX) or in the 1 st to 17 th embodiment described above.
  • m and n are 1.
  • R 3 and R 3 ' in formulas (INA), (INA'), (NB), (V), (Vl), (VIII), (IX) and (X), are each independently, C 1-8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2- s alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2- s alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , C 7-8 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is un
  • R 3 and R 3 ' are each independently, C 1-6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is
  • R 3 and R 3 ' are each independently, C 1-6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkynyl which is unsubstituted or substituted one or more times by R 10 .
  • the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (V), (Vl), (VIII), (IX) and (X) or in the 1 st to 21 st embodiments described above.
  • R 3 and R 3 ' in formulas (NIA), (INA'), (NB), (V), (Vl),
  • (VIII), (IX) and (X) are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH 2 )-, which are unsubstituted or substituted one or more times by R 10 .
  • the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (V), (Vl), (VIII), (IX) and (X) or in the 1 st to 21 st embodiments described above.
  • R 3 and R 3 ' in formulas (NIA), (INA'), (NB), (V), (Vl), (VIII), (IX) and (X), are each independently phenyl which is unsubstituted or substituted one or more times by R 11 .
  • the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (V), (Vl), (VIII), (IX) and (X) or in the 1 st to 21 st embodiments described above.
  • R 3 and R 3 ' in formulas (NIA), (INA'), (NB), (V), (Vl), (VIII), (IX) and (X), are each independently benzyl which is unsubstituted or substituted one or more times by R 11 .
  • the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (V), (Vl), (VIII), (IX) and (X) or in the 1 st to 21 st embodiments described above.
  • (Vl), (VII), (VIII), (IX), (X) and (Xl) are each independently H, d -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • the remainder of the variables are as described above in formulas (INA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) or in the 1 st to 26 th embodiments described above.
  • R a and R c in formulas (INA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), are each independently H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and R b , and R d . are each independently H or C ⁇ alkyl.
  • R a -R d in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V),
  • R a -R d are each independently H or C 1-3 alkyl.
  • the remainder of the variables are as described above in formulas (NIA), (INA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) or in the 1 st to 26 th embodiments described above.
  • R 8 and R 8 ' in formulas (IVA), (VA), (VII) and (Xl), are
  • the remainder of the variables are as described in formulas (IVA), (VA), (VII) and (Xl) or in the 1 st to
  • R 7 and R 7 ' in formulas (IVA), (VA), (VII) and (Xl), are each independently phenyl which is unsubstituted or substituted one or more times by R 11 .
  • the remainder of the variables are as described in formulas (IVA), (VA), (VII) and (Xl) or in the 1 st to 30 th embodiments described above.
  • R 7 and R 7 ' in formulas (IVA), (VA), (VII) and (Xl), are each R 7 and R 7 ' are each independently, C 1-6 alkyl which is unsubstituted or substituted one or more times by R 10 .
  • the remainder of the variables are as described in formulas (IVA), (VA), (VII) and (Xl) or in the 1 st to 30 th embodiments described above.
  • R 7 and R 7 ' are each independently methyl, ethyl, propyl, isopropyl, methoxyisopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2- methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • the remainder of the variables are as described in formulas (IVA), (VA), (VII) and (Xl) or in the 1 st to 30 th embodiments described above.
  • R 7 and R 8 or R r and R 8 together with the carbon to which they are attached are each independently:
  • the present invention provides compounds described in the following embodiments.
  • the compounds of the present invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • A' is C 2 - A alkenyl, C 2- 5 alkynyl, C3- 1 0 cycloalkyl, C 6-14 aryl, 4-12 membered heterocycle or 5-12 membered heteroaryl; C and C are each independently a 4-7 membered heterocycle;
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7- 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • R 3 and R 3 ' are each independently H, C 1 ⁇ 8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted
  • R 5 and R 5 ' are each independently H, halogen, -NR a R b , -C(O)NR a R b> -(CH 2 ) 1-6 OH, C 1 .
  • R 4 can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein two occurrence of R 4 ' can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R
  • X and Y are each independently
  • R 4 is H, C 1-6 alkyl, or halogenated C 1-6 alky; m, and n, combined are 1 , 2, 3 or 4; p is O, 1 , 2, 3 or 4; q and r are each independently 0, 1 , 2, 3 or 4;
  • R 1 on adjacent carbons can be taken together with the carbons to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R 10 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , wherein R a -R d are each independently H, C 1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C 6-1 2 aryl, C 7 - 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl; R 2 and R 2 ' are each independently H, halogen, C 1-6 alkyl, or C ⁇ alkoxy;
  • X and Y are each independently , or a bond;
  • R 3 and R 3 ' are each independently H, C 1-12 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membere
  • R 4 is H, C 1-6 alkyl, or halogenated C 1-6 alkyl, or can be merged with R 3 or R 3 ' to form a 3-12 membered heterocycle;
  • R 5 and R 5 ' are each independently H, halogen, C 1-4 alkyl, hydroxyl, C 1-4 alkoxy, or C- ⁇ - 4 halogenated alkyl;
  • R 6 and R 6 ' are each independently H, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl; m, n, and p are each independently 0, 1 , 2, 3 or 4; q and r are each independently 0, 1 , 2, or 3.
  • R 7 and R 7 ' are each independently C 1-8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl,
  • A' in formulas (I) and (II) is cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxadiazolyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, thienopyrrolyl, quin
  • A' in formulas (I) and (II) is thienyl, pyrimidyl, pyridazinyl, thiazolyl, N-methylimidazolyl, piperazinyl, thiadiazolyl, 1 ,4- diazepanyl or triazole.
  • the remainder of the variables are as described above for formula (I) or (II).
  • A' in formulas (I) and (II) is thienyl.
  • the remainder of the variables are as described above for formula (I) or (II).
  • X and Y in formulas (I), (II) and are .
  • the remainder of the variables are as described above for formula (I), (II) and (III) or in the first embodiment described above.
  • R 5 and R 5 ' in formulas (I), (II), (III) and (IV) are each independently H, halogen, methyl, ethyl, t-butoxy-, or hydroxyl.
  • R 5 and R 5 ' are fluoro.
  • R 5 and R 5 ' are H.
  • the remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first or second embodiments described above.
  • R 5 and R 5 ' in formulas (I), (II), (III) and (IV) are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di- fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH 2 OH, -NR a N b , t-butoxy-, or hydroxyl; or two R 5 groups together with the atoms to which they are attached
  • R 5 and R 5 ' are each independently methyl, ethyl, methoxy, difluromethyl, trifluoromethyl, or two R 5 groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl and/or two R 5 ' groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl.
  • the remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first or second embodiments described above.
  • R 5 and R 5 ' in formulas (I), (II), (III) and (IV) are methyl.
  • the remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first or second embodiments described above.
  • m and n in formulas (I), (II), (III) and (IV) are each independently 0, 1 , or 2. Alternatively, m and n are 2. In another alternative, m and n are 1. The remainder of variables are as described in formulas (I), (II), and (IV) or in the first to fifth embodiments described above.
  • R 6 are R 6 ' in formulas (I), (II), (III) and (IV) are H or methyl. Alternatively, R 6 are R 6 ' in formulas (I), (II), (III) and (IV) are H. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to sixth embodiments described above.
  • R 1 in formulas (I), (II), (III) and (IV) is halogen, C 1-3 alkyl, hydroxyl, cyano, benzyloxy, or C 1-3 alkoxy.
  • R 1 is chloro, fluoro, methyl, hydroxyl, benzyloxy, cyano, or methoxy. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to seventh embodiments described above.
  • p in formulas (I), (II), (III) and (IV) is 2.
  • p is 1. In another alternative, p is 0.
  • the remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to eighth embodiments described above.
  • R 2 and R 2 ' in formulas (I), (II), (III) and (IV) are fluoro.
  • R 2 and R 2 ' in formulas (I), (II), (III) and (IV) are H.
  • the remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to ninth embodiments described above.
  • R 2 and R 2 ' are fluoro and q and r are 1.
  • R 3 and R 3 ' in formulas (I), (II), (III) and (IV) are each independently, C 1-8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-S alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , C 7-8 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4
  • R 3 and R 3 ' are each independently, C 1-6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one
  • R 3 and R 3 ' are each independently, C 1-6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkynyl which is unsubstituted or substituted one or more times by R 10 .
  • the remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to tenth embodiments described above.
  • R 3 and R 3 ' are each independently phenyl which is unsubstituted or substituted one or more times by R 11 .
  • the remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to tenth embodiments described above.
  • R 3 and R 3 ' are each independently benzyl which is unsubstituted or substituted one or more times by R 11 .
  • R 3 and R 3 ' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or
  • R 7 and R 7 ' are each independently C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl;
  • the remainder of the variables are as described in formula (IV) above or in the first to twelfth embodiments described above.
  • R a -R b are each independently H, C 1-6 alkyl, phenyl, tetrahydrofuran, or benzyl.
  • the remainder of the variables are as described in formula (IV) above or in the first to twelfth embodiments described above.
  • R 7 and R 7 ' in formula (IV) are each independently phenyl.
  • the remainder of the variables are as described in formula (IV) above or in the first to fourteenth embodiments described above.
  • R 7 and R 7 ' in formula (IV) are each independently, C 1-6 alkyl. The remainder of the variables are as described in formula (IV) above or in the first to fourteenth embodiments described above.
  • R 7 and R 7 ' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. The remainder of the variables are as described in formula (IV) above or in the first to fourteenth embodiments described above.
  • R 7 and R 8 or R 7 ' and R 8 ' together with the carbon to which they are attached are each independently:
  • 6 alkyl C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • R 11 is halogen, -OR a , -NR a R b , hydroxyl, cyano, C 1-6 alkyl, wherein R a -R b are each independently H, C 1-3 alkyl.
  • R 12 is halogen, -OR a , oxo, -NR a R b , hydroxyl, cyano, C 1-6 alkyl, wherein R a -R b are each independently H, C 1 3 alkyl.
  • R a -R d are each independently H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
  • R a and R c are each independently H, C 1-6 alkyl, C 2-6 alkenyl,
  • R a -R d are each independently H or C 1-3 alkyl.
  • the heterocycle groups described above is unsubstituted.
  • the heteroaryl groups described above is unsubstituted.
  • the compounds of the present invention are selected from compounds shown in Table 1 or pharmaceutically acceptable salts thereof.
  • the variables used herein are as defined in the specific embodiments as shown in Table 1 .
  • Compounds shown in Table 1 are representative compounds of the present invention and have exhibited inhibitory activities against Hepatitis C virus in a cell culture assay, except for compounds 22, 23, 35, 308, 309 and 333-335.
  • Compounds 22, 23, 35, 57, 308, and 309 are synthetic intermediates for inhibitory compounds of the present invention.
  • Compounds 333-335 have not been tested for their inhibitory activities.
  • the compounds of the present invention are selected from compounds 1 , 2, 4-14, 25, 26-34, 36-39, 41 -43, 48-67, 69-89, 91 -100, 102- 111 , 113-145, 147, 148-152, 154, 161 , 164, 166, 168, 170, 171 , 175, 177-181 , 189, 190-193, 195-198, 201 , 203-208, 211 -213, 216-218, 220, 225-228, 230-232, 234, 235, 236, 240, 241 , 243, 244, 246, 250, 254-257, 259, 265, 267, 272, 308, 334 and
  • A is C 2-4 alkenyl, C 2 . 5 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, 4-12 membered 20 heterocycle or 5-12 membered heteroaryl;
  • B and B' are each independently a 4-7 membered heterocycle
  • R 1 and R 1 ' are each independently H, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl;
  • R 2 and R 2 ' are each independently H, halogen, C 1-6 alkyl, or C ⁇ alkoxy;
  • X and Y are each independently , or a bond;
  • R 3 and R 3 ' are each independently H, C 1-12 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membere
  • R 4 is H, C 1-6 alkyl, or halogenated C 1-6 alkyl, or can be merged with R 3 or R 3 ' to form a 3-12 membered heterocycle;
  • R 5 and R 5 ' are each independently H, halogen, C 1-4 alkyl, hydroxyl, C 1-4 alkoxy, or C 1-4 halogenated alkyl;
  • R a -R d are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C 6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • A is C 2-4 alkenyl, C 2-5 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, 4-12 membered heterocycle or 5-12 membered heteroaryl; B and B' are each independently a 4-7 membered heterocycle;
  • R 1 and R 1 ' are each independently H, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl;
  • R 2 and R 2 ' are each independently H, halogen, C 1-6 alkyl, or C 1-6 aIkOXy;
  • X and Y are each independently — , or a bond
  • R 3 and R 3 ' are each independently H, C 1-12 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 ,
  • R 4 is H, C 1-6 alkyl, or halogenated d -6 alkyl, or can be merged with R 3 or R 3 ' to form a 3-12 membered heterocycle
  • R 5 and R 5 ' are each independently H, halogen, C 1-4 alkyl, hydroxyl, C 1-4 alkoxy, or C 1-4 halogenated alkyl
  • A is -(C ⁇ C)-, phenyl, thiophene, pyridine, pyrimidine, or triazole.
  • R 5 ' in formulas (I), (II), (III), and (IV), are fluoro.
  • R 6 is halogen, C 1-3 alkyl, hydroxyl, cyano, benzyloxy, or C 1-3 alkoxy.
  • R 3 and R 3 ' are each independently, C 1- ⁇ alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , C 7-8 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-8 membered hetero
  • R 3 and R 3 ' are each independently, C 1-6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 6-7 membered heterocycle-alkyl which is unsubstit
  • R 3 and R 3 ' are each independently, C 1-6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkynyl which is unsubstituted or substituted one or more times by R 10 .
  • R 3 and R 3 ' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH 2 )-, which are unsubstituted or substituted one or more times by R 10 .
  • R a and R c are each independtly H, d. ⁇ alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and R b , and R d .are each independently H or methyl.
  • a compound according to embodiment 35 wherein R 11 is halogen, -OR a , -NR a R b , hydroxyl, cyano, C 1-6 alkyl, wherein R a -R b are each independently H, C 1-3 alkyl.
  • a compound according to embodiment 39 wherein R 12 is halogen, -OR 3 , oxo, -NR 3 R b , hydroxyl, cyano, C 1-6 alkyl, wherein R 3 -R b are each independently H, C 1-3 alkyl.
  • R 7 and R 7 ' are each independently C 1- ⁇ alkyl, C 2-8 alkenyl, C 2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl; and
  • R b are each independently H, C 1-6 alkyl, phenyl, tetrahydrofuran, or benzyl.
  • R 7 and R 7 ' are each independently phenyl.
  • a compound according to embodiment 46 wherein R 7 and R 7 ' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • a compound according to any one of embodiments 1 to 48 for treating or preventing a Hepatitis C viral infection.
  • a pharmaceutical composition comprising at least one compound according to any one of claims 1 to 48 and at least one pharmaceutically acceptable carrier or excipient.
  • a pharmaceutical combination comprising at least one compound according to any one of embodiments 1 to 48 and at least one additional agent.
  • the pharmaceutical combination according to embodiment 51 wherein said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • the pharmaceutical combination according to embodiment 51 wherein said at least one additional agent is selected from ribavirin and interferon- ⁇ .
  • the pharmaceutical combination according to any one of embodiments 51 to 54, wherein said compound and said additional agent are in dosage unit forms suitable for sequential administration.
  • embodiment 57 the use according to embodiment 56, further comprising administering at least one additional agent.
  • said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • a pharmaceutical formulation comprising at least one compound as defined in anyone of embodiments 1 to 48 and at least one pharmaceutically acceptable carrier or excipient.
  • each A is independently C 6-14 aryl, 4-12 membered heterocycle, C 3-10 cycloalkyl, or 5-12 membered heteroaryl;
  • B and B' are each independently absent, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl; wherein B and B' are not both absent when q is 1 ;
  • C and C are each independently a 4-7 membered heterocycle;
  • R 4 and R 4 ' are each independently halogen, -NR 3 R b , -C(0)NR 3 R b , -(CH 2 V 60H, d_ 6 alkyl, d_ 6 halogenated alkyl, hydroxyl, C 6-14 aryl, or C 1 -6 alkoxy; wherein two occurrence of R 4 can be taken together with the atoms to which they are attached to form a d_ 6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein two occurrence of R 4 ' can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7
  • X and Y are each independently
  • R 5 and R 5 ' are each independently H, C 1-18 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 ,
  • C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12 ;
  • each A is independently C 6-14 aryl, 4-12 membered heterocycle, C3- 1 0 cycloalkyl, or 5-12 membered heteroaryl;
  • B and B' are each independently absent, C 1-6 alkyl, C 2- 6 alkenyl, or C 2- 6 alkynyl;
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkyny
  • R 3 and R 3 ' are each independently H, C 1-6 alkyl, -(CH 2 V 6 OH, C 2-6 alkenyl, or
  • R 4 and R 4 ' are each independently halogen, -C(O)NR a R b> -(CH 2 V 6 OH, C 1-6 alkyl, C 1-6 halogenated alkyl, C 6-14 aryl, or C 1-6 alkoxy; wherein two occurrence of R 4 can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein two occurrence of R 4 ' can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted
  • X and Y are each independently , or a bond; wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
  • R 5 and R 5 ' are each independently H, C 1-18 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7 - 16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted
  • R 6 is H, C 1-6 alkyl, or halogenated C 1-6 alkyl; m, and n, combined are 1 , 2, 3 or 4; p is 0, 1 , 2, 3 or 4; q is 0, 1 or 2; each s is independently 0, 1 , 2, 3 or 4;
  • each A is independently C 6-14 aryl, 4-12 membered heterocycle, C 3-10 cycloalkyl, or 5-12 membered heteroaryl;
  • B and B' are each independently absent, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl;
  • C and C are each independently a 4-7 membered heterocycle
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • R 3 and R 3 ' are each independently H, C 1-6 alkyl, -(CH 2 )i- 6 ⁇ H, C 2-6 alkenyl, or C 2- 6 alkynyl;
  • R 4 and R 4 ' are each independently halogen, -NR a R b , -C(O)NR a R b , -(CH 2 )i-
  • R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein two occurrence of R 4 ' can be taken together with the atoms to which they are attached to form a C 1-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R 11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R 12 ; wherein R a -R b are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
  • X and Y are each independently , or a b bon d d;
  • R 5 and R 5 ' are each independently H, C 1-1S alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-12 alkynyl which is unsubstituted or substituted one or more times by R 10 , C 6-14 aryl which is unsubstituted or substituted one or more times by R 11 , C 7-16 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-18 membered heterocycle-alkyl which is unsubstituted or
  • each A is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxine, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxaliny
  • each A is independently cyclopropyl, cyclohexyl, phenyl, or naphthalene, wherein each A is independently substituted with (R 1 J p .
  • each A is independently selected from the group consisting of:
  • each A is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, quinolinyl, or triazolyl.
  • each A is independently selected from the group consisting of:
  • each A is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (Ri) p .
  • the compound according to any one of embodiments 1 to 80, wherein R 1 is halogen, C 1-4 alkyl which is unsubstituted or substituted one or more times by R 10 , -C( O)OR a , -C(O)NR a R b , hydroxyl, cyano, or C 1-3 alkoxy.
  • each R 2 ' is independently fluoro or methyl.
  • each R 2 is independently fluoro or methyl.
  • R 3 and R 3 ' are H or methyl.
  • R 4 and R 4 ' are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, - CH 2 OH, -NR a N b , t-butoxy-, or hydroxyl; or two R 4 groups together with the atoms to which they are attached form fused cyclopropyl, spiro cyclopropyl or two R 4 ' groups together with the atoms to which they are attached
  • R 5 and R 5 ' are each independently, C 1- ⁇ alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , C 7-8 aralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-8 member
  • R 5 and R 5 ' are each independently, C 1-6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 6-7 membered heterocycle-alkyl which is unsub
  • R 5 and R 5 ' are each independently, C 1-6 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-6 alkynyl which is unsubstituted or substituted one or more times by R 10 .
  • R a -R d are each independently H, C 1-6 alkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl.
  • R a and R c are each independently H, C 1-6 alkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, phenyl, C 7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and R b , and R d .are each independently H or C 1-3 alkyl.
  • R 7 and R 7 ' are each independently C 1-8 alkyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkenyl which is unsubstituted or substituted one or more times by R 10 , C 2-8 alkynyl which is unsubstituted or substituted one or more times by R 10 , phenyl which is unsubstituted or substituted one or more times by R 11 , benzyl which is unsubstituted or substituted one or more times by R 11 , 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R 11 , 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R 11 , 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R 12 , or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R 12
  • R a -R d are each independently H, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 6-12 aryl, C 7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
  • n and n combined are 0, 1 , 2, 3 or 4.
  • the compound according to any one of embodiments 1 to 111 , wherein R 7 and R 8 or R 7 * and R 8' together with the carbon to which they are attached are each independently:
  • the present invention provides a compound according to the invention described herein for treating or preventing a Flaviviridae viral infection in a host.
  • the present invention provides a pharmaceutical composition comprising at least one compound according to the invention described herein and at least one pharmaceutically acceptable carrier or excipient.
  • the present invention provides a pharmaceutical composition comprising at least one compound according to the invention described herein and at least one pharmaceutically acceptable carrier or excipient, for treating or preventing a Flaviviridae viral infection in a host.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising at least one compound according to the invention described herein ,and further comprising administering at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • IRS internal ribosome entry site
  • a combination comprising a least one compound according to the invention described herein and one or more additional agents chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agent, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • additional agents chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agent, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • the compound and additional agent are administered sequentially. In another combination embodiment, the compound and additional agent are administered simultaneously.
  • compositions and combinations may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier therefore comprise a further aspect of the invention.
  • additional agents for the compositions and combinations include, for example, ribavirin, amantadine, merimepodib, Levovirin, Viramidine, and maxamine.
  • viral serine protease inhibitor means an agent that is effective to inhibit the function of the viral serine protease including HCV serine protease in a mammal.
  • Inhibitors of HCV serine protease include, for example, those compounds described in WO 99/07733 (Boehringer Ingelheim), WO
  • viral polymerase inhibitors means an agent that is effective to inhibit the function of a viral polymerase including an HCV polymerase in a mammal.
  • Inhibitors of HCV polymerase include non-nucleosides, for example, those compounds described in: WO 03/010140 (Boehringer Ingelheim), WO 03/026587 (Bristol Myers
  • inhibitors of HCV polymerase also include nucleoside analogs, for example, those compounds described in: WO 01 /90121 A2 (Idenix), WO 02/069903 A2 (Biocryst Pharmaceuticals Inc.), and WO 02/057287 A2(Merck/lsis) and WO 02/057425 A2 (Merck/lsis).
  • inhibitors of an HCV polymerase include VCH-759
  • HCV-796 (Viropharma) and GSK625433 (GlaxoSmithKline).
  • viral helicase inhibitors as used herein means an agent that is effective to inhibit the function of a viral helicase including a Flaviviridae helicase in a mammal.
  • Immunomodulatory agent as used herein means those agents that are effective to enhance or potentiate the immune system response in a mammal.
  • Immunomodulatory agents include, for example, class I interferons (such as ⁇ -, ⁇ - , ⁇ - and ⁇ - interferons, ⁇ -interferons, consensus interferons and asialo- interferons), class Il interferons (such as ⁇ -interferons) and pegylated interferons.
  • class I interferons such as ⁇ -, ⁇ - , ⁇ - and ⁇ - interferons, ⁇ -interferons, consensus interferons and asialo- interferons
  • class Il interferons such as ⁇ -interferons
  • pegylated interferons pegylated interferons.
  • Immunomodulatory agent as used herein include IL- 29 (PEG-lnterferon Lambda, ZymoGenetics), Belerofon (Nautilus Biotech) injectable or oral, Oral Interferon alpha (Amarillo Biosciences), BLX-883 (Locteron, Biolex Therapeutics/Octoplus), Omega Interferon (Intarcia Therapeutics), multiferon (Viragen), Albuferon (Human Genome Sciences), consensus Interferon (Infergen, Three Rivers Pharmaceuticals), Medusa Interferon (Flamel Technologies), NOV-205 (Novelos Therapeutics), Oglufanide disodium (Implicit Bioscience), SCV-07 (SciClone), Zadaxin® (thymalfasin, SciClone/Sigma- Tau), AB68 (XTL bio) and Civacir (NABI).
  • IL- 29 PEG-lnterferon Lambda, ZymoGenetics
  • class I interferon means an interferon selected from a group of interferons that all bind to receptor type 1. This includes both naturally and synthetically produced class I interferons. Examples of class I interferons include ⁇ -, ⁇ -, ⁇ - and ⁇ - interferons, ⁇ -interferons, consensus interferons and asialo-interferons.
  • class Il interferon as used herein means an interferon selected from a group of interferons that all bind to receptor type II. Examples of class Il interferons include ⁇ -interferons.
  • Antisense agents include, for example, ISIS-14803.
  • ISIS-14803 ISIS Pharmaceuticals
  • PTC therapeutics PTC therapeutics
  • the additional agent is interferon ⁇ , ribavirin, silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine or cyclosporin.
  • the additional agent is interferon ⁇ , or ribavirin.
  • the additional agent is interferon ⁇ 1A, interferon ⁇ 1 B, interferon ⁇ 2A, or interferon ⁇ 2B.
  • Interferon is available in pegylated and non pegylated forms.
  • Pegylated interferons include PEGASYS tm and Peg-intron tm .
  • the additional agent is interferon ⁇ 1A, interferon ⁇
  • interferon ⁇ 2A (Roferon), PEG -interferon ⁇ 2A (Pegasys), interferon ⁇ 2B (Intron A) or PEG- interferon ⁇ 2B (Peg-lntron).
  • the additional agents is standard or pegylated interferon ⁇ (Roferon, Pegasys, lntron A, Peg-lntron) in combinaition with ribavirin.
  • the additional agent is chosen from A-831 (AZD0530,
  • TLR9 agonist IMO-2125 (Idera Pharmaceuticals), PYN17 (Phynova), Vavituximab (Tarvacin, Peregrine), DEBIO- 025 (DEBIO), NIM-811 (Novartis), SCY635 (Scynexis), PF-03491390 (IDN-6556, Pfizer), Suvus (formerly BIVN-401 , Virostat, Bioenvision), MX-3253 (Celgosivir, Migenix), Viramidine (Taribavirin, Valeant Pharmaceuticals), Hepaconda (Giaconda), TT033 (Benitec/Tacere Bio/Pfizer), SIRNA-034 (Sirna Therapeutics aquired by Merck) and EHC-18 (Enzo Biochem), ACH-1095 (Achillion/Gilead), JKB- 022 (Jenkin), CTS-1027 (Conat).
  • the additional agent is a therapeutic vaccine chosen from CSL123 (Chiron/CSL), IC41 (Intercell Novartis), Gl 5005 (Glo situmune), TG4040 (Transgene), Chronvac C (Tripep/lnovio), GNI-103 (GENimmune), HCV/MF59 (Chiron/Novartis), PeviPROTM (Pevion biotect).
  • the recommended dose of PEGASYS tm monotherapy for chronic hepatitis C is 180 mg (1.0 mL vial or 0.5 mL prefilled syringe) once weekly for 48 weeks by subcutaneous administration in the abdomen or thigh.
  • the recommended dose of PEGASYS tm when used in combination with ribavirin for chronic hepatitis C is 180 mg (1.0 mL vial or 0.5 mL prefilled syringe) once weekly.
  • the daily dose of Ribavirin is 800 mg to 1200 mg administered orally in two divided doses.
  • the dose should be individualized to the patient depending on baseline disease characteristics (e.g., genotype), response to therapy, and tolerability of the regimen.
  • the recommended dose of PEG-lntron tm regimen is 1.0 mg/kg/week subcutaneously for one year. The dose should be administered on the same day of the week. When administered in combination with ribavirin, the recommended dose of PEG-lntron is 1.5 micrograms/kg/week.
  • viral serine protease inhibitor is a flaviviridae serine protease inhibitor.
  • viral polymerase inhibitor is a flaviviridae polymerase inhibitor.
  • viral helicase inhibitor is a flaviviridae helicase inhibitor.
  • viral serine protease inhibitor is HCV serine protease inhibitor
  • viral polymerase inhibitor is HCV polymerase inhibitor
  • viral helicase inhibitor is HCV helicase inhibitor.
  • the present invention provides a method for treating or preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to formula (I), (II), (III), or (IV).
  • the viral infection is chosen from Flavivirus infections.
  • the Flavivirus infection is Hepatitis C virus (HCV), bovine viral diarrhea virus (BVDV), hog cholera virus, dengue fever virus, Japanese encephalitis virus or yellow fever virus.
  • HCV Hepatitis C virus
  • BVDV bovine viral diarrhea virus
  • hog cholera virus dengue fever virus
  • Japanese encephalitis virus yellow fever virus.
  • the Flaviviridea viral infection is hepatitis C viral infection (HCV).
  • the host is human.
  • the present invention provides a method for treating or preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to the invention described herein, and further comprising administering at least one additional agent.
  • the present invention provides a method for treating or preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to the invention described herein, and further comprising administering at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable carrier therefore comprise a further aspect of the invention.
  • the individual components for use in the method of the present invention or combinations of the present invention may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • the present invention provides the use of a compound according to the invention described herein for treating or preventing Flaviviridae viral infection in a host.
  • the present invention provides the use of a compound according to the invention described herein and further comprising at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (I RES). for treating or preventing Flaviviridae viral infection in a host.
  • at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (I RES).
  • the present invention provides the use of a compound according to the invention described herein for the manufacture of a medicament.
  • the present invention provides the use of a compound according to the invention described herein for the manufacture of a medicament for treating or preventing a viral Flaviviridae infection in a host.
  • the present invention provides the use of a compound according to the invention described herein and further comprising at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (I RES). for the manufacture of a medicament for treating or preventing a viral Flaviviridae infection in a host.
  • I RES internal ribosome entry site
  • the compounds in accordance with the present invention can exists as stereoisomers (for example, optical (+ and -), geometrical (cis and trans) and conformational isomers (axial and equatorial). All such stereoisomers are included in the scope of the present invention. It will be appreciated by those skilled in the art that the compounds in accordance with the present invention can contain a chiral center.
  • the compounds of formula may thus exist in the form of two different optical isomers (i.e. (+) or (-) enantiomers). All such enantiomers and mixtures thereof including racemic mixtures are included within the scope of the invention.
  • the single optical isomer or enantiomer can be obtained by method well known in the art, such as chiral HPLC, enzymatic resolution and chiral auxiliary.
  • the compounds of the present invention are provided in the form of a single stereoisomer at least 95%, at least 97% and at least 99% free of the corresponding stereoisomers.
  • the compound of the present invention are in the form of a single stereoisomer at least 95% free of the corresponding stereoisomers.
  • the compound of the present invention are in the form of a single stereoisomer at least 97% free of the corresponding stereoisomers.
  • the compound of the present invention are in the form of a single stereoisomer at least 99% free of the corresponding stereoisomers.
  • pharmaceutically acceptable salts of the compounds of the present invention are meant those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • acids examples include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toleune-p-sulphonic, tartaric, acetic, trifluoroacetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids.
  • Other acids such as oxalic, while not themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • Salts derived from amino acids are also included (e.g. L-arginine, L- Lysine).
  • Salts derived from appropriate bases include alkali metals (e.g. sodium, lithium, potassium) and alkaline earth metals (e.g. calcium, magnesium).
  • a reference hereinafter to a compound according to the invention includes that compound and its pharmaceutically acceptable salts.
  • polymorphism is an ability of a compound to crystallize as more than one distinct crystalline or "polymorphic" species.
  • a polymorph is a solid crystalline phase of a compound with at least two different arrangements or polymorphic forms of that compound molecule in the solid state.
  • Polymorphic forms of any given compound are defined by the same chemical formula or composition and are as distinct in chemical structure as crystalline structures of two different chemical compounds.
  • the compounds in accordance with the present invention can exist in different solvate forms, for example hydrates.
  • Solvates of the compounds of the invention may also form when solvent molecules are incorporated into the crystalline lattice structure of the compound molecule during the crystallization process.
  • compositions to treat or prevent the herein identified disorders.
  • isotopically labeled compounds wherein, for example, one or more hydrogen atoms in the compounds described herein are replaced with deuterium or tritium.
  • all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
  • the materials, methods, and examples are illustrative only and not intended to be limiting.
  • alkyl represents a linear, branched or cyclic hydrocarbon moiety.
  • alkenyl and alkynyl represent a linear, branched or cyclic hydrocarbon moiety which has one or more double bonds or triple bonds in the chain.
  • alkyl, alkenyl, and alkynyl groups include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, neohexyl, allyl, vinyl, acetylenyl, ethylenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, butadienyl, pentenyl, pentadienyl, hexenyl, heptenyl, hept
  • alkyl, alkenyl, and alkynyl also include combinations of linear and branched groups, e.g., cyclopropylmethyl, cyclohexylethyl, etc.
  • alkenyl also includes C1 alkenyl where the one carbon atom is attached to the remainder of the molecule via a double bond.
  • alkyl, alkenyl, and alkynyl can be optionally substituted such as in the case of haloalkyls in which one or more hydrogen atom is replaced by a halogen, e.g., an alkylhalide.
  • haloalkyls include but are not limited to trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, trifluoroethyl, difluoroethyl, fluoroethyl, trichloroethyl, dichloroethyl, chloroethyl, chlorofluoromethyl, chlorodifluoromethyl, dichlorofluoroethyl.
  • cycloalkyl and “cycloalkenyl” represent a cyclic hydrocarbon alkyl or alkenyl, respectively, and are meant to include monocyclic (e.g., cyclopropyl, cyclobutyl, cyclohexyl), spiro (e.g., spiro [2.3]hexanyl), fused (e.g., bicyclo[4.4.0]decanyl), and bridged (e.g., bicyclo[2.2.1 ]heptanyl) hydrocarbon moieties.
  • monocyclic e.g., cyclopropyl, cyclobutyl, cyclohexyl
  • spiro e.g., spiro [2.3]hexanyl
  • fused e.g., bicyclo[4.4.0]decanyl
  • bridged e.g., bicyclo[2.2.1 ]heptanyl
  • alkoxy represents an alkyl, alkenyl or alkynyl moiety, respectively, which is covalently bonded to the adjacent atom through an oxygen atom.
  • examples include but are not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec- butoxy, tert- butoxy, pentyloxy, isopentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, isohexyloxy, trifluoromethoxy and neohexyloxy.
  • aryl represents a carbocyclic moiety containing at least one benzenoid-type ring (i.e., may be monocyclic or polycyclic), and which where indicated may be optionally substituted with one or more substituents. Examples include but are not limited to phenyl, tolyl, dimethylphenyl, aminophenyl, anilinyl, naphthyl, anthryl, phenanthryl or biphenyl.
  • aralkyl represents an aryl group attached to the adjacent atom by an alkyl, alkenyl or alkynyl. Like the aryl groups, where indicated the aralkyl groups can also be optionally substituted. Examples include but are not limited to benzyl, benzhydryl, trityl, phenethyl, 3-phenylpropyl, 2- phenylpropyl, 4-phenylbutyl and naphthylmethyl.
  • heterocycle represents a non aromatic, saturated or partially saturated cyclic moiety wherein said cyclic moiety is interrupted by at least one heteroatom selected from oxygen (O), sulfur (S) or nitrogen (N). Heterocycles may be monocyclic or polycyclic rings.
  • Examples include but are not limited to azetidinyl, dioxolanyl, morpholinyl, morpholino, oxetanyl, piperazinyl, piperidyl, piperidinyl, cyclopentapyrazolyl, cyclopentaoxazinyl, cyclopentafuranyl, tetrahydrofuranyl, thiazolinyl, oxazolinyl, pyranyl, aziridinyl, azepinyl, dioxazepinyl, diazepinyl, oxyranyl, oxazinyl, pyrrolidinyl, and thiopyranyl, thiolanyl, pyrazolidinyl, dioxanyl, and imidazolidinyl.
  • heterocycle-alkyl represents heterocycle group attached to the adjacent atom by an alkyl, alkenyl or alkynyl group. It is understood that in, for example, a 4-18 member heterocycle-alkyl moiety, the 4-18 member represent the total of the ring atoms present in the heterocycle moiety and the carbon atoms present in the alkyl, alkenyl or alkynyl group.
  • heterocycle-alkyl groups can be optionally substituted one or more times by, for example, halogen, -OR a , oxo, -NR a R b ,
  • heteroaryl represents an aromatic cyclic moiety wherein said cyclic moiety is interrupted by at least one heteroatom selected from oxygen (O), sulfur (S) or nitrogen (N).
  • Heteroaryls may be monocyclic or polycyclic rings wherein at least one ring in the polycyclic ring system is aromatic and at least one ring (not necessarily the same ring contains a heteroatom.
  • Examples include but are not limited to dithiadiazinyl, furanyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridyl, pyrazolyl, pyrrolyl, thiatriazolyl, tetrazolyl, thiadiazolyl, triazolyl, thiazolyl, thienyl, tetrazinyl, thiadiazinyl, triazinyl, thiazinyl, furoisoxazolyl, imidazothiazolyl, thienoisothiazolyl, thienothiazolyl, imidazopyrazolyl, pyrrolopyrrolyl, thienothienyl, thiadiazolopyrimidinyl, thiazolothiazinyl, thiazolopyr
  • heteroaralkyl represents an optionally substituted heteroaryl group attached to the adjacent atom by an alkyl, alkenyl or alkynyl group.
  • the 6-18 member represents the total of the ring atoms present in the heterocycle moiety and the carbon atoms in the alkyl, alkenyl or alkynyl groups.
  • the following groups are encompassed by a 7 member heteroaralkyl (* represents the attachment point):
  • Halogen atom is specifically a fluorine atom, chlorine atom, bromine atom or iodine atom.
  • a dash (“-") that is not between two letters or symbols is used to indicate a point of attachement for a substitutent. For example, -CONR d R e is attached through the carbon of the amide.
  • a dash line (“ ") is used to indicate the point of attachment for the group.
  • A is attached through the carbon at position 1 and 4 in the following representation:
  • the sulfur atom can be at different oxidation levels, i.e., S, SO, or SO 2 . All such oxidation levels are within the scope of the present invention.
  • the term "independently" means that a substituent can be the same or a different definition for each item.
  • substituted refers to the replacement of hydrogen radicals on a carbon or nitrogen atom in a given structure with the radical of a specified substituent.
  • substituents are described above in the definitions and below in the description of compounds and examples thereof.
  • an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position.
  • the language, "which is unsubstituted or substituted one or more times by R 10 " means that when the group is substituted with more than one R 10 group, the R 10 groups can be different from each other.
  • a ring substituent, such as a heterocycle, can be bound to another ring, such as a cycloalkyl, to form a spiro- bicyclic ring system, e.g., both rings share one common atom.
  • a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • a compound represented by: also includes where the R group replaces the H on the nitrogen atom.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds of this invention wherein one or more hydrogen atoms are replaced deuterium or tritium, or one or more carbon atoms are replaced by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools, probes in biological assays, or antiviral compounds with improved therapeutic profile.
  • host or "patient” mean human male or female, for example child, adolescent or adult.
  • a suitable dose will be in the range of from about 0.1 to about 750 mg/kg of body weight per day, for example, in the range of 0.5 to 60 mg/kg/day, or, for example, in the range of 1 to 20 mg/kg/day.
  • the desired dose may conveniently be presented in a single dose or as divided dose administered at appropriate intervals, for example as two, three, four or more doses per day.
  • the compound is conveniently administered in unit dosage form; for example containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to 700 mg of active ingredient per unit dosage form.
  • the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75 ⁇ M, about 2 to 50 ⁇ M, about 3 to about 30 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 500 mg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.
  • each compound may be either the same as or differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
  • compositions comprising compounds of the present invention or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers therefore and, optionally, other therapeutic and/or prophylactic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • Pharmaceutical compositions include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral
  • formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • compositions suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution, a suspension or as an emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
  • the tablets may be coated according to methods well known in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, nonaqueous vehicles (which may include edible oils), or preservatives.
  • the compounds according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre- filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • transdermal patches may contain penetration enhancers such as linalool, carvacrol, thymol, citral, menthol and t-anethole.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • compositions suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • compositions suitable for rectal administration wherein the carrier is a solid are for example presented as unit dose suppositories.
  • Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in moulds.
  • Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • the compounds of the invention may be used as a liquid spray or dispersible powder or in the form of drops. Drops may be formulated with an aqueous or non-aqueous base also comprising one more dispersing agents, solubilizing agents or suspending agents.
  • Liquid sprays are conveniently delivered from pressurized packs.
  • the compounds according to the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray.
  • Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the powder composition may be presented in unit dosage form in, for example, capsules or cartridges or e.g. gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
  • PdCl 2 dppf (1 ,1 '-Bis-(diphenylphosphino)-ferrocene)palladium (II) dichloride 5
  • Pd(PPh 3 ) 4 Tetrakis(triphenylphosphine) palladium
  • the compounds of this invention may be prepared in light of the specification using steps generally known to those of ordinary skill in the art. Those compounds may be analyzed by known methods, including but not limited to LCMS (liquid chromatography mass spectrometry) HPLC and NMR (nuclear magnetic resonance). It should be understood that the specific conditions shown below are only examples, and are not meant to limit the scope of the conditions that can be used for making compounds of this invention. Instead, this invention also includes conditions that would be apparent to those skilled in that art in light of this specification for making the compounds of this invention. Unless otherwise indicated, all variables in the following schemes are as defined herein. General Schemes:
  • Mass spec samples were analyzed on a MicroMass Quattro Micro mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using chromatography. Mobile phase for all mass spec, analyses consisted of 1 OmM pH 7 ammonium acetate and a 1 :1 acetonitrile-methanol mixture. Method A: Column gradient conditions were 5%- 100% acetonitrile-methanol over 3.5 mins gradient time and 4.8 mins run time on an ACE5C8 3.0 x 75mm column. Flow rate was 1.2 ml/min.
  • Method B Column gradient were 5%-100% acetonitrile-methanol over 10 mins gradient time and 12 mins run time on a ACE5C8 4.6 x 150 mm column. Flow rate was 1.5 mL/min.
  • Rt(min) refers to the LCMS retention time, in minutes, associated with the compound. Unless otherwise indicated, the LCMS method utilized to obtain the reported retention time is as detailed above. If the Rt(min) is ⁇ 5 min method A was used, if the Rt(min) is >5 min then method B was used.
  • the benzimidazole is formed by coupling the diamino compound with the appropriate carboxylic acid, preactivated carboxylic acid, mixed anhydride or anhydride in solvents such as THF, DMF or DCM and in the presence of a base such as TEA or DIPEA to form the corresponding amide.
  • the amide is than treated with an acid at 40-80°C for 2-24 hours.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Compounds represented by formula (I) or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B', X, Y, R1, R1 ', R2, R2', R3, R3', R5, R5', R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Description

BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR
PREVENTION OF FLAVIVIRUS INFECTIONS
RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application Serial No. 61 /226,152, filed July 16, 2009 and U.S. Provisional Patent Application Serial No. 61 /317,017, filed March 24, 2010, the entire teachings of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
The present invention relates to novel compounds and a method for the treatment or prevention of Flavivirus infections using novel compounds. Hepatitis is a disease occurring throughout the world. It is generally of viral nature, although there are other causes known. Viral hepatitis is by far the most common form of hepatitis. Nearly 750,000 Americans are affected by hepatitis each year, and out of those, more than 150,000 are infected with the hepatitis C virus ("HCV").
HCV is a positive-stranded RNA virus belonging to the Flaviviridae family and has close relationship to the pestiviruses that include hog cholera virus and bovine viral diarrhea virus (BVDV). HCV is believed to replicate through the production of a complementary negative- strand RNA template. Due to the lack of efficient culture replication system for the virus, HCV particles were isolated from pooled human plasma and shown, by electron microscopy, to have a diameter of about 50-60 nm. The HCV genome is a single-stranded, positive-sense RNA of about 9,600 bp coding for a polyprotein of 3009-3030 amino-acids, which is cleaved co and post- translationally into mature viral proteins (core, E1 , E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). It is believed that the structural glycoproteins, E1 and E2, are embedded into a viral lipid envelope and form stable heterodimers. It is also believed that the structural core protein interacts with the viral RNA genome to form the nucleocapsid. The nonstructural proteins designated NS2 to NS5 include proteins with enzymatic functions involved in virus replication and protein processing including a polymerase, protease and helicase. The main source of contamination with HCV is blood. The magnitude of the HCV infection as a health problem is illustrated by the prevalence among high-risk groups. For example, 60% to 90% of hemophiliacs and more than 80% of intravenous drug abusers in western countries are chronically infected with HCV. For intravenous drug abusers, the prevalence varies from about 28% to 70% depending on the population studied. The proportion of new HCV infections associated with post-transfusion has been markedly reduced lately due to advances in diagnostic tools used to screen blood donors.
Combination of pegylated interferon plus ribavirin is the treatment of choice for chronic HCV infection. This treatment does not provide sustained viral response
(SVR) in a majority of patients infected with the most prevalent genotype (1a and
1 b). Furthermore, significant side effects prevent compliance to the current regimen and may require dose reduction or discontinuation in some patients.
There is therefore a great need for the development of anti-viral agents for use in treating or preventing Flavivirus infections. SUMMARY OF THE INVENTION
The present invention is directed to compounds desribed herein, e.g., compounds represented by formulas (I), (II), (III), (IV), (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) described herein.
In one embodiment, the present invention is directed to a method treating or preventing a Hepatitis C viral infection in a human comprising administering to the human a therapeutically effective amount of a compound described herein.
In another embodiment, the present invention is directed to a
pharmaceutical composition comprising at least one compound described herein and at least one pharmaceutically acceptable carrier or excipients.
The present invention is also directed to the use of a compound described herein for treating or preventing a Hepatitis C viral infection in a human. DETAILED DESCRIPTION OF THE INVENTION
In one aspect, the present invention provides a compound of formula (I):
Figure imgf000005_0001
wherein,
A is C2-4 alkenyl, C2-5 alkynyl, C3-10 cycloalkyl, C6-14 aryl, or 4-12 membered heterocycle, 5-12 membered heteroaryl;
B and B' are each independently a 4-7 membered heterocycle;
R1 and R1' are each independently H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
R2 and R2' are each independently H, halogen, C1-6 alkyl, or C1-6 aIkOXy;
X and Y are each independently
O O
, or a bond;
Figure imgf000005_0002
R3 and R3' are each independently H, C1-12 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently H, halogen, C1-4 alkyl, hydroxyl, C1-4alkoxy, or C1-4 halogenated alkyl; R6 is H, halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C1-6 hahogenated alkyl or any two occurrence of R6 on adjacent carbons can be taken together with the carbons to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R10 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 , wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-
18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; m, and n, are each independently 0, 1 , 2, 3 or 4; p is O, 1 , 2, 3 or 4; q, and r are each independently 0, 1 , 2 or 3.
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R11 is halogen, -0Ra, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra,
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R12 is halogen, -0Ra, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=0)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; or a pharmaceutically acceptable salts thereof. In another aspect, there is provided a method for treating or preventing a
Flaviviridae viral infection in a patient comprising administering to the patient a therapeutically effective amount of a compound, composition or combination of the invention. In another aspect, there is provided a pharmaceutical composition comprising at least one compound of the invention and at least one pharmaceutically acceptable carrier or excipient. In another aspect, there is provided a combination comprising a compound of the invention and one or more additional agents chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agent, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
In a further aspect, there is provided the use of a compound, composition or combination of the invention for treating or preventing a Flaviviridae viral infection in a human.
In still another aspect, there is provided the use of a compound, composition or combination of the invention for the manufacture of a medicament for treating or preventing a viral Flaviviridae infection in a human. In one embodiment, compounds of the present invention comprise those wherein the following embodiments are present, either independently or in combination.
In accordance with a further embodiment, the compounds of the present invention are represented by formula (II)
Figure imgf000008_0001
or pharmaceutically acceptable salts thereof;
In accordance with a further embodiment, the compounds of the present invention are represented by formula
Figure imgf000009_0001
or pharmaceutically acceptable salts thereof; In accordance with a further embodiment the compounds of the present invention are represented by formula (IV):
Figure imgf000009_0002
or pharmaceutically acceptable salts thereof; wherein
R7 and R7' are each independently C1-β alkyl, C2-8 alkenyl, C2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl; and
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
According to a further embodiment, A is phenyl, thiophene, pyridine, pyrimidine, or triazole.
According to a further embodiment, A is phenyl, or thiophene. According to a further embodiment, A is phenyl.
According to a further embodiment, B and B' in formulas (I) are each independently a pyrrolidine or a piperidine.
According to a further embodiment, B in formulas (I) is a pyrrolidine.
According to a further embodiment, B in formulas (I) is a piperidine. According to a further embodiment, B' in formulas (I) is a pyrrolidine. According to a further embodiment, B' in formulas (I) is a piperidine.
According to a further embodiment, X, is
Figure imgf000010_0001
According to a further embodiment X is
Figure imgf000010_0002
According to a further embodiment X is
Figure imgf000011_0001
According to a further embodiment X is
Figure imgf000011_0005
According to a further embodiment, X is a bond
According to a further embodiment, Y is
Figure imgf000011_0002
According to a further embodiment, Y is
Figure imgf000011_0003
According to a further embodiment, Y is
Figure imgf000011_0004
According to a further embodiment, Y is
Figure imgf000011_0006
According to a further embodiment, Y is a bond. According to a further embodiment, m and/or n are each independently 0, 1 , 2, or 3. According to a further embodiment, m and/or n are each independently 0,
1 , or 2
According to a further embodiment, m and/or n are each independently 0, or 1.
According to a further embodiment, m and/or n are each independently 2. According to a further embodiment, m and/or n are each independently 1. According to a further embodiment, m and/or n are each independently 0.
According to a further embodiment, p is 0, 1 , 2, or 3. According to a further embodiment, p is 0, 1 , or 2.
According to a further embodiment, p is 0 or 1. According to a further embodiment, p is 0. According to a further embodiment, p is 1.
According to a further embodiment, p is 2. According to a further embodiment, R1 and R1' are each independently H.
According to a further embodiment, q and r are each independently 0, 1 , or 2.
According to a further embodiment, q and r are each independently 0, or 1 . According to a further embodiment, q and r are each independently 1. According to a further embodiment, q and r are each independently 0.
According to a further embodiment, R2 and R2' are each independently H or Halogen.
According to a further embodiment, R2 and R2' are each independently H or fluoro.
According to a further embodiment, R2 and R2 are each independently fluoro. According to a further embodiment, R2 and R2', are each independently H.
According to a further embodiment, R5 and R5', are each independently H, Halogen, methyl, ethyl, t-butoxy-, or hydroxyl. According to a further embodiment, R5 and R5' are each independently H or Halogen.
According to a further embodiment, R5 and R5' are each independently H or fluoro.
According to a further embodiment, R5 and R5' are fluoro.
According to a further embodiment, R5 and R5' are fluoro and m, and n, are 2.
According to a further embodiment, R5 and R5' are each independently H.
According to a further embodiment, R6 is halogen, C1-3 alkyl, hydroxyl, cyano, benzyloxy, or C1-3 alkoxy. According to a further embodiment, R6 is chloro, fluoro, methyl, hydroxyl, benzyloxy, cyano, or methoxy.
According to a further embodiment, R6 is fluoro, methyl, or methoxy, and p is 2.
According to a further embodiment, R6 is H.
According to a further embodiment, R3 and R3' are each independently, C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
According to a further embodiment, R3 and R3' are each independently, C1- 6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
According to a further embodiment, R3 and R3' are each independently, C1.
6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12. According to a further embodiment, R3 and R3' are each independently,
C-ι-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10. According to a further embodiment, R3 and R3' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
According to a further embodiment, R3 and R3' are each independently benzyl which is unsubstituted or substituted one or more times by R11.
According to a further embodiment, R3 and R3' are each independently benzyl.
According to a further embodiment, R3 and R3' are each independently, C1. n alkyl which is unsubstituted or substituted one or more times by R10.
According to a further embodiment, R3 and R3' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2- methylbutyl, 3-methylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-, which in each case is unsubstituted or substituted one or more times by R10.
According to a further embodiment, R3 and R3' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2- methylbutyl, 3-methylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-.
According to a further embodiment, R3 and R3' are each independently tert-butyl.
According to a further embodiment, R3 and R3' are each independently H.
According to a further embodiment, R3 and R3' are each independently 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12.
According to a further embodiment, R3 and R3' are each independently tetrahydyrofuranyl.
According to a further embodiment, R3 and R3' are each independently 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12. According to a further embodiment, R10 is halogen, -ORa, oxo, -NRaRb, =NO-
Rc , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, - NRbSO2Ra, -NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra and Rc are each independtly H, C-ι-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-n afyl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl.
According to a further embodiment, R10 is -NRaRb, -NRdC(=O)NRaRb, - NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl. According to a further embodiment, R10 is -NRaRb, -NRdC(=O)NRaRb, -
NRbC(=O)Ra, -NRbC(=O)ORa, or -NRbSO2Ra, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R10 is -NRaRb, -NRdC(=O)NRaRb, -
NRbC(=O)Ra, -NRbC(=O)ORa, or -NRbSO2Ra, wherein Ra is C1 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and Rb, and Rd are each independently H or methyl.
According to a further embodiment, R10 is -NRaRb, -NRbC(=O)ORa,, wherein Ra-Rb are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C7-8 aralkyl.
According to a further embodiment, R10 is -NRbC(=O)ORa,, wherein Ra-Rb are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C7-8 aralkyl.
According to a further embodiment, R10 is -NRbC(=O)ORa,, wherein Ra is C1- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C7-8 aralkyl, and Rb is H or methyl.
According to a further embodiment, R10 is -NRbC(=O)ORa,, wherein Ra is C1. 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C7-8 aralkyl, and Rb is H. According to a further embodiment, R10 is halogen, -ORa, oxo, -C(=O)ORa, -
C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, cyano, wherein Ra-Rb are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R10 is -ORa, -OC(=O)NRaRb, -OC(=O)Ra, -
OC(=O)ORa, hydroxyl, wherein Ra-Rb are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl. According to a further embodiment, R10 is oxo, -C(=O)ORa, -C(O)NRaRb, -
C(=O)OH, -C(=O)Ra, cyano, wherein Ra-Rb are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R10 is halogen, -ORa, oxo, -C(=O)ORa, -
C(O)NRaRb, -C(=O)OH, -OC(=O)NRaRb, hydroxyl, cyano, wherein Ra-Rb are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R10 is ORa, -C(=O)ORa, -C(O)NRaRb, - C(=O)OH, -OC(=O)NRaRb, hydroxyl, wherein Ra-Rb are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl. According to a further embodiment, R10 is halogen, hydroxyl, or -NH2.
According to a further embodiment, R10 is halogen.
According to a further embodiment, R11 is halogen, -ORa, -NRaRb, - C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, cyano, -SO2NRaRb, -
NRbSO2Ra, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1. 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R11 is halogen, -ORa, -NRaRb, - C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -SO2NRaRb, - NRbSO2Ra, -NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6- 12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra and Rc are each independtly H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl.
According to a further embodiment, R11 is halogen, -ORa, -NRaRb, - C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl. According to a further embodiment, R11 is halogen, -ORa, -NRaRb, -
C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and Rb, and Rd are each independently H or methyl.
According to a further embodiment, R11 is halogen, -0Ra, -NRaRb, hydroxyl, cyano, C1-6 alkyl, wherein Ra-Rb are each independently H, C1-3 alkyl.
According to a further embodiment, R11 is halogen, hydroxyl, cyano, or - NH2. According to a further embodiment, R11 is halogen. According to a further embodiment, R12 is halogen, -ORa, oxo, -NRaRb, =NO- Rc , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, - NRbSO2Ra, -NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6. 12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra and Rc are each independtly H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl.
According to a further embodiment, R12 is halogen, -ORa, oxo, -NRaRb, - C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -NRdC(=0)NR3Rb, -NRbC(=0)R3, -
NRbC(=0)0R3, -0C(=0)NR3Rb, -0C(=0)R3, -0C(=0)0R3, hydroxyl, cyano, -S02NR3Rb, -
NRbS02R3, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein R3, Rb, and Rd are each independently H, C1- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R12 is halogen, -OR3, oxo, -NR3Rb, - C(0)NR3Rb, -C(=O)OH, -C(=O)Ra, -NRdC(=0)NR3Rb, -NRbC(=0)R3, -NRbC(=0)0R3, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein R3, Rb, and Rd are each independently
H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R12 is halogen, -OR3, oxo, -NR3Rb, -
C(O)NR3Rb, -C(=O)OH, -C(=O)Ra, -NRdC(=0)NR3Rb, -NRbC(=0)R3, -NRbC(=0)0R3, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and Rb, and Rd are each independently H or methyl.
According to a further embodiment, R12 is halogen, -0Ra, oxo, -NRaRb, hydroxyl, cyano, C1-6 alkyl, wherein Ra-Rb are each independently H, C1-3 alkyl. According to a further embodiment, R12 is halogen.
According to a further embodiment, R8 and R8' in formula (IV), are each independently -NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R8 and R8' in formula (IV), are each independently -NRaRb, -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R8 and R8' in formula (IV), are each independently -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
According to a further embodiment, R8 and R8' in formula (IV), are each independently -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, tetrahydrofuran, or benzyl.
According to a further embodiment, R8 and R8' in formula (IV), are each independently -NRbC(=O)ORa, wherein Ra is C1-6 alkyl, tetrahydrofuran, or benzyl, and Rb is H. According to a further embodiment, R8 and R8' in formula (IV), are each independently -NRbC(=O)ORa, wherein Ra is C1-6 alkyl, tetrahydrofuran, or benzyl, and Rb is methyl. According to a further embodiment, R8 and R8' in formula (IV), are each independently -NRbC(=O)ORa, wherein Ra is C1-6 alkyl and Rb is H, or methyl.
According to a further embodiment, R8 and R8' in formula (IV), are each independently -NRbC(=O)ORa, wherein Ra is C1-6 alkyl and Rb is H.
According to a further embodiment, R7 and R7' in formula (IV), are each independently phenyl.
According to a further embodiment, R7 and R7' in formula (IV), are each independently benzyl.
According to a further embodiment, R7 and R7' in formula (IV), are each independently, C1-6 alkyl. According to a further embodiment, R7 and R7' in formula (IV), are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. According to a further embodiment, R7 and R7' in formula (IV), are each independently methyl.
According to a further embodiment, R7 and R7' in formula (IV), are each independently ethyl.
According to a further embodiment, R7 and R7' in formula (IV), are each independently propyl.
According to a further embodiment, R7 and R7' in formula (IV), are each independently isopropyl. According to a further embodiment, R7 and R7' in formula (IV), are each independently butyl. According to a further embodiment, R7 and R7' in formula (IV), are each independently tert-butyl.
According to a further embodiment, R7 and R7' in formula (IV), are each independently cyclopropyl.
According to a further embodiment, R7 and R7' in formula (IV), are each independently cyclobutyl.
According to a further embodiment, R7 and R7' in formula (IV), are each independently cyclopentyl.
According to a further embodiment, R7 and R7' in formula (IV), are each independently cyclohexyl. In accordance with a further embodiment of the invention, the compounds of the present invention are selected from the compounds of the invention, wherein:
R1 and R1' are H;
R2 and R2' are each independently H, or halogen; q and r are each independently 0, or 1.
X and Y are each independently — , or a bond;
Figure imgf000023_0001
R3 and R3' are each independently H, C1-12 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; R4 is H, C1-6 alkyl, or halogenated d-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently H, or halogen; R6 is H, halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, "C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C1-6 halogenated alkyl, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C2-16 aralkyl;
m, and n, are each independently 0, 1 , or 2; p is O, 1 , or 2;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H, C1-i2 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C1-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. In accordance with a further embodiment of the invention, the compounds of the present invention are selected from the compounds of the invention, wherein:
R1 and R1' are H;
R2 and R2' are each independently H, or halogen; q and r are each independently 0, or 1.
X and Y are each independently — , or a bond;
Figure imgf000026_0001
R3 and R3' are each independently H, C1-12 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently H, or halogen; R6 is H, halogen, -0Ra, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, "C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, d_6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or d_6 halogenated alkyl, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C7-16 aralkyl; m, and n, are each independently O, 1 , or 2; p is O, 1 , or 2;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra and Rc are each independtly H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra,
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra and Rc are each independtly H, C1-12 alkyl, C2. 12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl; and
R12 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, -
NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-I2 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra and Rc are each independtly H, C1-12 alkyl, C2. n alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl,
6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl. In accordance with a further embodiment of the invention, the compounds of the present invention are selected from the compounds of the invention wherein: R1 and R1' are H;
R2 and R2' are each independently H, or halogen; q and r are each independently 0, or 1 ;
X and Y are each independently
Figure imgf000028_0001
, or a bond;
R3 and R3' are each independently H, C1-12 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-^ aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11,
6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently H, or halogen;
R6 is H, halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -
C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra,
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C1^ halogenated alkyl, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C7-16 aralkyl; m, and n, are each independently 0, 1 , or 2; p is O, 1 , or 2;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, -
NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, "C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and R12 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In accordance with a further embodiment of the invention, the compounds of the present invention are selected from the compounds of the invention, wherein: R1 and R1' are H;
R2 and R2' are each independently H, or halogen; q and r are each independently 0, or 1 ;
X and Y are each independently
Figure imgf000030_0001
or a bond;
R3 and R3' are each independently, C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently H, or halogen; R6 is H, halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, "C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C1-6 halogenated alkyl, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C7-16 aralkyl; m, and n, are each independently 0, 1 , or 2; p is O, 1 , or 2;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H,
C-ι-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -
C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, -
NRbSO2NR3Rb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In accordance with a further embodiment of the invention, the compounds of the present invention are selected from the compounds of the invention, wherein:
R1 and R1' are H;
R2 and R2' are each independently H, or halogen; q and r are each independently 0, or 1 ;
X and Y are
Figure imgf000032_0001
R3 and R3' are each independently H, C1-12 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently H, or halogen; R6 is H, halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, "C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, -
NRbSO2NRaRb, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C1.*, halogenated alkyl, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C7-16 aralkyl; m, and n, are each independently 0, 1 , or 2; p is O, 1 , or 2;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra,
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and R12 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In accordance with a further embodiment of the invention, the compounds of the present invention are selected from the compounds of formula (IV), wherein:
R1 and R1' are H;
R2 and R2' are each independently H or Halogen;
q and r are each independently 0, or 1.
R5 and R5' are each independently H or Halogen;
R6 is halogen, C1-3 alkyl, hydroxyl, cyano, benzyloxy, or C1-3 alkoxy; m, and n, are each independently 0, 1 , or 2; p is 0, 1 , or 2;
R7 and R7' are each independently C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl; and
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. In accordance with a further embodiment of the invention, the compounds of the present invention are selected from the compounds of formula (IV), wherein:
R1 and R1' are H;
R2 and R2' are H;
R5 and R5' are H;
R6 is halogen, C1-3 alkyl, hydroxyl, cyano, benzyloxy, or C1-3 alkoxy;
P is 0, 1 , or 2.
R7 and R7' are each independently C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl; and
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In accordance with a further embodiment of the invention, the compounds of the present invention are selected from the compounds of formula (IV), wherein:
R1 and R1' are each H;
R2 and R2' are each H; R5 and R5' are each H;
R6 is halogen, C1-3 alkyl, hydroxyl, cyano, benzyloxy, or C1-3 alkoxy; p is 0, 1 , or 2. R7 and R7' are each independently C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl; and
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -
C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)0R3, -
OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -
SO2NRaRb, -NRbS02R3, -NRbS02NR3Rb, -P(=0)0R30Rb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10;
In one embodiment in the compounds of the present invention, herein as valency allows in B, B', R3-Rd, R1 , R2, R2', R3, R3', R4, R4 ', R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one or more times by halogen, -OR3', oxo, -NR3.Rb>, =NO-RC>, -C(=0)0R3>, -
C(0)NR3.Rb., -C(=O)OH, -C(=0)R3., -C(=N0Rc.)R3., -C(=NRc.)NR3.Rb., -
NRd.C(=0)NR3.Rb., -NRb.C(=0)R3., -NRd.C(=NRc.)NR3.Rb., -NRb.C(=0)0R3., -
0C(=0)NR3.Rb., -0C(=0)R3., -0C(=0)0R3., hydroxyl, nitro, azido, cyano, -S(O)0-3R3', - S02NR3'Rb', -NRb'S02R3>; wherein R3'-Rd> are each independently H, C1-12 alkyl.
In one embodiment in the compounds of the present invention p is 0, 1 or 2.
In one embodiment in the compounds of the present invention p is 0 or 1.
In one embodiment in the compounds of the present invention p is 0.
In one embodiment in the compounds of the present invention p is 2.
In one embodiment in the compounds of the present invention R4 and R4' are H.
In one embodiment in the compounds of the present invention R1 is halogen, C1-3 alkyl, hydroxyl, cyano, Or C1-3 alkoxy. In one embodiment in the compounds of the present invention R1 is chloro, fluoro, methyl, hydroxyl, cyano, or methoxy.
In one embodiment in the compounds of the present invention n R1 is H. A compound according to claim 31 , wherein R10 is halogen, -ORa, oxo, - C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, cyano, wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -
-C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -
OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -
SO2NRaRb, -NRbSO2Ra, or -NRbS02NR3Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein R3-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl,
5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R11 is halogen, -OR3, -NR3Rb, -C(=O)ORa, -C(0)NR3Rb, -C(=O)OH, -C(=O)Ra, -
NRdC(=0)NR3Rb, -NRbC(=0)R3, -NRbC(=0)0R3, -0C(=0)NR3Rb, -0C(=0)R3, -
0C(=0)0R3, hydroxyl, cyano, -S02NR3Rb, -NRbS02R3, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein R3, Rb, and Rd are each independently are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R11 is halogen, -OR3, -NR3Rb, -C(0)NR3Rb, -C(=O)OH, -C(=O)Ra, -NRdC(=0)NR3Rb, - NRbC(=0)R3, -NRbC(=0)0R3, -0C(=0)NR3Rb, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein R3, Rb, and Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R11 is halogen, -ORa, -NRaRb, hydroxyl, cyano, C1-6 alkyl, wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, CM6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R12 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, - NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, C1-12 alkyl, C2-12 alkenyl, C2. 12 alkynyl, C6.n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, CM6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R12 is halogen, -ORa, oxo, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, - OC(=O)ORa, hydroxyl, cyano, -SO2NRaRb, -NRbSO2Ra, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1-12 alkyl, C1-12 alkenyl, C2-12 alkynyl, C6-12 aryl, CM6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention R12 is halogen, -ORa, oxo, -NRaRb, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, - NRbC(=O)Ra, -NRbC(=O)ORa, -OC(=O)NRaRb, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. In one embodiment in the compounds of the present invention R12 is halogen, -ORa, oxo, -NRaRb, hydroxyl, cyano, d-6 alkyl, wherein Ra-Rb are are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In one embodiment in the compounds of the present invention wherein as valency allows in B, B', Ra-Rd, Ri, R2, R2', R3, R3', R4, R4 , R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one or more times by halogen, -ORa. -NRa.Rb., C(=O)ORa., -C(O)NRa.Rb., -C(=O)OH, hydroxyl, nitro, azido, cyano,'; wherein Ra'-Rd> are each independently H, C1-12 alkyl.
In one embodiment in the compounds of the present invention wherein as valency allows in B, B', Ra-Rd, R1, R2, R2', R3, R3', R4, RV, R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by halogen.
In one embodiment in the compounds of the present invention wherein as valency allows in B, B', Ra-Rd, Ri, R2, R2', R3, R3', R4, R4 , R10, R11 and R12 each of alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle, or heterocycle-alkyl is independently unsubstituted or substituted one time by fluoro.
The use of a compound of the present invention for treating an Hepatitis
C viral infection in a human. The use of a compound of the present invention further comprising administering at least one additional agent. The use of a compound of the present invention wherein said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site
(IRES).
The use of a compound of the present invention, wherein said at least one additional agent is selected from ribavirin and interferon-α.
The use of a compound of the present invention for the manufacture of a medicament. A pharmaceutical formulation comprising at least one compound of the present invention and at least one pharmaceutically acceptable carrier or excipient.
The use of a compound of the present invention for treating an Hepatitis C viral infection in a human. The use of a compound of the present invention further comprising administering at least one additional agent. The use of a compound of the present invention wherein said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site
(IRES). The use of a compound of the present invention wherein said at least one additional agent is selected from ribavirin and interferon-α.
The use of a compound of the present invention for the manufacture of a medicament.
A pharmaceutical formulation comprising at least one compound of the present invention and at least one pharmaceutically acceptable carrier or excipient. According to an aspect of the invention, the compounds of the invention are selected from:
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
In another aspect, the present invention provides a compound described in the following embodiments.
In one embodiment, the compounds of the present invention is
represented by formula (NIA):
Figure imgf000045_0001
(NIA)
or pharmaceutically acceptable salts thereof, wherein :
each A is independently C6-14 aryl, 4-12 membered heterocycle, C3.i0 cycloalkyl, or
5-12 membered heteroaryl;
B and B' are each independently absent, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl; R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -
C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -
OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, - NRbSO2Ra, -NRbSO2NRaRb, -P(=O)ORaORb, d-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7- 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2' and R2 are each independently halogen, C1-10 alkyl, C1-6 halogenated alkyl, -(CH2)1-6OH, -ORa, -C(=O)ORa,
NRaRb, -NRbC(=O)Ra,-C(O)NRaRb, -S(O)0-3R3, C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, C1-18 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
X and Y are each independently
or a bond;
Figure imgf000046_0001
to the nitrogen of ring C or C;
R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl;
R5 and R5' are each independently halogen, -C(O)NRaRb, -(CH2)i-6θH, C1-β alkyl, C1-6 halogenated alkyl, or C6-14 aryl; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a
3-7 cycloalkyl which is unsubstituted or substituted one or more times by
R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, C1-12 alkyl,
C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or
4-18 membered heterocycle-alkyl;
R6 and R6' are each independently H, C1-6 alkyl, -(CH2J1-6OH, C2-6 alkenyl, or C2-6 alkynyl;
m and n, combined are 1 , 2, 3 or 4;
p is 0, 1 , 2, 3 or 4;
q' is 0, 1 or 2;
q and r are each independently 0, 1 , 2, 3 or 4; R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -
C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NR3Rt, or -P(=O)ORaORb,;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb,
NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(Oy3R3, - SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6.n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-
18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -0Ra, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NR3Rb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In another embodiment, the compounds of the present invention is represented by formula (NIA'):
Figure imgf000047_0001
(NIA')
or pharmaceutically acceptable salts thereof, wherein:
B and B' are each independently absent or -(C≡C)-; R5 and R5' are each independently halogen, -C(O)NRaRb, -(CH2)i-6θH, C1-6 alkyl, C1-6 halogenated alkyl, C6-14 aryl, or C1-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1- 6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by
R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
the remainder of the variables are as described above for formula (NIA).
In another embodiment, the compounds of the present invention are represented by formula (NIB):
Figure imgf000048_0001
(HB)
or pharmaceutically acceptable salts thereof, wherein
each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl;
B and B' are each independently absent, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl; R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -
C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0- 3Ra, -SO2NRaRb, -NRbSO2R3, -NRbSO2NRaRb, -P(=O)ORaORb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is
unsubstituted or substituted one or more times by R12;
Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7- 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2' and R2 are each independently halogen, CM0 alkyl, C1-6 halogenated
alkyl, -(CH2)1-6OH, -OR3, -C(=O)ORa, -NR3Rb, -NRbC(=0)R3,- C(0)NR3Rb, -S(0)o-3R3, C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, CM8 alkyl which is unsubstituted or
substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is
unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11,
6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
X and Y are each independently
, or a bond;
Figure imgf000049_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring
C or C;
R4 is H, C1-6 alkyl, or halogenated d_6 alky;
R5 and R5' are each independently halogen, -NR3Rb, -C(0)NR3Rb, -(CH2)1-6OH, C1-6 alkyl, C1-6 halogenated alkyl, hydroxyl, C6-14 aryl, or C1-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, c6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R6 and R6' are each independently H, C1-6 alkyl, -(CH2)i-6OH, C2-6 alkenyl, or C2-6 alkynyl;
m, and n, combined are 1 , 2, 3 or 4;
p is 0, 1 , 2, 3 or 4;
q' is 0, 1 or 2;
q and r are each independently 0, 1 , 2, 3 or 4;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb,;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -
NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - 0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, - SO2NRaRb, -NRbSO2Ra, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -OR3, oxo, -NR3Rb, =NO-RC , -C(=O)ORa, -C(0)NR3Rb, -C(=O)OH, - C(=0)R3, -C(=N0Rc)R3, -C(=NRc)NR3Rb, -NRdC(=0)NR3Rb, -NRbC(=0)R3, - NRdC(=NRc)NR3Rb, -NRbC(=0)0R3, -0C(=0)NR3Rb, -0C(=0)R3, -0C(=0)0R3, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -S02NR3Rb, -NRbS02R3, - NRbSO2NRaRb, or -P(=O)ORaORb, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered
heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered
heterocycle-alkyl.
In another embodiment, the compounds of the present invention are represented by formula (IVA):
Figure imgf000051_0001
or pharmaceutically acceptable salts thereof, wherein:
R7 and R7' are each independently C^ alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by
R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl,
C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
m and n combined are 0, 1 , 2, 3 or 4; and the remainder of the variables are as described above for formula (NIA).
In another embodiment, the compounds of the present invention are represented by formula (VA):
Figure imgf000052_0001
(VA),
or pharmaceutically acceptable salts thereof, wherein the variables are as described above for formula (IVA). In another embodiment, the compounds of the present invention are represented by formula (V):
Figure imgf000052_0002
(V),
or pharmaceutically acceptable salts thereof, wherein the variables are as described above for formula (NIA).
In another embodiment, the compounds of the present invention are represented by formula (Vl):
Figure imgf000053_0001
(Vl),
or pharmaceutically acceptable salts thereof, wherein the variables are as described above for formula (V).
In another embodiment, the compounds of the present invention are represented by formula (VII) :
Figure imgf000053_0002
(VII)
or pharmaceutically acceptable salts thereof, wherein
R7 and R7' are each independently C^ alkyl which is unsubstituted or substituted one or more times by R10, C2-s alkenyl which is unsubstituted or substituted one or more times by R10, C2-s alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, d.^ alkyl, C2-12 alkenyl, c2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
and the remainder of the variables are as described above for formula (Vl).
In another embodiment, the compounds of the present invention are represented by formla (VIII):
Figure imgf000054_0001
(VIM)
or pharmaceutically acceptable salts thereof, wherein
C and C are each independently a 4-7 membered heterocycle;
R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, - NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -
OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(Oy3R3, -SO2NRaRb, - NRbSO2Ra, -NRbSO2NRaRb, -P(=O)ORaORb, C^ alkyl which is unsubstituted or substituted one or more times by R10, C2-β alkenyl which is unsubstituted or substituted one or more times by R10, C2-β alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12; R2 and R2' are each independently halogen, C1^0 alkyl, C1-6 halogenated
alkyl, -(CH2)1-6OH, -ORa, -C(=O)ORa, -NRaRb, -NRbC(=O)Ra,- C(O)NR3Rb, -S(O)0 3R3, C6-12 aryl, or 5-12 membered heteroaryl;
Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7- 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
X and Y are each independently
, or a bond;
Figure imgf000055_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R3 and R3' are each independently H, C1^8 alkyl which is unsubstituted or
substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is
unsubstituted or substituted one or more times by R10, C6.u aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently halogen, -NRaRb, -C(O)NRaRbj -(CH2)i-6OH, C1-6 alkyl, C1-6 halogenated alkyl, hydroxyl, C6.-|4 aryl, or d-6 alkoxy; wherein two occurrence of R5 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R5' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ;
R6 and R6' are each independently H, C1-6 alkyl, -(CH2)i-6OH, C2-6 alkenyl, or C2-6 alkynyl;
m, and n, are each independently 0, 1 , 2, 3 or 4;
q and r are each independently 0, 1 , 2, or 3;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=0)0R3, -OC(=O)NRaRb, -0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb,;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -
NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - 0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, - SO2NRaRb, -NRbSO2Ra, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R12 is halogen, -OR3, oxo, -NR3Rb, =NO-RC , -C(=O)ORa, -C(0)NR3Rb, -C(=O)OH, - C(=O)Ra, -C(=N0Rc)R3, -C(=NRc)NR3Rb, -NRdC(=0)NR3Rb, -NRbC(=0)R3, - NRdC(=NRc)NR3Rb, -NRbC(=0)0R3, -0C(=0)NR3Rb, -0C(=0)R3, -0C(=0)0R3, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -S02NR3Rb, -NRbS02R3, -
NRbSO2NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered
heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered
heterocycle-alkyl;
Figure imgf000056_0001
is selected from the group consisting of:
Figure imgf000057_0001
wherein D is a 5-7 cycloalkyl which is unsubstituted or substituted by (Ri)ti, a 5-7 membered heterocycle which is unsubstituted or substituted by (R1J11 or a 5-7 membered heteroaryl which is unsubstituted or substituted by (R1)I1; p is 0, 1 , 2, 3 or 4; and
t1 + t2 = p.
In another embodiment, the compounds of the present invention are represented by formula (IX):
Figure imgf000058_0001
(IX),
or pharmaceutically acceptable salts thereof, wherein the variabes are as described above for formula (VIII).
In another embodiment, the compounds of the present invention are represented by formula (X) :
Figure imgf000058_0002
(X),
or pharmaceutically acceptable salts thereof, wherein the variabes are as described above for formula (VIII).
In another embodiment, the compounds of the present invention are represented by formula (Xl):
Figure imgf000059_0001
(Xl)
or pharmaceutically acceptable salts thereof, wherein :
R7 and R7' are each independently C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and the remainder of the variables are as described above for formula (VIII).
According to a 1st embodiment, each A in formula (NIA), (NIA'), (NB), (IVA),
(VA) and (V), is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or triazolyl; and wherein each A is independently substituted with (R1Jp.
According to a further embodiment, each A in formula (NIA), (HIA'), (NB),
(IVA), (VA) and (V), is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or triazolyl; and wherein each A is independently substituted with (Ri)p.
According to another further embodiment, each A in formula (NIA), (NIA'), (NB), (IVA), (VA) and (V), independently cyclopropyl, cyclohexyl, phenyl, or naphthalene, wherein each A is independently substituted with (R1Jp.
According to another further embodiment, each A in formula (INA), (NIA'), (NB), (IVA), (VA) and (V), is independently selected from the group consisting of:
Figure imgf000060_0001
Figure imgf000060_0002
wherein t1 + t2 = p.
According to another further embodiment, each A in formula (NIA), (NIA'), (NB), (IVA), (VA) and (V), is:
Figure imgf000061_0001
According to another further embodiment, each A in formula (NIA), (HIA'), (NB), (IVA), (VA) and (V), is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl,
dihydrobenzodioxinyl, thienofuranyl, thienothienyl, quinolinyl, or triazolyl, each of which is substituted with (R1Jp.
According to another further embodiment, each A in formula (NIA), (NIA'),
(NB), (IVA), (VA) and (V), is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, quinolinyl, or triazolyl, each of which is substituted with (R1Jp.
According to another further embodiment, each A in formula (NIA), (NIA'), (NB), (IVA), (VA) and (V), is independently selected from the group consisting of:
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000063_0002
; and
t1 + t2 = p
According to another further embodiment, each A in formula (NIA), (HIA'), (NB), (IVA), (VA) and (V), is independently selected from the group consisting of:
Figure imgf000064_0001
Figure imgf000065_0001
and t1 + t2 = p.
According to another furhter embodiment, each A in formula (NIA), (HIA'), (NB), (IVA), (VA), (V), (VIII), (IX), (X) and (Xl), is independently selected from the group consisting of:
Figure imgf000065_0002
Figure imgf000066_0001
(A5a).
According to another further embodiment, each A in formula (NIA), (HIA'), (NB), (IVA), (VA) and (V), is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (R1Jp.
The remainder of the variables for any embodiments described in the 1 st embodiment are as described in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (VIII), (IX), (X) and (Xl).
According to a 2nd embodiment, B and B' in formulas (INA), (NIA'), (NB), (IVA), (VA) and (V), are independently absent, C1-6 alkyl or C2-6 alkynyl; and the remainder of the variables are as described in formula (NIA), (NIA'), (NB), (IVA), (VA) and (V) or any embodiments in the 1 st embodiment described above.
According to a 3rd embodiment, B and B' in formulas (INA), (NIA'), (NB),
(IVA), (VA) and (V), are independently absent, -(CH2J2- or -(C≡C)-; and the remainder of the variables are as described in formula (NIA), (NIA'), (NB), (IVA), (VA) and (V) or in any embodiments in the 1 st embodiment described above.
According to a 4th embodiment, B and B' in formulas (INA), (NIA'), (NB), (IVA), (VA) and (V), are independently absent or -(C≡C)-; and the remainder of the variables are as described in formula (INA), (NIA'), (NB), (IVA), (VA) and (V) or in any embodiments in the 1 st embodiment described above..
According to a 5th embodiment, for formula (NIA), (INA'), (NB), (IVA), (VA),
(V), (Vl), (VII), (VIII), (IX), (X) and (Xl), the distance between C and C is between about 16 A to about 24 A in length. The remainder of the variables are as described in formulas (NIA), (INA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) or in the 1 st to 4th embodiments described above. According to a 6th embodiment,
Figure imgf000067_0001
in formulas
(NIA), (NIA'), (NB), (IVA), (VA) and (V), is selected from the group consisting of:
Figure imgf000067_0002
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000069_0002
Figure imgf000070_0001
Figure imgf000070_0002
Figure imgf000070_0003
Figure imgf000071_0001
Figure imgf000071_0002
Figure imgf000071_0003
Figure imgf000072_0001
Figure imgf000072_0002
t1 + t2 = p; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
In further embodiment of the r th embodiment,
Figure imgf000072_0003
in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), is selected from the group consisting of:
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000075_0002
Figure imgf000076_0001
Figure imgf000076_0002
Figure imgf000076_0003
Figure imgf000077_0001
Figure imgf000077_0002
Figure imgf000077_0003
Figure imgf000078_0001
Figure imgf000078_0003
,- and t1 + t2 = p; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
According to a 7th embodiment,
Figure imgf000078_0002
formulas
(NIA), (NIA'), (NB), (IVA), (VA) and (V), is selected from the group consisting of:
Figure imgf000079_0001
Figure imgf000079_0002
Figure imgf000079_0003
t1 + t2 = p; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
According to a 8th embodiment,
Figure imgf000079_0004
in formulas
(NIA), (NIA'), (NB), (IVA), (VA) and (V), is selected from the group consisting of:
Figure imgf000080_0001
t1 + t2 = p; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
In a further embodiments of the 8th embodiment,
in formulas (NIA), (INA'), (NB), (IVA), (VA) and (V), is
Figure imgf000080_0002
t1 + t2 = p; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
Accroding to a further embodiment of the 8th embodiment,
in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), is
Figure imgf000080_0003
the remainder of the variables are as described above in formulas (INA), (INA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above. Accroding to another further embodiment of the 8th embodiment,
Figure imgf000081_0005
in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), is
Figure imgf000081_0006
; t1 + t2 = p; and the remainder of the variables are as described above in formulas formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
Accroding to another further embodiment of the 8th
embodiment
Figure imgf000081_0001
, in formulas (NIA), (NIA'), (NB), (IVA),
(VA) and (V), is
Figure imgf000081_0002
; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
Accroding to a 9th embodiment,
Figure imgf000081_0003
in formulas _
(NIA), (NIA'), (NB), (IVA), (VA) and (V), is
Figure imgf000081_0004
(A1 a); and the remainder of the variables are as described above in formulas (NIA), (HIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
Accroding to a 10 embodiment,
Figure imgf000082_0001
in formulas
(NIA), (NIA'), (NB), (IVA), (VA) and (V), is
Figure imgf000082_0002
(A1 b); and the remainder of the variables are as described above in formulas formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
Accroding to a 11 embodiment,
Figure imgf000082_0003
in formulas
(NIA), (NIA'), (NB), (IVA), (VA) and (V), is
Figure imgf000082_0004
(A1c); and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
Accroding to a 12 embodiment,
Figure imgf000083_0001
in formulas
(NIA), (NIA'), (NB), (IVA), (VA) and (V), is
Figure imgf000083_0002
(Ai d); and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA) and (V), or in the 1 st to 5th embodiment described above.
According to a 13th embodiment, R1 in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl),is halogen, C1-4alkyl which is unsubstituted or substituted one or more times by R10, -C(=O)ORa, -C(O)NRaRb, hydroxyl, cyano, or C1-3 alkoxy; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), or in the 1 st to 12th embodiment described above.
According to a 14th embodiment, R1 in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), is chloro, fluoro, bromo, methyl, ethyl, propyl, butyl, -CH2OH, difluoromethyl, trifluoromethyl, hydroxyl, cyano, or methoxy; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), or in the 1 st to 12th embodiment described above.
According to a 15th embodiment, each R2' in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), is independently fluoro or methyl. Alternatively, q in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), is 0. The remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), or in the 1 st to 14th embodiment described above.
According to a 16st embodiment, each R2 in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), is independently fluoro or methyl. Alternatively, r in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), is 0. The remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), or in the 1 st to 15th embodiment described above.
According to a 17th embodiment, R6 and R6' in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), are H or methyl; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), or in the 1 st to 16th
embodiment described above.
According to a 18th embodiment, R5 and R5' in formulas (INA), (INA'), (IVA) and (VA), (NB), (VIII), (IX), (X) and (Xl), are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, -NRaNb, t-butoxy-, or hydroxyl or two R5 groups together with the atoms
to which they are attached form fused cyclopropyl, spiro cyclopropyl or
Figure imgf000084_0001
, two R5' groups together with the atoms to which they are attached form fused
cyclopropyl, spiro cyclopropyl or
Figure imgf000084_0002
. In a further embodiment, R5 and R5' in formulas (INA), (INA'), (IVA) and (VA), are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, -NRaNb, or t-butoxy-,; or two R5 groups together with the atoms to which
they are attached form fused cyclopropyl, spiro cyclopropyl; or
Figure imgf000084_0003
, two R5' groups together with the atoms to which they are attached form fused
cyclopropyl, spiro cyclopropyl or
Figure imgf000084_0004
; and the remainder of the variables are as described above in formulas (INA), (INA'), (NB), (IVA), (VA), (VIII), (IX), (X) and (Xl), or in the 1 st to 17th embodiment described above.
According to a 19th embodiment, R5 and R5' in formulas (INA), (INA'), (NB), (IVA), (VA), (VIII), (IX), (X) and (Xl), each independently methyl, methoxy, ethyl, di-fluoromethyl, trifluoromethyl, or two R5 groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl or two R5' groups together with the atoms to which they are attached form fused
cyclopropyl or spiro cyclopropyl; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (VIII), (IX), (X) and (Xl), or in the 1st to 17th embodiment described above. In a further embodiment, R5 and R5' in formulas (NIA), (NIA'), (IVA) and (VA), each independently methyl, ethyl, di-fluoromethyl, trifluoromethyl, or two R5 groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl or two R5' groups together with the atoms to which they are attached form fused
cyclopropyl or spiro cyclopropyl; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (VIII), (IX), (X) and (Xl), or in the 1st to 17th embodiment described above.
According to a 19th embodiment, R5 and R5' in formulas (INA), (INA'), (NB), (IVA), (VA), (VIII), (IX), (X) and (Xl), and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (VIII), (IX), (X) and (Xl), or in the 1st to 17th embodiment described above.
According to a 20th embodiment, m and n in formulas (NIA), (NIA'), (NB), (IVA), (VIII) and (IX), are 1 or 2; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VIII) and (IX) or in the 1 st to 17th embodiment described above. In a further embodiment, m and n are 1.
According to a 21st embodiment, X and Y in formulas (INA), (NIA'), (NB),
(V), (Vl), (VIII), (IX) and (X),
Figure imgf000085_0001
.
According to a 22nd embodiment, R3 and R3' in formulas (INA), (INA'), (NB), (V), (Vl), (VIII), (IX) and (X), are each independently, C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-s alkenyl which is unsubstituted or substituted one or more times by R10, C2-s alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; and the remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (V), (Vl), (VIII), (IX) and (X) or in the 1 st to 21st embodiments described above. In a further embodiment, R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is
unsubstituted or substituted one or more times by R11, benzyl which is
unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12. The remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (V), (Vl), (VIII), (IX) and (X) or in the 1 st to 21 st embodiments described above.
In another further embodiment, R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10. The remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (V), (Vl), (VIII), (IX) and (X) or in the 1 st to 21st embodiments described above.
In a 23rd embodiment, R3 and R3' in formulas (NIA), (INA'), (NB), (V), (Vl),
(VIII), (IX) and (X), are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-, which are unsubstituted or substituted one or more times by R10. The remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (V), (Vl), (VIII), (IX) and (X) or in the 1st to 21 st embodiments described above.
In a 24th embodiment, R3 and R3' in formulas (NIA), (INA'), (NB), (V), (Vl), (VIII), (IX) and (X), are each independently phenyl which is unsubstituted or substituted one or more times by R11. The remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (V), (Vl), (VIII), (IX) and (X) or in the 1st to 21 st embodiments described above.
In a 25th embodiment, R3 and R3' in formulas (NIA), (INA'), (NB), (V), (Vl), (VIII), (IX) and (X), are each independently benzyl which is unsubstituted or substituted one or more times by R11. The remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (V), (Vl), (VIII), (IX) and (X) or in the 1st to 21 st embodiments described above.
In a 26th embodiment, R10 in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), is halogen, -ORa, oxo, -NRaRb, =NO-RC , - C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, - NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra -Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. The remainder of the variables are as described above in formulas (INA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) or in the 1st to 25th embodiments described above.
In a further embodiment, R10 in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), -NRaRb, -
NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or - NRbSO2NRaRb. The remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) or in the 1 st to 25th embodiments described above.
In another further embodiment, R10
is -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, or -NRbSO2Ra. The remainder of the variables are as described above in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) or in the 1 st to 25th
embodiments described above.
In a 27th embodiment, Ra-Rd in formulas (INA), (INA'), (NB), (IVA), (VA), (V),
(Vl), (VII), (VIII), (IX), (X) and (Xl), are each independently H, d-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl. The remainder of the variables are as described above in formulas (INA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) or in the 1st to 26th embodiments described above.
In a further embodiment, Ra and Rc in formulas (INA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl), are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and Rb, and Rd. are each independently H or C^ alkyl. The remainder of the variables are as described above in formulas (NIA), (HIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) or in the 1 st to 26th
embodiments described above.
5 In a 28th embodiment, Ra-Rd in formulas (NIA), (NIA'), (NB), (IVA), (VA), (V),
(Vl), (VII), (VIII), (IX), (X) and (Xl), Ra-Rd are each independently H or C1-3 alkyl. The remainder of the variables are as described above in formulas (NIA), (INA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) or in the 1 st to 26th embodiments described above.
10 In a 29th embodiment, R8 and R8' in formulas (IVA), (VA), (VII) and (Xl), are
R8 and R8' are each independently -NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, wherein Ra- Rb are each independently H, d-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl. The remainder of the variables are as described in formulas
15 (IVA), (VA), (VII) and (Xl) or in the 1st to 28th embodiments described above.
In a 30th embodiment, R8 and R8' in formulas (IVA), (VA), (VII) and (Xl), are R8 and R8' are each independently -NRbC(=O)ORa, wherein Ra-Rb are each independently H, d-6 alkyl, phenyl, tetrahydrofuran, or benzyl. The remainder of the variables are as described in formulas (IVA), (VA), (VII) and (Xl) or in the 1 st to
20 28th embodiments described above.
In a 31 st embodiment, R7 and R7' in formulas (IVA), (VA), (VII) and (Xl), are each independently phenyl which is unsubstituted or substituted one or more times by R11. The remainder of the variables are as described in formulas (IVA), (VA), (VII) and (Xl) or in the 1 st to 30th embodiments described above.
25 In a 32nd embodiment, R7 and R7' in formulas (IVA), (VA), (VII) and (Xl), are each R7 and R7' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10. The remainder of the variables are as described in formulas (IVA), (VA), (VII) and (Xl) or in the 1 st to 30th embodiments described above.
30 In a further embodiment, R7 and R7' are each independently methyl, ethyl, propyl, isopropyl, methoxyisopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2- methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. The remainder of the variables are as described in formulas (IVA), (VA), (VII) and (Xl) or in the 1 st to 30th embodiments described above. In a 33rd embodiment, for formulas (IVA), (VA), (VII) and (Xl), R7 and R8 or Rr and R8. together with the carbon to which they are attached are each independently:
Figure imgf000089_0001
The remainder of the variables are as described in formulas (IVA), (VA), (VII) and (Xl) or in the 1 st to 28th embodiments described above.
In another aspect, the present invention provides compounds described in the following embodiments.
In one embodiment, the compounds of the present invention is
represented by formula (I) :
Figure imgf000089_0002
(I)
or pharmaceutically acceptable salts thereof, wherein,
A' is C2-A alkenyl, C2-5 alkynyl, C3-10 cycloalkyl, C6-14 aryl, 4-12 membered heterocycle or 5-12 membered heteroaryl; C and C are each independently a 4-7 membered heterocycle;
R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb,
C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb,
NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-
3Ra, -SO2NRaRb, -NRbSO2Ra, -NRbS02NR3Rb, -P(=0)0R30Rb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7- 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2^ and R2 are each independently halogen, C1-10 alkyl, C1-6 halogenated alkyl, -(CH2)1-6OH, -OR3, -C(=O)ORa, -NRaRb, -NRbC(=O)Ra,- C(O)NR3Rb, -S(O)0 3R3, C6-I2 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, C1^8 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R5 and R5' are each independently H, halogen, -NRaRb, -C(O)NRaRb> -(CH2)1-6OH, C1.
6 alkyl, C1-6 halogenated alkyl, hydroxyl, C6-14 aryl, or C^ alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; R6 and R6' are each independently H, C1-6 alkyl, -(CH2)1-6OH, C2-6 alkenyl, or C2-6 alkynyl;
X and Y are each independently
or a bond;
Figure imgf000091_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R4 is H, C1-6 alkyl, or halogenated C1-6 alky; m, and n, combined are 1 , 2, 3 or 4; p is O, 1 , 2, 3 or 4; q and r are each independently 0, 1 , 2, 3 or 4;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -
C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb,;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)0R3, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, - SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -OR3, oxo, -NR3Rb, =NO-RC , -C(=0)0R3, -C(0)NR3Rb, -C(=O)OH, - C(=O)Ra, -C(=N0Rc)R3, -C(=NRc)NR3Rb, -NRdC(=0)NR3Rb, -NRbC(=0)R3, - NRdC(=NRc)NR3Rb, -NRbC(=0)0R3, -0C(=0)NR3Rb, -0C(=0)R3, -0C(=0)0R3, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -S02NR3Rb, -NRbS02R3, - NRbSO2NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
wherein
Figure imgf000092_0001
is not,
Figure imgf000092_0004
or
Figure imgf000092_0003
, optionally substituted ethyl, phenyl, oxazolyl, furanyl, pyridyl, bicycle[2,2,2]octanyl, isoquinolinyl, and naphthyl. In another embodiment, the compounds of the present invention are represented by formula (II):
Figure imgf000092_0002
or pharmaceutically acceptable salts thereof, wherein the variables are as described above in formula (I). In another embodiment, the compounds of the present invention are represented by formula
Figure imgf000093_0001
or pharmaceutically acceptable salts thereof, wherein two of R1 on adjacent carbons can be taken together with the carbons to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R10 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 , wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl; R2 and R2' are each independently H, halogen, C1-6 alkyl, or C^ alkoxy;
X and Y are each independently , or a bond;
Figure imgf000093_0002
R3 and R3' are each independently H, C1-12 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently H, halogen, C1-4 alkyl, hydroxyl, C1-4 alkoxy, or C-ι-4 halogenated alkyl;
R6 and R6' are each independently H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl; m, n, and p are each independently 0, 1 , 2, 3 or 4; q and r are each independently 0, 1 , 2, or 3. R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra,
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R12 is halogen, -0Ra, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In another embodiment, the compounds of the present invention are represented by formula (IV) :
Figure imgf000095_0001
(IV)
or pharmaceutically acceptable salts thereof; wherein
R7 and R7' are each independently C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl,
C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The remainder of the variables in formula (IV) are as described above for formula
In a first embodiment of the aspect, A' in formulas (I) and (II) is cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxadiazolyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or triazolyl; each of which is substituted with (R1Jp. The remainder of the variables are as described above for formula (I) or (II).
In a further embodiment, A' in formulas (I) and (II) is thienyl, pyrimidyl, pyridazinyl, thiazolyl, N-methylimidazolyl, piperazinyl, thiadiazolyl, 1 ,4- diazepanyl or triazole. The remainder of the variables are as described above for formula (I) or (II).
In a further embodiment, A' in formulas (I) and (II) is thienyl. The remainder of the variables are as described above for formula (I) or (II).
In a second embodiment of the aspect, X and Y in formulas (I), (II) and are
Figure imgf000097_0001
. The remainder of the variables are as described above for formula (I), (II) and (III) or in the first embodiment described above.
In a third embodiment, R5 and R5' in formulas (I), (II), (III) and (IV) are each independently H, halogen, methyl, ethyl, t-butoxy-, or hydroxyl. Alternatively, R5 and R5' are fluoro. In another alternative, R5 and R5' are H. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first or second embodiments described above.
In a fourth embodiment, R5 and R5' in formulas (I), (II), (III) and (IV) are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di- fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, -NRaNb, t-butoxy-, or hydroxyl; or two R5 groups together with the atoms to which they are attached
form fused cyclopropyl, spiro cyclopropyl or
Figure imgf000097_0002
and/or two R5' groups with the atoms to which they are attached form fused cyclopropyl, spiro cyclopropyl or
Figure imgf000097_0003
. The remainder of variables are as described in formulas (I), (II), and (IV) or in the first or second embodiments described above.
In a further embodiment, R5 and R5' are each independently methyl, ethyl, methoxy, difluromethyl, trifluoromethyl, or two R5 groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl and/or two R5' groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first or second embodiments described above.
In a fifth embodiment, R5 and R5' in formulas (I), (II), (III) and (IV) are methyl. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first or second embodiments described above.
In a sixth embodiment, m and n in formulas (I), (II), (III) and (IV) are each independently 0, 1 , or 2. Alternatively, m and n are 2. In another alternative, m and n are 1. The remainder of variables are as described in formulas (I), (II), and (IV) or in the first to fifth embodiments described above. In a seventh embodiment, R6 are R6' in formulas (I), (II), (III) and (IV) are H or methyl. Alternatively, R6 are R6' in formulas (I), (II), (III) and (IV) are H. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to sixth embodiments described above.
In a eighth embodiment, R1 in formulas (I), (II), (III) and (IV) is halogen, C1-3 alkyl, hydroxyl, cyano, benzyloxy, or C1-3 alkoxy. In a further embodiment, R1 is chloro, fluoro, methyl, hydroxyl, benzyloxy, cyano, or methoxy. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to seventh embodiments described above.
In a ninth embodiment, p in formulas (I), (II), (III) and (IV) is 2.
Alternatively, p is 1. In another alternative, p is 0. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to eighth embodiments described above.
In a tenth embodiment, R2 and R2' in formulas (I), (II), (III) and (IV) are fluoro. Alternatively, R2 and R2' in formulas (I), (II), (III) and (IV) are H. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to ninth embodiments described above. In a further embodiment, R2 and R2' are fluoro and q and r are 1.
In a eleventh embodiment, R3 and R3' in formulas (I), (II), (III) and (IV) are each independently, C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-S alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to tenth embodiments described above.
In a further embodiment, R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to tenth embodiments described above.
In another further embodiment, R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to tenth embodiments described above.
In another further embodiment, R3 and R3' are each independently phenyl which is unsubstituted or substituted one or more times by R11. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to tenth embodiments described above.
In another further embodiment, R3 and R3' are each independently benzyl which is unsubstituted or substituted one or more times by R11.
In a twelfth embodiment, R3 and R3' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or
cyclohexyl(CH2)-, which are unsubstituted or substituted one or more times by R10. The remainder of variables are as described in formulas (I), (II), (III) and (IV) or in the first to tenth embodiments described above.
In a thirteenth embodiment, for formula (IV), R7 and R7' are each independently C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl;
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and the remainder of the variables are as described in formula (IV) above or in the first to twelfth embodiments described above.
In a fourteenth embodiment, R8 and R8' in formula (IV) are each independently -NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl. The remainder of the variables are as described in formula (IV) above or in the first to twelfth embodiments described above.
In a further embodiment, R8 and R8' are each independently -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, tetrahydrofuran, or benzyl. The remainder of the variables are as described in formula (IV) above or in the first to twelfth embodiments described above.
In a fifteenth embodiment, R7 and R7' in formula (IV) are each independently phenyl. The remainder of the variables are as described in formula (IV) above or in the first to fourteenth embodiments described above.
In a sixteenth embodiment, R7 and R7' in formula (IV) are each independently, C1-6 alkyl. The remainder of the variables are as described in formula (IV) above or in the first to fourteenth embodiments described above. In a further embodiment, R7 and R7' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. The remainder of the variables are as described in formula (IV) above or in the first to fourteenth embodiments described above.
In a seventeenth embodiment, for formula (IV), R7 and R8 or R7' and R8' together with the carbon to which they are attached are each independently:
Figure imgf000100_0001
The remainder of the variables are as described in formula (IV) above or in the first to twelfth embodiments described above. In a futher embodiment, for formulas (I), (II), (III), (IV), (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) and any foregoing embodiments, R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, - C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, or - P(=O)ORaORb, wherein Ra and Rc are each independtly H, d_12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl.
Alternatively, R10 is -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, d-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In another alternative, R10 is -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRbC(=O)ORa, or -NRbSO2Ra, wherein Ra,Rb, and Rd are each independently H, d-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In yet another alternative, R10 is halogen, -ORa, oxo, -C(=O)ORa, - C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, cyano, wherein Ra-Rb are each independently H, d_6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In a futher embodiment, for formulas (I), (II), (III), (IV), (NIA), (INA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) and any foregoing embodiments, R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, or - P(=O)ORaORb, C1-12 alkyl, C2-M alkenyl, C2-M alkynyl, C6-12 aryl, C7-1β aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra and Rc are each independtly H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl.
Alternatively, R11 is halogen, -0Ra, -NRaRb, -C(=O)ORa, -C(O)NRaRb, - C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, cyano, -SO2NRaRb, -NRbSO2Ra, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In another alternative, R11 is halogen, -ORa, -NRaRb, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, -OC(=O)NRaRb, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1. 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In yet another alternative, R11 is halogen, -ORa, -NRaRb, hydroxyl, cyano, C1-6 alkyl, wherein Ra-Rb are each independently H, C1-3 alkyl.
In a futher embodiment, for formulas (I), (II), (III), (IV), (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) and any foregoing embodiments, R12 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, - C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, or - P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra and Rc are each independtly H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl. Alternatively, R12 is halogen, -ORa, oxo, -NRaRb, -C(=O)ORa, -C(O)NRaRb, - C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, cyano, -SO2NRaRb, -NRbSO2Ra, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In another alternative, R12 is halogen, -ORa, oxo, -NRaRb, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRbC(=O)ORa, -OC(=O)NRaRb, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In yet another alternative, R12 is halogen, -ORa, oxo, -NRaRb, hydroxyl, cyano, C1-6 alkyl, wherein Ra-Rb are each independently H, C1 3 alkyl.
In a futher embodiment, for formulas (I), (II), (III), (IV), (NIA), (NIA'), (NB),
(IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) and any foregoing embodiments, Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
Alternatively, Ra and Rc are each independently H, C1-6 alkyl, C2-6 alkenyl,
C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or C1-3 alkyl.
In another alternative, Ra-Rd are each independently H or C1-3 alkyl.
In a further embodiment, for formulas (I), (II), (III), (IV), (NIA), (NIA'),
(NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) and any foregoing embodiments, the heterocyle in the groups (e.g., heterocycle and hetercycle- alkyl) represented by R3, R3', Ra-Rd, R7 and R7' are selected from the group consisting of morphonlinyl, morpholino, tetrahydrofuranyl, pyrrolidinyl, azepanyl, tetrahydropyranyl, oxazolinyl, piperazinyl and piperadinyl, each of which is optionally substituted with one or more times by halogen, C1-3 alkyl, halogenated C1-3 alkyl, oxo, hydroxyl, -C(=O)O-(C1-3 alkyl), C1-3 alkoxy, or halogenated C1-3 alkoxy. Alteratively, the heterocyle in the groups represented by R3, R3', Ra-Rd, R7 and R7' are selected from the group consisting of morphonlinyl, morpholino, tetrahydrofuranyl, pyrrolidinyl, azepanyl, tetrahydropyranyl and oxazolinyl, each of which is optionally substituted with one or more times by halogen, C1-3 alkyl, halogenated C1-3 alkyl, oxo, hydroxyl, -C(=O)O-(C1-3 alkyl), C1-3 alkoxy, or halogenated C1-3 alkoxy. In one embodiment, the heterocycle groups described above is optionally substituted with one or more times by oxo, hydroxyl or -C(=O)O-(C1-3 alkyl). Alternatively, the heterocycle groups described above is unsubstituted.
In a further embodiement, for formulas (I), (II), (III), (IV), (NIA), (NIA'), (NB), (IVA), (VA), (V), (Vl), (VII), (VIII), (IX), (X) and (Xl) and any foregoing embodiments, the heteroaryl in the groups (e.g., heteroaryl and heteroaralkyl) represented by R3, R3', Ra-Rd, R7 and R7' are selected from the group consisting of furanyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridyl, pyrroly, thienyl, triazolyl, imidazolyl, indolyl, quinolinyl and isoquinolinyl, each of which is optionally substituted with halogen, C1-3 alkyl, halogenated C1-3 alkyl, hydroxyl, -C(=O)O-(C1-3 alkyl), C1-3 alkoxy, or halogenated C1-3 alkoxy. Alternatively, the heteroaryl in the groups (e.g., heteroaryl and heteroaralkyl) represented by R3, R3', Ra-Rd, R7 and R7' are selected from the group consisting of indolyl and pyrimidinyl, each of which is optionally substituted one or more times by halogen, C1-3 alkyl, halogenated C1-3 alkyl, hydroxyl, -C(=O)O-(C1-3 alkyl), C1-3 alkoxy, or halogenated C1-3 alkoxy. In one embodiment, the heteroaryl groups described above is unsubstituted.
In another aspect, the compounds of the present invention are selected from compounds shown in Table 1 or pharmaceutically acceptable salts thereof. In certain embodiments, the variables used herein are as defined in the specific embodiments as shown in Table 1 .
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Figure imgf000203_0001
Figure imgf000204_0001
Figure imgf000205_0001
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
Figure imgf000219_0001
Figure imgf000220_0001
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Figure imgf000225_0001
Figure imgf000226_0001
Figure imgf000227_0001
Figure imgf000228_0001
Figure imgf000229_0001
Figure imgf000230_0001
Figure imgf000231_0001
Figure imgf000232_0001
Figure imgf000233_0001
Figure imgf000234_0001
Figure imgf000235_0001
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Figure imgf000240_0001
Figure imgf000241_0001
Figure imgf000242_0001
Figure imgf000243_0001
Figure imgf000244_0001
Figure imgf000245_0001
Figure imgf000246_0001
Figure imgf000247_0001
Figure imgf000248_0001
Figure imgf000249_0001
Figure imgf000250_0001
Figure imgf000251_0001
Figure imgf000252_0001
Figure imgf000253_0001
Figure imgf000254_0001
Figure imgf000255_0001
Figure imgf000256_0001
Figure imgf000257_0001
Figure imgf000258_0001
Figure imgf000259_0001
Figure imgf000260_0001
Figure imgf000261_0001
Figure imgf000262_0001
Figure imgf000263_0001
Figure imgf000264_0001
Figure imgf000265_0001
Figure imgf000266_0001
Figure imgf000267_0001
Figure imgf000268_0001
Figure imgf000269_0001
Figure imgf000270_0001
Figure imgf000271_0001
Compounds shown in Table 1 are representative compounds of the present invention and have exhibited inhibitory activities against Hepatitis C virus in a cell culture assay, except for compounds 22, 23, 35, 308, 309 and 333-335.
Compounds 22, 23, 35, 57, 308, and 309 are synthetic intermediates for inhibitory compounds of the present invention. Compounds 333-335 have not been tested for their inhibitory activities.
5 In one embodiment, the compounds of the present invention are selected from compounds 1 , 2, 4-14, 25, 26-34, 36-39, 41 -43, 48-67, 69-89, 91 -100, 102- 111 , 113-145, 147, 148-152, 154, 161 , 164, 166, 168, 170, 171 , 175, 177-181 , 189, 190-193, 195-198, 201 , 203-208, 211 -213, 216-218, 220, 225-228, 230-232, 234, 235, 236, 240, 241 , 243, 244, 246, 250, 254-257, 259, 265, 267, 272, 308, 334 and
10 335.
In another aspect, the compounds of the present invention are described in the following embodiments.
In embodiment 1 , a compound of formula (7):
Figure imgf000272_0001
wherein,
A is C2-4 alkenyl, C2.5 alkynyl, C3-10 cycloalkyl, C6-14 aryl, 4-12 membered 20 heterocycle or 5-12 membered heteroaryl;
B and B' are each independently a 4-7 membered heterocycle;
R1 and R1 ' are each independently H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
25
R2 and R2' are each independently H, halogen, C1-6 alkyl, or C^ alkoxy;
X and Y are each independently , or a bond;
Figure imgf000272_0002
R3 and R3' are each independently H, C1-12 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently H, halogen, C1-4 alkyl, hydroxyl, C1-4alkoxy, or C1-4 halogenated alkyl; R6 is H, halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, ~C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C1-6 halogenated alkyl or any two occurrence of R6 on adjacent carbons can be taken together with the carbons to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R10 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 , wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-
18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; m, n, and p are each independently 0, 1 , 2, 3 or 4; q and r are each independently 0, 1 , 2, or 3. R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -SO2NRaRb, -NRbSO2Ra, -
NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6.n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R12 is halogen, -0Ra, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; or a pharmaceutically acceptable salts thereof. In embodiment 1 a, a compound of formula (7):
Figure imgf000275_0001
wherein,
A is C2-4 alkenyl, C2-5 alkynyl, C3-10 cycloalkyl, C6-14 aryl, 4-12 membered heterocycle or 5-12 membered heteroaryl; B and B' are each independently a 4-7 membered heterocycle;
R1 and R1' are each independently H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
R2 and R2' are each independently H, halogen, C1-6 alkyl, or C1-6 aIkOXy;
X and Y are each independently — , or a bond;
R3 and R3' are each independently H, C1-12 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11,
6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; R4 is H, C1-6 alkyl, or halogenated d-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle; R5 and R5' are each independently H, halogen, C1-4 alkyl, hydroxyl, C1-4 alkoxy, or C1-4 halogenated alkyl;
R6 is H, halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C1-6 halogenated alkyl or any two occurrence of R6 on adjacent carbons can be taken together with the carbons to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R10 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 , wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; m, n, and p are each independently 0, 1 , 2, 3 or 4; q and r are each independently 0, 1 , 2, or 3.
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H,
C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; or a pharmaceutically acceptable salts thereof
wherein
Figure imgf000277_0001
is not,
Figure imgf000277_0003
, or
Figure imgf000277_0002
, optionally substituted ethyl, phenyl, oxazolyl, or furanyl.
In embodiment 2, a compound according to embodiment 1 , wherein said compound is of formula (II):
Figure imgf000278_0001
or pharmaceutically acceptable salts thereof; In embodiment 3, a compound according to any one of embodiments 1 and
2, wherein A is -(C≡C)-, phenyl, thiophene, pyridine, pyrimidine, or triazole.
In embodiment 4, a compound according to any one of embodiments 1 and 2, wherein A is phenyl, thiophene, pyridine, pyrimidine, or triazole.
In embodiment 5, a compound according to embodiment 3, wherein A is phenyl, or thiophene. In embodiment 6, a compound according to any one of embodiments 1 to 5, wherein wherein said compound is of formula (III):
Figure imgf000278_0002
or pharmaceutically acceptable salts thereof;
In embodiment 7, a compound according to any one of embodiments 1 to 6, wherein X and Y are
Figure imgf000279_0001
In embodiment 8, a compound according to any one of embodiments 1 to 7, wherein R5 and R5' in formulas (I), (II), (III), and (IV), are each independently H, Halogen, methyl, ethyl, t-butoxy-, or hydroxyl.
In embodiment 9, a compound according to embodiment 7, wherein R5 and R5' in formulas (I), (II), (III), and (IV), are H. In embodiment 10, a compound according to embodiment 7, wherein R5 and
R5' in formulas (I), (II), (III), and (IV), are fluoro.
In embodiment 11 , a compound according to any one of embodiments 1 to 10, wherein m, or n, are each independently 0, 1 , or 2.
In embodiment 12, a compound according to embodiment 10, wherein m, or n, are 2.
In embodiment 13, a compound according to embodiment 10, wherein m, or n, are 1.
In embodiment 14, a compound according to any one of embodiments 1 to
13, wherein R1 and R1' are H. In embodiment 15, a compound according to any one of embodiments 1 to
14, wherein R6 is halogen, C1-3 alkyl, hydroxyl, cyano, benzyloxy, or C1-3 alkoxy.
In embodiment 16, a compound according to embodiment 15, wherein R6 is chloro, fluoro, methyl, hydroxyl, benzyloxy, cyano, or methoxy.
In embodiment 17, a compound according to any one of embodiments 1 to 14, wherein R6 is H. In embodiment 18, a compound according to any one of embodiments 1 to 17, wherein p is 2. In embodiment 19, a compound according to any one of embodiments 1 to
17, wherein p is 1.
In embodiment 20. a compound according to any one of embodiments 1 to 19, wherein R2 and R2' are fluoro.
In embodiment 21 , a compound according to any one of embodiments 1 to 19, wherein R2 and R2' are H.
In embodiment 22, a compound according to any one of embodiments 1 to 21 , wherein q and r are 1.
In embodiment 23, a compound according to any one of embodiments 1 to 22, wherein R3 and R3' are each independently, C1-β alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12. In embodiment 24, a compound according to embodiment 23, wherein R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
In embodiment 25, a compound according to embodiment 23, wherein R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10.
In embodiment 26, a compound according to embodiment 23, wherein R3 and R3' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
In embodiment 27, a compound according to embodiment 23, wherein R3 and R3' are each independently benzyl which is unsubstituted or substituted one or more times by R11.
In embodiment 28, a compound according to any one of embodiments 1 to 22, wherein R3 and R3' are each independently, C1-12 alkyl which is unsubstituted or substituted one or more times by R10. In embodiment 29, a compound according to embodiment 28, wherein R3 and R3' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-, which are unsubstituted or substituted one or more times by R10.
In embodiment 30, a compound according to any one of embodiments 1 to 29, wherein R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, - C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -
S(O)0-3R3, -SO2NRaRb, -NRbS02R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, wherein Ra and Rc are each independtly H, d.^ alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl.
In embodiment 31 , a compound according to any one of embodiments 1 to 29, wherein R10 is -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, - NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In embodiment 32, a compound according to embodiment 31 , wherein R10 is -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, or -NRbSO2Ra, wherein R3, Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl. In embodiment 33, a compound according to any one of embodiments 1 to
29, wherein R10 is halogen, -ORa, oxo, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, cyano, wherein Ra-Rb are each independently H, d-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-S aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In embodiment 34, a compound according to any one of embodiments 1 to 29, wherein R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, - C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, - NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra,
-OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(Oy3Ra, -SO2NRaRb, - NRbSO2Ra, -NRbSO2NR3Rb, or -P(=O)ORaORb, d-12 alkyl, C1-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra and Rc are each independtly H, C-i-12 alkyl, C2.12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl.
In embodiment 35, a compound according to any one of embodiments 1 to 29, wherein R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, cyano, -SO2NRaRb, -NRbSO2Ra, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In embodiment 36, a compound according to embodiment 35, wherein R11 is halogen, -ORa, -NRaRb, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, - NRbC(=O)Ra, -NRbC(=O)ORa, -OC(=O)NRaRb, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In embodiment 37, a compound according to embodiment 35, wherein R11 is halogen, -ORa, -NRaRb, hydroxyl, cyano, C1-6 alkyl, wherein Ra-Rb are each independently H, C1-3 alkyl.
In embodiment 38, a compound according to any one of embodiments 1 to 29, wherein R12 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, - C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, - S(O)0-3Ra, -S02NRaRb, -NRbS02Ra, -NRbS02NR3Rb, or -P(=0)0R30Rb, CL12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein R3 and Rc are each independtly H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl. In embodiment 39, a compound according to any one of embodiments 1 to
29, wherein R12 is halogen, -OR3, oxo, -NR3Rb, -C(=0)0R3, -C(0)NR3Rb, - C(=O)OH, -C(=O)Ra, -NRdC(=0)NR3Rb, -NRbC(=0)R3, -NRbC(=0)0R3, - 0C(=0)NR3Rb, -OC(=O)Ra, -0C(=0)0R3, hydroxy I, cyano, -S02NR3Rb, - NRbSO2R3, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein R3, Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In embodiment 40, a compound according to embodiment 39 wherein R12 is halogen, -OR3, oxo, -NR3Rb, -C(0)NR3Rb, -C(=O)OH, -C(=O)Ra, - NRdC(=0)NR3Rb, -NRbC(=0)R3, -NRbC(=0)0R3, -0C(=0)NR3Rb, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein R3, Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In embodiment 41 , a compound according to embodiment 39, wherein R12 is halogen, -OR3, oxo, -NR3Rb, hydroxyl, cyano, C1-6 alkyl, wherein R3-Rb are each independently H, C1-3 alkyl.
In embodiment 42, a compound according to any one of embodiments 1 to 22, wherein wherein said compound is of formula (IV):
Figure imgf000285_0001
or pharmaceutically acceptable salts thereof; wherein
R7 and R7' are each independently C1-β alkyl, C2-8 alkenyl, C2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl; and
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -
NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In embodiment 43, a compound according to embodiment 42, wherein R8 and R8' are each independently -NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In embodiment 44, a compound according to embodiment 43, wherein R8 and R8' in formulas (IV), are each independently -NRbC(=O)ORa, wherein Ra-
Rb are each independently H, C1-6 alkyl, phenyl, tetrahydrofuran, or benzyl. In embodiment 45, a compound according to any one of embodiments 42 to 44, wherein R7 and R7' are each independently phenyl.
In embodiment 46, a compound according to any one of embodiments 42 to 44, wherein R7 and R7' are each independently, C1-6 alkyl.
In embodiment 47, a compound according to embodiment 46, wherein R7 and R7' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
In embodiment 48, a compound selected from:
Figure imgf000286_0001
Figure imgf000287_0001
Figure imgf000288_0001
Figure imgf000289_0001
Figure imgf000290_0001
or a pharmaceutically acceptable salt.
In embodiment 49, a compound according to any one of embodiments 1 to 48, for treating or preventing a Hepatitis C viral infection. In embodiment 50, a pharmaceutical composition comprising at least one compound according to any one of claims 1 to 48 and at least one pharmaceutically acceptable carrier or excipient. In embodiment 51 , a pharmaceutical combination comprising at least one compound according to any one of embodiments 1 to 48 and at least one additional agent.
In embodiment 52, the pharmaceutical combination according to embodiment 51 , wherein said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
In embodiment 53, the pharmaceutical combination according to embodiment 51 , wherein said at least one additional agent is selected from ribavirin and interferon-α. In embodiment 54, the pharmaceutical combination according to any one of embodiments 51 to 54, wherein said compound and said additional agent are in dosage unit forms suitable for sequential administration.
In embodiment 55, the pharmaceutical combination according to any one of embodiments 51 to 54, wherein said compound and said additional agent are in dosage unit forms suitable for simultaneous administration.
In embodiment 56, the use of a compound according to any one of embodiments 1 to 48 for treating an Hepatitis C viral infection in a human.
In embodiment 57, the use according to embodiment 56, further comprising administering at least one additional agent.
In embodiment 58, the use according to embodiment 57 wherein said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
In embodiment 59. the use according to embodiment 57, wherein said at least one additional agent is selected from ribavirin and interferon-α.
In embodiment 60, the use of a compound according to any one of embodiments 1 to 48 for the manufacture of a medicament.
In embodiment 61 , a pharmaceutical formulation comprising at least one compound as defined in anyone of embodiments 1 to 48 and at least one pharmaceutically acceptable carrier or excipient.
In embodiment 62, compounds of the present invention are represented by formula (IA):
Figure imgf000292_0001
or pharmaceutically acceptable salts thereof, wherein each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl; B and B' are each independently absent, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl; wherein B and B' are not both absent when q is 1 ;
C and C are each independently a 4-7 membered heterocycle; R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb,
NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, - S(O)0-3Ra, -SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, -P(=O)ORaORb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5- 7 membered heterocycle which is unsubstituted or substituted one or more times by R12; Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; R2' and R2 are independently halogen, C1-10 alkyl, C1-6 halogenated alkyl, -(CH2)1-6OH, -OR3, -C(=O)ORa, -NR3Rb, -NRbC(=0)R3,- C(O)NR3Rb, -S(0)o-3R3, C6-12 aryl, or 5-12 membered heteroaryl; R3 and R3' are each independently H, C1-6 alkyl, -(CH2V6OH, C2-6 alkenyl, or
C2-6 alkynyl;
R4 and R4' are each independently halogen, -NR3Rb, -C(0)NR3Rb, -(CH2V 60H, d_6 alkyl, d_6 halogenated alkyl, hydroxyl, C6-14 aryl, or C1 -6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a d_6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ;
X and Y are each independently
.-'
Figure imgf000294_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R5 and R5' are each independently H, C1-18 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11,
C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R6 is H, C1-6 alkyl, or halogenated C1-6 alkyl; m, and n, are each independently 0, 1 , 2, 3 or 4; p is 0, 1 , 2, 3 or 4; q is 1 or 2; each s is independently 0, 1 , 2, 3 or 4; R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, - C(=O)OH, -C(=0)R3, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, - NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0- 3Ra, -SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, or -P(=O)ORaORb,;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb,
NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - 0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, - SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, C^ alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R 12 is halogen, -OR3, oxo, -NR3Rb, =NO-RC , -C(=0)0R3, - C(O)NR3Rb, -C(=O)OH, -C(=O)Ra, -C(=N0Rc)R3, -C(=NRc)NR3Rb, - NRdC(=0)NR3Rb, -NRbC(=0)R3, -NRdC(=NRc)NR3Rb, -NRbC(=0)0R3, - 0C(=0)NR3Rb, -0C(=0)R3, -0C(=0)0R3, hydroxyl, nitro, azido, cyano, - S(OV3R3, -SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. In embodiment 63, the compounds of the present invention are represented by formula (HA):
Figure imgf000295_0001
or a pharmaceutically acceptable salt thereof.
In embodimnent 64, the compounds of the present invention are represented by formula (NIA):
Figure imgf000296_0001
or a pharmaceutically acceptable salt thereof, wherein each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl;
B and B' are each independently absent, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(Oy3R3, -
SO2NRaRb, -NRbSO2Ra, -NRbS02NR3Rb, -P(=0)0R30Rb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12; Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2' and R2 are each independently halogen, C1-10 alkyl, C1-6 halogenated alkyl, -(CH2)1-6OH, -0Ra, -C(=O)ORa,
NRaRb, -NRbC(=O)Ra,-C(O)NRaRb, -S(O)0-3Ra, C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, C1-6 alkyl, -(CH2V6OH, C2-6 alkenyl, or
C2-6 alkynyl;
R4 and R4' are each independently halogen, -C(O)NRaRb> -(CH2V6OH, C1-6 alkyl, C1-6 halogenated alkyl, C6-14 aryl, or C1-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
X and Y are each independently , or a bond;
Figure imgf000297_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R5 and R5' are each independently H, C1-18 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R6 is H, C1-6 alkyl, or halogenated C1-6 alkyl; m, and n, combined are 1 , 2, 3 or 4; p is 0, 1 , 2, 3 or 4; q is 0, 1 or 2; each s is independently 0, 1 , 2, 3 or 4;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -
C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -
NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -
S(0)o-3Ra, -SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb,;
R11 is halogen, -OR3, -NR3Rb, -C(=0)0R3, -C(0)NR3Rb, -C(=O)OH, -C(=O)Ra, -
C(=N0Rc)R3, -C(=NRc)NR3Rb, -NRdC(=0)NR3Rb,
NRbC(=0)R3, -NRdC(=NRc)NR3Rb, -NRbC(=0)0R3, -0C(=0)NR3Rb, -
0C(=0)R3, -0C(=0)0R3, hydroxyl, nitro, azido, cyano, -S(Oy3R3, - SO2NRaRb, -NRbSO2Ra, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
>12 is halogen, -OR3, oxo, -NR3Rb, =NO-RC , -C(=0)0R3, - C(O)NR3Rb, -C(=O)OH, -C(=O)Ra, -C(=N0Rc)R3, -C(=NRc)NR3Rb, - NRdC(=0)NR3Rb, -NRbC(=0)R3, -NRdC(=NRc)NR3Rb, -NRbC(=0)0R3, - 0C(=0)NR3Rb, -OC(=O)Ra, -0C(=0)0R3, hydroxyl, nitro, azido, cyano, - S(O)0-3Ra, -SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. In embodiment 65, the compounds of the present invention are represented by formula (HIB):
Figure imgf000299_0001
or a pharmaceutically acceptable salt thereof, wherein each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl; B and B' are each independently absent, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
C and C are each independently a 4-7 membered heterocycle;
R1 is halogen, -OR3, -NR3Rb, -C(=0)0R3, -C(0)NR3Rb,
C(=O)OH, -C(=0)R3, -C(=N0Rc)R3, -C(=NRc)NR3Rb, NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, - S(O)0-3Ra, -SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, -P(=O)ORaORb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5- 7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2' and R2 are each independently halogen, C1-10 alkyl, C1-6 halogenated alkyl, -(CH2)1-6OH, -ORa, -C(=O)ORa, -NRaRb, -NRbC(=O)Ra,- C(O)NR3Rb, -S(0)o-3Ra, C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, C1-6 alkyl, -(CH2)i-6θH, C2-6 alkenyl, or C2-6 alkynyl; R4 and R4' are each independently halogen, -NRaRb, -C(O)NRaRb, -(CH2)i-
6OH, C1-6 alkyl, C1-6 halogenated alkyl, hydroxyl, C6-14 aryl, or C1-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by
R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
X and Y are each independently , or a b bon dd;
Figure imgf000301_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R5 and R5' are each independently H, C1-1S alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; R6 is H, C1-6 alkyl, or halogenated C1-6 alky; m, and n, combined are 1 , 2, 3 or 4; p is 0, 1 , 2, 3 or 4; q is 0, 1 or 2; R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -
C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -
NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -
OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, - S(O)0-3Ra, -SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, or -P(=O)ORaORb,;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb,
NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - 0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(Oy3Ra, -
SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -OR3, oxo, -NR3Rb, =NO-RC , -C(=O)ORa, - C(O)NR3Rb, -C(=O)OH, -C(=0)R3, -C(=N0Rc)R3, -C(=NRc)NR3Rb, - NRdC(=0)NR3Rb, -NRbC(=0)R3, -NRdC(=NRc)NR3Rb, -NRbC(=0)0R3, - 0C(=0)NR3Rb, -OC(=O)Ra, -0C(=0)0R3, hydroxyl, nitro, azido, cyano, - S(O)0-3R3, -SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. In embodiment 66, the compound according to any one of embodiments 62 herein
each A is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxine, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or triazolyl; and wherein each A is independently substituted with (R1Jp. In embodiment 67, the compound according to embodiment 66, wherein each A is independently cyclopropyl, cyclohexyl, phenyl, or naphthalene, wherein each A is independently substituted with (R1Jp.
In embodiment 68, The compound according to embodiment 67 wherein each A is independently selected from the group consisting of:
Figure imgf000303_0001
t1 + t2 = p.
In embodiment 69, the compound according to embodiment 68, wherein A is:
Figure imgf000303_0002
In embodiment 70. the compound according to embodiment 66, wherein each A is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, quinolinyl, or triazolyl. In embodiment 71 , the compound according to embodiment 71 , wherein each A is independently selected from the group consisting of:
Figure imgf000305_0001
Figure imgf000306_0001
and
t1 + t2 = p.
In embodiment 72, the compound according to any one of embodiments 62-65, wherein each A is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (Ri)p.
In embodiment 73, the compound according to any one of embodiments 62 to 72, wherein B and B' are independently absent, C1-6 alkyl or C2-6 alkynyl. In embodiment 74, the compound according to embodiment 73, wherein B and B' are independently absent, -(CH2)2- or -(C≡C)-. In embodiment 75, The compound according to embodiment 74, wherein B and B' are independently absent or -(C≡C)-.
In embodiment 76, The compound according to any one of embodiments 62 to 75, wherein the distance between C and C is between about 16 A and about 24 A in length.
In embodiment 77, the compound according to any one of embodiments 62
to 76, wherein
Figure imgf000307_0001
is selected from the group consisting of:
Figure imgf000307_0002
Figure imgf000308_0001
Figure imgf000309_0001
Figure imgf000310_0001
Figure imgf000310_0002
Figure imgf000311_0001
Figure imgf000311_0002
Figure imgf000311_0003
Figure imgf000312_0001
Figure imgf000312_0002
Figure imgf000312_0003
Figure imgf000313_0001
Figure imgf000313_0003
and t1 + t2 = p.
mbodiment 78, The compound according to embodiment 77, wherein
Figure imgf000313_0002
is selected from the group consisting of:
Figure imgf000314_0001
Figure imgf000314_0002
Figure imgf000314_0003
t1 + t2 = p.
In embodiment 79, the compound according to any one of embodiments 1 -
61 , wherein
Figure imgf000314_0004
is selected from the group consisting of: and
Figure imgf000315_0002
Figure imgf000315_0001
and
t1 + t2 = p.
In embodiment 80, The compound according to any one of embodiments 1 - 1 , wherein
Figure imgf000315_0003
Figure imgf000315_0004
and
t1 + t2 = p.
In embodiment 80a, the compound according to any one of embodiments
-61 , wherein
Figure imgf000315_0005
is:
Figure imgf000315_0006
t1 + t2 = p. In embodiment 80b, the compound according to any one of embodiments -
1 -61 , wherein
Figure imgf000316_0001
and
Figure imgf000316_0002
t1 + t2 = p.
In embodiment 80c, the compound according to any one of embodiment 1 -61 ,
wherein
Figure imgf000316_0003
Figure imgf000316_0004
; and
t1 + t2 = p.
In embodiment 81 , the compound according to any one of embodiments 1 to 80, wherein R1 is halogen, C1-4 alkyl which is unsubstituted or substituted one or more times by R10, -C(=O)ORa, -C(O)NRaRb, hydroxyl, cyano, or C1-3 alkoxy. In embodiment 82, The compound according to embodiment 81 , wherein R1 is chloro, fluoro, bromo, methyl, ethyl, propyl, butyl, -CH2OH, difluoromethyl, trifluoromethyl, -C(=O)ORa, hydroxyl, cyano, or methoxy.
In embodiment 83, the compound according to any one of embodiments 1 to 81 , wherein each R2' is independently fluoro or methyl. In embodiment 84, the compound according to embodiment 83, wherein s is 0.
In embodiment 85, the compound according to any one of embodiments 1 to 84, wherein each R2 is independently fluoro or methyl.
In embodiment 86, the compound according to claims 85, wherein s is 0.
In embodiment 87, The compound according to any one of embodiments 1 to
86, wherein R3 and R3' are H or methyl.
In embodiment 88, the compound according to any one of embodiments 1 to
87, wherein R4 and R4' are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, - CH2OH, -NRaNb, t-butoxy-, or hydroxyl; or two R4 groups together with the atoms to which they are attached form fused cyclopropyl, spiro cyclopropyl or
Figure imgf000317_0001
two R4' groups together with the atoms to which they are attached
form fused cyclopropyl, spiro cyclopropyl or
Figure imgf000317_0002
In embodiment 89, the compound according to embodiment 88, wherein R4 and R4' are each independently methyl, ethyl, methoxy, di-fluoromethyl, trifluoromethyl, or two R4 groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl or two R4' groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl.
In embodiment 90, the compound according to embodiment 89, wherein R4 and R4' are methyl.
In embodiment 91. the compound according to anyone of embodiments 1 to 91 , wherein m and n are independently 1 or 2. In embodiment 92, the compound according to embodiment 91 , wherein m and n are 1.
In embodiment 93, the compound according to any one of embodiments 1 to 92, wherein X and Y are
Figure imgf000318_0001
In embodiment 94, the compound according to any one of embodiments 1 to 93, wherein R5 and R5' are each independently, C1-β alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
In embodiment 95, the compound according to embodiment 94, wherein R5 and R5' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12. In embodiment 96, the compound according to embodiment 95, wherein R5 and R5' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10.
In embodiment 97, the compound according to embodiments 1 -93, wherein R5 and R5' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-, which are unsubstituted or substituted one or more times by R10.
In embodiment 98, the compound according to embodiment 97, wherein R5 and R5' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
In embodiment 99, the compound according to embodiment 98, wherein R5 and R5' are each independently benzyl which is unsubstituted or substituted one or more times by R11.
In embodiment 100, the compound according to any one of embodiments 1 to 99, wherein R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, - NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, - OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra -Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
In embodiment 101 , the compound according to embodiment 100 wherein R10 is -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - NRbSO2Ra, or -NRbSO2NRaRb. In embodiment 102, the compound according to embodiment 101 , wherein R10 is -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, or -NRbSO2Ra. In embodiment 103, the compound according to any one of embodiment 1 to 102, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl.
In embodiment 104, the compound according to claim 103, wherein Ra and Rc are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or C1-3 alkyl.
In embodiment 105, the compound according to claim 104, wherein Ra-Rd are each independently H or C1-3 alkyl.
In embodiment 106, the compound according to any one of embodiments 1 to 105, wherein said compound is of formula (IVA):
Figure imgf000320_0001
or a pharmaceutically acceptable salt thereof wherein
R7 and R7' are each independently C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein
Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
m and n combined are 0, 1 , 2, 3 or 4.
In embodiment 107, the compound according to embodiment 106, wherein R8 and R8' are each independently -NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
In embodiment 108, the compound according to claim 107, wherein R8 and R8' in formulas (IV), are each independently -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, tetrahydrofuran, or benzyl.
In embodiment 109, the compound according to any one of claims 107 to 108, wherein R7 and R7' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
In embodiment 110, the compound according to any one of embodiments 108 to 109, wherein R7 and R7' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10. In embodiment 111 , the compound according to claim 110 wherein R7 and R7' are each independently methyl, ethyl, propyl, isopropyl, methoxyisopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
In embodiment 112, the compound according to any one of embodiments 1 to 111 , wherein R7 and R8 or R7* and R8' together with the carbon to which they are attached are each independently:
Figure imgf000322_0001
In embodiment 113, the compound according to any one of embodiments 1 to 112, wherein said compound is of formula (VA):
Figure imgf000322_0002
or a pharmaceutically acceptable salt thereof.
In one embodiment, the present invention provides a compound according to the invention described herein for treating or preventing a Flaviviridae viral infection in a host. In one embodiment, the present invention provides a pharmaceutical composition comprising at least one compound according to the invention described herein and at least one pharmaceutically acceptable carrier or excipient.
In one embodiment, the present invention provides a pharmaceutical composition comprising at least one compound according to the invention described herein and at least one pharmaceutically acceptable carrier or excipient, for treating or preventing a Flaviviridae viral infection in a host.
In one embodiment, the present invention provides a pharmaceutical composition comprising at least one compound according to the invention described herein ,and further comprising administering at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES). In another embodiment, there is provided a combination comprising a least one compound according to the invention described herein and one or more additional agents.
In another embodiment, there is provided a combination comprising a least one compound according to the invention described herein and one or more additional agents chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agent, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
In one combination embodiment, the compound and additional agent are administered sequentially. In another combination embodiment, the compound and additional agent are administered simultaneously.
The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier therefore comprise a further aspect of the invention. The additional agents for the compositions and combinations include, for example, ribavirin, amantadine, merimepodib, Levovirin, Viramidine, and maxamine.
The term "viral serine protease inhibitor" as used herein means an agent that is effective to inhibit the function of the viral serine protease including HCV serine protease in a mammal. Inhibitors of HCV serine protease include, for example, those compounds described in WO 99/07733 (Boehringer Ingelheim), WO
99/07734 (Boehringer Ingelheim), WO 00/09558 (Boehringer Ingelheim), WO
00/09543 (Boehringer Ingelheim), WO 00/59929 (Boehringer Ingelheim), WO 02/060926 (BMS), WO 2006039488 (Vertex), WO 2005077969 (Vertex), WO
2005035525 (Vertex), WO 2005028502 (Vertex) WO 2005007681 (Vertex), WO
2004092162 (Vertex), WO 2004092161 (Vertex), WO 2003035060 (Vertex), of WO
03/087092 (Vertex), WO 02/18369 (Vertex), or WO98/17679 (Vertex). Specific examples of viral serine protease inhibitors include Telaprevir
(VX-950, Vertex), VX-500 (Vertex), VX-813 (Vertex), VX-985 (Vertex), TMC435350 (Tibotec/Medivir), MK-7009 (Merck), ITMN- 191 (R7227, InterMune/Roche) and Boceprevir (SCH503034, Schering). The term "viral polymerase inhibitors" as used herein means an agent that is effective to inhibit the function of a viral polymerase including an HCV polymerase in a mammal. Inhibitors of HCV polymerase include non-nucleosides, for example, those compounds described in: WO 03/010140 (Boehringer Ingelheim), WO 03/026587 (Bristol Myers
Squibb); WO 02/100846 A1 , WO 02/100851 A2, WO 01 /85172 AI (GSK), WO
02/098424 A1 (GSK), WO 00/06529 (Merck), WO 02/06246 A1 (Merck), WO
01 /47883 (Japan Tobacco), WO 03/000254 (Japan Tobacco) and EP 1 256 628 A2 (Agou ron).
Furthermore other inhibitors of HCV polymerase also include nucleoside analogs, for example, those compounds described in: WO 01 /90121 A2 (Idenix), WO 02/069903 A2 (Biocryst Pharmaceuticals Inc.), and WO 02/057287 A2(Merck/lsis) and WO 02/057425 A2 (Merck/lsis).
Specific examples of inhibitors of an HCV polymerase, include VCH-759
(ViroChem Pharma), VCH-916 (ViroChem Pharma), VCH-222 (ViroChem Pharma),
R1626 (Roche), R7128 (Roche/Pharmasset), PF-868554 (Pfizer), MK-0608 (Merck/lsis), MK-3281 (Merck), A-837093 (Abbott), GS 9190 (Gilead), ana598
(Anadys), HCV-796 (Viropharma) and GSK625433 (GlaxoSmithKline).
The term "viral helicase inhibitors" as used herein means an agent that is effective to inhibit the function of a viral helicase including a Flaviviridae helicase in a mammal.
"Immunomodulatory agent" as used herein means those agents that are effective to enhance or potentiate the immune system response in a mammal.
Immunomodulatory agents include, for example, class I interferons (such as α-, β- ,δ- and Ω- interferons, τ-interferons, consensus interferons and asialo- interferons), class Il interferons (such as γ-interferons) and pegylated interferons.
Specific examples of Immunomodulatory agent as used herein include IL- 29 (PEG-lnterferon Lambda, ZymoGenetics), Belerofon (Nautilus Biotech) injectable or oral, Oral Interferon alpha (Amarillo Biosciences), BLX-883 (Locteron, Biolex Therapeutics/Octoplus), Omega Interferon (Intarcia Therapeutics), multiferon (Viragen), Albuferon (Human Genome Sciences), consensus Interferon (Infergen, Three Rivers Pharmaceuticals), Medusa Interferon (Flamel Technologies), NOV-205 (Novelos Therapeutics), Oglufanide disodium (Implicit Bioscience), SCV-07 (SciClone), Zadaxin® (thymalfasin, SciClone/Sigma- Tau), AB68 (XTL bio) and Civacir (NABI).
The term "class I interferon" as used herein means an interferon selected from a group of interferons that all bind to receptor type 1. This includes both naturally and synthetically produced class I interferons. Examples of class I interferons include α-, β-,δ- and Ω- interferons, τ-interferons, consensus interferons and asialo-interferons. The term "class Il interferon" as used herein means an interferon selected from a group of interferons that all bind to receptor type II. Examples of class Il interferons include γ-interferons.
Antisense agents include, for example, ISIS-14803.
Inhibitors of internal ribosome entry site (IRES) include ISIS-14803 (ISIS Pharmaceuticals) and those compounds described in WO 2006019831 (PTC therapeutics).
In one embodiment, the additional agent is interferon α, ribavirin, silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine or cyclosporin.
In one embodiment, the additional agent is interferon α, or ribavirin.
In one embodiment, the additional agent is interferon α 1A, interferon α 1 B, interferon α 2A, or interferon α 2B.
Interferon is available in pegylated and non pegylated forms. Pegylated interferons include PEGASYStm and Peg-introntm. In one embodiment, the additional agent is interferon α 1A, interferon α
1 B, interferon α 2A (Roferon), PEG -interferon α 2A (Pegasys), interferon α 2B (Intron A) or PEG- interferon α 2B (Peg-lntron). In one embodiment, the additional agents is standard or pegylated interferon α (Roferon, Pegasys, lntron A, Peg-lntron) in combinaition with ribavirin. In one embodiment, the additional agent is chosen from A-831 (AZD0530,
Arrow Therapeutics acquired by AstraZeneca), TLR9 agonist : IMO-2125 (Idera Pharmaceuticals), PYN17 (Phynova), Vavituximab (Tarvacin, Peregrine), DEBIO- 025 (DEBIO), NIM-811 (Novartis), SCY635 (Scynexis), PF-03491390 (IDN-6556, Pfizer), Suvus (formerly BIVN-401 , Virostat, Bioenvision), MX-3253 (Celgosivir, Migenix), Viramidine (Taribavirin, Valeant Pharmaceuticals), Hepaconda (Giaconda), TT033 (Benitec/Tacere Bio/Pfizer), SIRNA-034 (Sirna Therapeutics aquired by Merck) and EHC-18 (Enzo Biochem), ACH-1095 (Achillion/Gilead), JKB- 022 (Jenkin), CTS-1027 (Conatus), MitoQ (mitoquinone, Antipodean Pharmaceuticals), Alinia (nitazoxanide, Romark Laboratories) and Bavituximab (Peregrine Pharm).
In one embodiment, the additional agent is a therapeutic vaccine chosen from CSL123 (Chiron/CSL), IC41 (Intercell Novartis), Gl 5005 (Globeimmune), TG4040 (Transgene), Chronvac C (Tripep/lnovio), GNI-103 (GENimmune), HCV/MF59 (Chiron/Novartis), PeviPRO™ (Pevion biotect).
The recommended dose of PEGASYStm monotherapy for chronic hepatitis C is 180 mg (1.0 mL vial or 0.5 mL prefilled syringe) once weekly for 48 weeks by subcutaneous administration in the abdomen or thigh.
The recommended dose of PEGASYStm when used in combination with ribavirin for chronic hepatitis C is 180 mg (1.0 mL vial or 0.5 mL prefilled syringe) once weekly. The daily dose of Ribavirin is 800 mg to 1200 mg administered orally in two divided doses. The dose should be individualized to the patient depending on baseline disease characteristics (e.g., genotype), response to therapy, and tolerability of the regimen. The recommended dose of PEG-lntrontm regimen is 1.0 mg/kg/week subcutaneously for one year. The dose should be administered on the same day of the week. When administered in combination with ribavirin, the recommended dose of PEG-lntron is 1.5 micrograms/kg/week.
In one embodiment, viral serine protease inhibitor is a flaviviridae serine protease inhibitor.
In one embodiment, viral polymerase inhibitor is a flaviviridae polymerase inhibitor.
In one embodiment, viral helicase inhibitor is a flaviviridae helicase inhibitor.
In further embodiments:
viral serine protease inhibitor is HCV serine protease inhibitor;
viral polymerase inhibitor is HCV polymerase inhibitor;
viral helicase inhibitor is HCV helicase inhibitor.
In one embodiment, the present invention provides a method for treating or preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to formula (I), (II), (III), or (IV).
In one embodiment, the viral infection is chosen from Flavivirus infections.
In one embodiment, the Flavivirus infection is Hepatitis C virus (HCV), bovine viral diarrhea virus (BVDV), hog cholera virus, dengue fever virus, Japanese encephalitis virus or yellow fever virus.
In one embodiment, the Flaviviridea viral infection is hepatitis C viral infection (HCV). In one embodiment, the host is human.
In one embodiment, the present invention provides a method for treating or preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to the invention described herein, and further comprising administering at least one additional agent.
In one embodiment, the present invention provides a method for treating or preventing a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to the invention described herein, and further comprising administering at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier therefore comprise a further aspect of the invention. The individual components for use in the method of the present invention or combinations of the present invention may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
In one embodiment, the present invention provides the use of a compound according to the invention described herein for treating or preventing Flaviviridae viral infection in a host.
In one embodiment, the present invention provides the use of a compound according to the invention described herein and further comprising at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (I RES). for treating or preventing Flaviviridae viral infection in a host.
In one embodiment, the present invention provides the use of a compound according to the invention described herein for the manufacture of a medicament.
In one embodiment, the present invention provides the use of a compound according to the invention described herein for the manufacture of a medicament for treating or preventing a viral Flaviviridae infection in a host. In one embodiment, the present invention provides the use of a compound according to the invention described herein and further comprising at least one additional agent chosen from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (I RES). for the manufacture of a medicament for treating or preventing a viral Flaviviridae infection in a host.
It will be appreciated by those skilled in the art that the compounds in accordance with the present invention can exists as stereoisomers (for example, optical (+ and -), geometrical (cis and trans) and conformational isomers (axial and equatorial). All such stereoisomers are included in the scope of the present invention. It will be appreciated by those skilled in the art that the compounds in accordance with the present invention can contain a chiral center. The compounds of formula may thus exist in the form of two different optical isomers (i.e. (+) or (-) enantiomers). All such enantiomers and mixtures thereof including racemic mixtures are included within the scope of the invention. The single optical isomer or enantiomer can be obtained by method well known in the art, such as chiral HPLC, enzymatic resolution and chiral auxiliary.
In one embodiment, the compounds of the present invention are provided in the form of a single stereoisomer at least 95%, at least 97% and at least 99% free of the corresponding stereoisomers.
In a further embodiment the compound of the present invention are in the form of a single stereoisomer at least 95% free of the corresponding stereoisomers.
In a further embodiment the compound of the present invention are in the form of a single stereoisomer at least 97% free of the corresponding stereoisomers.
In a further embodiment the compound of the present invention are in the form of a single stereoisomer at least 99% free of the corresponding stereoisomers. There is also provided pharmaceutically acceptable salts of the compounds of the present invention. By the term pharmaceutically acceptable salts of compounds are meant those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toleune-p-sulphonic, tartaric, acetic, trifluoroacetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids. Other acids such as oxalic, while not themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
Salts derived from amino acids are also included (e.g. L-arginine, L- Lysine). Salts derived from appropriate bases include alkali metals (e.g. sodium, lithium, potassium) and alkaline earth metals (e.g. calcium, magnesium).
A reference hereinafter to a compound according to the invention includes that compound and its pharmaceutically acceptable salts.
With regards to pharmaceutically acceptable salts, see also the list of FDA approved commercially marketed salts listed in Table I of Berge et al., Pharmaceutical Salts, J. of Phar. Sci., vol. 66, no. 1 , January 1977, pp. 1 -19, the disclosure of which is incorporated herein by reference.
It will be appreciated by those skilled in the art that the compounds in accordance with the present invention can exist in different polymorphic forms. As known in the art, polymorphism is an ability of a compound to crystallize as more than one distinct crystalline or "polymorphic" species. A polymorph is a solid crystalline phase of a compound with at least two different arrangements or polymorphic forms of that compound molecule in the solid state. Polymorphic forms of any given compound are defined by the same chemical formula or composition and are as distinct in chemical structure as crystalline structures of two different chemical compounds.
It will further be appreciated by those skilled in the art that the compounds in accordance with the present invention can exist in different solvate forms, for example hydrates. Solvates of the compounds of the invention may also form when solvent molecules are incorporated into the crystalline lattice structure of the compound molecule during the crystallization process.
In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs, and esters, of the compounds of this invention may also be employed in compositions to treat or prevent the herein identified disorders.
Also included in the present invention are isotopically labeled compounds, wherein, for example, one or more hydrogen atoms in the compounds described herein are replaced with deuterium or tritium. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. The term "alkyl" represents a linear, branched or cyclic hydrocarbon moiety. The terms "alkenyl" and "alkynyl" represent a linear, branched or cyclic hydrocarbon moiety which has one or more double bonds or triple bonds in the chain. Examples of alkyl, alkenyl, and alkynyl groups include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, neohexyl, allyl, vinyl, acetylenyl, ethylenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, butadienyl, pentenyl, pentadienyl, hexenyl, heptenyl, heptadienyl, heptatrienyl, octenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclohexenyl, cyclohexdienyl and cyclohexyl. The terms alkyl, alkenyl, and alkynyl, also include combinations of linear and branched groups, e.g., cyclopropylmethyl, cyclohexylethyl, etc. The term alkenyl also includes C1 alkenyl where the one carbon atom is attached to the remainder of the molecule via a double bond. Where indicated the "alkyl," "alkenyl," and "alkynyl" can be optionally substituted such as in the case of haloalkyls in which one or more hydrogen atom is replaced by a halogen, e.g., an alkylhalide. Examples of haloalkyls include but are not limited to trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, trifluoroethyl, difluoroethyl, fluoroethyl, trichloroethyl, dichloroethyl, chloroethyl, chlorofluoromethyl, chlorodifluoromethyl, dichlorofluoroethyl. Aside from halogens, where indicated, the alkyl, alkenyl or alkynyl groups can also be optionally substituted by, for example, halogen, -ORa, oxo, -NRaRb, =NO-RC , - C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -SO2NRaRb, - NRbSO2Ra, -NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H, C-i-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. The terms "cycloalkyl", and "cycloalkenyl" represent a cyclic hydrocarbon alkyl or alkenyl, respectively, and are meant to include monocyclic (e.g., cyclopropyl, cyclobutyl, cyclohexyl), spiro (e.g., spiro [2.3]hexanyl), fused (e.g., bicyclo[4.4.0]decanyl), and bridged (e.g., bicyclo[2.2.1 ]heptanyl) hydrocarbon moieties.
The terms "alkoxy," "alkenyloxy," and "alkynyloxy" represent an alkyl, alkenyl or alkynyl moiety, respectively, which is covalently bonded to the adjacent atom through an oxygen atom. Examples include but are not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec- butoxy, tert- butoxy, pentyloxy, isopentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, isohexyloxy, trifluoromethoxy and neohexyloxy. Like the alkyl, alkenyl and alkynyl groups, where indicated the alkoxy, alkenyloxy, and alkynyloxy groups can be optionally substituted by, for example, halogen, - ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6.n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle- alkyl.
The term "aryl" represents a carbocyclic moiety containing at least one benzenoid-type ring (i.e., may be monocyclic or polycyclic), and which where indicated may be optionally substituted with one or more substituents. Examples include but are not limited to phenyl, tolyl, dimethylphenyl, aminophenyl, anilinyl, naphthyl, anthryl, phenanthryl or biphenyl. The aryl groups can be optionally substituted where indicated by, for example, halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. The term "aralkyl" represents an aryl group attached to the adjacent atom by an alkyl, alkenyl or alkynyl. Like the aryl groups, where indicated the aralkyl groups can also be optionally substituted. Examples include but are not limited to benzyl, benzhydryl, trityl, phenethyl, 3-phenylpropyl, 2- phenylpropyl, 4-phenylbutyl and naphthylmethyl. Where indicated, the aralkyl groups can be optionally substituted one or more times by, for example, halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The term "heterocycle" represents a non aromatic, saturated or partially saturated cyclic moiety wherein said cyclic moiety is interrupted by at least one heteroatom selected from oxygen (O), sulfur (S) or nitrogen (N). Heterocycles may be monocyclic or polycyclic rings. Examples include but are not limited to azetidinyl, dioxolanyl, morpholinyl, morpholino, oxetanyl, piperazinyl, piperidyl, piperidinyl, cyclopentapyrazolyl, cyclopentaoxazinyl, cyclopentafuranyl, tetrahydrofuranyl, thiazolinyl, oxazolinyl, pyranyl, aziridinyl, azepinyl, dioxazepinyl, diazepinyl, oxyranyl, oxazinyl, pyrrolidinyl, and thiopyranyl, thiolanyl, pyrazolidinyl, dioxanyl, and imidazolidinyl. Where indicated, the heterocyclic groups can be optionally substituted one or more times by, for example, halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The term "heterocycle-alkyl" represents heterocycle group attached to the adjacent atom by an alkyl, alkenyl or alkynyl group. It is understood that in, for example, a 4-18 member heterocycle-alkyl moiety, the 4-18 member represent the total of the ring atoms present in the heterocycle moiety and the carbon atoms present in the alkyl, alkenyl or alkynyl group.
For example, the following groups are encompassed by a 7 member heterocycle-alkyl (* represents the attachment point):
Figure imgf000336_0001
Where indicated the heterocycle-alkyl groups can be optionally substituted one or more times by, for example, halogen, -ORa, oxo, -NRaRb,
=NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -
C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -
NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, CM6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The term "heteroaryl" represents an aromatic cyclic moiety wherein said cyclic moiety is interrupted by at least one heteroatom selected from oxygen (O), sulfur (S) or nitrogen (N). Heteroaryls may be monocyclic or polycyclic rings wherein at least one ring in the polycyclic ring system is aromatic and at least one ring (not necessarily the same ring contains a heteroatom. Examples include but are not limited to dithiadiazinyl, furanyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridyl, pyrazolyl, pyrrolyl, thiatriazolyl, tetrazolyl, thiadiazolyl, triazolyl, thiazolyl, thienyl, tetrazinyl, thiadiazinyl, triazinyl, thiazinyl, furoisoxazolyl, imidazothiazolyl, thienoisothiazolyl, thienothiazolyl, imidazopyrazolyl, pyrrolopyrrolyl, thienothienyl, thiadiazolopyrimidinyl, thiazolothiazinyl, thiazolopyrimidinyl, thiazolopyridinyl, oxazolopyrimidinyl, oxazo Io pyridyl, benzoxazolyl, benzisothiazolyl, benzothiazolyl, benzodioxolyl, dihydrobenzodioxinyl, benzothiadiazolyl, thienofuranyl, imidazopyrazinyl, purinyl, pyrazolopyrimidinyl, imidazopyridinyl, benzimidazolyl, indazolyl, benzoxathiolyl, benzodioxolyl, benzodithiolyl, indolizinyl, indolinyl, isoindolinyl, furopyrimidinyl, furopyridyl, benzofuranyl, isobenzofuranyl, thienopyrimidinyl, thienopyridyl, benzothienyl, benzoxazinyl, benzothiazinyl, quinazolinyl, naphthyridinyl, quinolinyl, isoquinolinyl, benzopyranyl, pyridopyridazinyl, chromen, benzodiazinyl. Where indicated the heteroaryl groups can be optionally substituted one or more times by, for example, halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6.n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
The term "heteroaralkyl" represents an optionally substituted heteroaryl group attached to the adjacent atom by an alkyl, alkenyl or alkynyl group. Where indicated the heteroaralkyl groups can be optionally substituted one or more times by, for example, halogen, -ORa, -NRaRb, - C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0- 3Ra, -SO2NRaRb, -NRbSO2Ra, -NRbS02NR3Rb, or -P(=0)0R30Rb, CL12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein R3-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl. It is understood that in, for example, a 6- 18 member heteroaralkyl moiety, the 6-18 member represents the total of the ring atoms present in the heterocycle moiety and the carbon atoms in the alkyl, alkenyl or alkynyl groups. For example, the following groups are encompassed by a 7 member heteroaralkyl (* represents the attachment point):
Figure imgf000338_0001
"Halogen atom" is specifically a fluorine atom, chlorine atom, bromine atom or iodine atom.
The term "oxo" represents =0. A dash ("-") that is not between two letters or symbols is used to indicate a point of attachement for a substitutent. For example, -CONRdRe is attached through the carbon of the amide.
A dash line (" ") is used to indicate the point of attachment for the group. For example, A is attached through the carbon at position 1 and 4 in the following representation:
Figure imgf000339_0001
When there is a sulfur atom present, the sulfur atom can be at different oxidation levels, i.e., S, SO, or SO2. All such oxidation levels are within the scope of the present invention. The term "independently" means that a substituent can be the same or a different definition for each item.
In general, the term "substituted," whether preceded by the term "optionally" or not, refers to the replacement of hydrogen radicals on a carbon or nitrogen atom in a given structure with the radical of a specified substituent. Specific substituents are described above in the definitions and below in the description of compounds and examples thereof. Unless otherwise indicated, an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position. For example, the language, "which is unsubstituted or substituted one or more times by R10" means that when the group is substituted with more than one R10 group, the R10 groups can be different from each other. A ring substituent, such as a heterocycle, can be bound to another ring, such as a cycloalkyl, to form a spiro- bicyclic ring system, e.g., both rings share one common atom.
As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds. The term "stable", as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week. When two alkoxy groups are bound to the same atom or adjacent atoms, the two alkoxy groups can form a ring together with the atom(s) to which they are bound.
In certain embodiments, a compound represented by:
Figure imgf000340_0001
also includes where the R group replaces the H on the nitrogen atom. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds of this invention, wherein one or more hydrogen atoms are replaced deuterium or tritium, or one or more carbon atoms are replaced by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, probes in biological assays, or antiviral compounds with improved therapeutic profile.
The terms "host" or "patient" mean human male or female, for example child, adolescent or adult.
It will be appreciated that the amount of a compound of the invention required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition for which treatment is required and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general however a suitable dose will be in the range of from about 0.1 to about 750 mg/kg of body weight per day, for example, in the range of 0.5 to 60 mg/kg/day, or, for example, in the range of 1 to 20 mg/kg/day.
The desired dose may conveniently be presented in a single dose or as divided dose administered at appropriate intervals, for example as two, three, four or more doses per day.
The compound is conveniently administered in unit dosage form; for example containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to 700 mg of active ingredient per unit dosage form.
Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75μM, about 2 to 50 μM, about 3 to about 30 μM. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 500 mg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.
When the compounds of the present invention or a pharmaceutically acceptable salts thereof is used in combination with a second therapeutic agent active against the same virus the dose of each compound may be either the same as or differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical composition. The invention thus further provides a pharmaceutical composition comprising compounds of the present invention or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers therefore and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Pharmaceutical compositions include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral
(including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
Pharmaceutical compositions suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution, a suspension or as an emulsion. The active ingredient may also be presented as a bolus, electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, nonaqueous vehicles (which may include edible oils), or preservatives.
The compounds according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre- filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. For topical administration to the epidermis, the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Such transdermal patches may contain penetration enhancers such as linalool, carvacrol, thymol, citral, menthol and t-anethole. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
Compositions suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Pharmaceutical compositions suitable for rectal administration wherein the carrier is a solid are for example presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in moulds. Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
For intra-nasal administration the compounds of the invention may be used as a liquid spray or dispersible powder or in the form of drops. Drops may be formulated with an aqueous or non-aqueous base also comprising one more dispersing agents, solubilizing agents or suspending agents. Liquid sprays are conveniently delivered from pressurized packs. For administration by inhalation the compounds according to the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.
Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges or e.g. gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
When desired the above described formulations adapted to give sustained release of the active ingredient may be employed. The following general schemes and examples are provided to illustrate various embodiments of the present invention and shall not be considered as limiting in scope. It will be appreciated by those of skill in the art that other compounds of the present invention can be obtained by substituting the generically or specifically described reactants and/or operating conditions used in the following examples.
In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius; and, unless otherwise indicated, all parts and percentages are by weight.
Analytical HPLC is carried out under standard conditions using a Varian Pursuit XRs C18 column, 50 x 4.6 mm, 3 μm for methods A and E and a Phenomenex Gemini C18 column, 250 x 4.6 mm, 3μm, 11 θA for methods B, C and D. Elution is performed using a linear gradient with a flow rate of 1 mL/min. as described in the following table (Solvent A is 0.01% TFA in H2O; solvent B is 0.01% TFA in CH3CN):
Figure imgf000345_0001
5 The following abbreviations may be used as follows:
Ac acetyl
AcOH acetic acid
aq aqueous
(BoC)2O di-tert-butyldicarbonate
0 DCM dichloromethane
DIPEA Diisopropylethylamine
DME 1 ,2-dimethoxyethane
DMF dimethylformamide
DMSO Dimethylsulfoxide
5 DBU 1 ,8-diazabicyclo£5.4.0lundec-7-ene
Et2O Diethyl ether
EtOAc Ethyl acetate
HATU O-(7-Azabenzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate
0 H2O water
MeCN Acetonitrile
MeOH Methanol
Moc Methoxycarbonyl
PdCl2dppf (1 ,1 '-Bis-(diphenylphosphino)-ferrocene)palladium (II) dichloride 5 Pd(PPh3)4 Tetrakis(triphenylphosphine) palladium
rt room temperature
TEA Triethylamine
TFA Trifluoroacetic acid
THF Tetrahydrofuran
0 The compounds of this invention may be prepared in light of the specification using steps generally known to those of ordinary skill in the art. Those compounds may be analyzed by known methods, including but not limited to LCMS (liquid chromatography mass spectrometry) HPLC and NMR (nuclear magnetic resonance). It should be understood that the specific conditions shown below are only examples, and are not meant to limit the scope of the conditions that can be used for making compounds of this invention. Instead, this invention also includes conditions that would be apparent to those skilled in that art in light of this specification for making the compounds of this invention. Unless otherwise indicated, all variables in the following schemes are as defined herein. General Schemes:
Mass spec, samples were analyzed on a MicroMass Quattro Micro mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using chromatography. Mobile phase for all mass spec, analyses consisted of 1 OmM pH 7 ammonium acetate and a 1 :1 acetonitrile-methanol mixture. Method A: Column gradient conditions were 5%- 100% acetonitrile-methanol over 3.5 mins gradient time and 4.8 mins run time on an ACE5C8 3.0 x 75mm column. Flow rate was 1.2 ml/min. Method B: Column gradient were 5%-100% acetonitrile-methanol over 10 mins gradient time and 12 mins run time on a ACE5C8 4.6 x 150 mm column. Flow rate was 1.5 mL/min. As used herein, the term "Rt(min)" refers to the LCMS retention time, in minutes, associated with the compound. Unless otherwise indicated, the LCMS method utilized to obtain the reported retention time is as detailed above. If the Rt(min) is < 5 min method A was used, if the Rt(min) is >5 min then method B was used.
1 H-NMR spectra were recorded at 400 MHz using a Bruker DPX 400 instrument.
General procedure 1
Figure imgf000346_0001
The benzimidazole is formed by coupling the diamino compound with the appropriate carboxylic acid, preactivated carboxylic acid, mixed anhydride or anhydride in solvents such as THF, DMF or DCM and in the presence of a base such as TEA or DIPEA to form the corresponding amide. The amide is than treated with an acid at 40-80°C for 2-24 hours.
Intermediate 1
(S)-2-(5-lodo-1 H-benzoimidazol-2-yl)-pyrrolidine-1 -carboxylic acid tert-butyl ester
Figure imgf000347_0001
To a dry 1000 mL round bottom flask under Nitrogen, is added 4-lodo-benzene- 1 ,2-diamine (45g) , (S)-Pyrrolidine-1 ,2-dicarboxylic acid 1 -tert-butyl ester (41.39g) and THF (450 ml). The reaction mixture is stirred until complete dissolution then cool to 0-2°C. Diisopropylethylamine (50.17 ml) is added dropwise to control the exotherm then HATU (80.38g) is added in one portion. The reaction mixture is stirred in an ice bath for 3 hours and follows by HPLC to monitor completion of reaction. To this solution are added 500 ml of water then 500 ml of ethyl acetate. The aqueous phase extracted twice with ethyl acetate. The organic phases are combined and evaporated half. To the organic phase is added 450 ml of acetic acid and the mixture is evaporated to 300 ml. This procedure is repeated 3 times for a residual of -470 ml, and the mixture is then heated at 50° C over night. Toluene (200 ml) is added and evaporated to a small residue (repeat 6 times). To this solution is added 450 ml of ethyl acetate. The organic phase is washed with saturated sodium carbonate, dried over sodium sulfate, filtered and evaporated to dryness. The residue is purified on a pad of silica using 25%ethyl acetate/ hexane mixture to give compound (67 g) as a beige powder. 1H NMR (400 MHz, MeOD): δ [ppm] 8.0-7.7 (bs, 1 H), 7.5 (m, 1 H), 7.4-7.1 (bs, 1 H), 5.1 -4.9 (m, 1 H), 3.8-3.6 (m, 1 H), 3.6-3.4 (m, 1 H), 2.6-2.2 (m, 1 H), 2.2-1.8 (m, 3 H), 1.4 (s, 3 H), 1.1 (s, 6 H)
LC/MS: m/z = 413.95 (M + H+).
General procedure 2
Figure imgf000348_0001
Intermediate 3
{(S)-1-[(S)-2-(5-lodo-1 H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl- propyl}-carbamic acid methyl ester
Figure imgf000348_0002
Step 1
To a stirring mixture of compound 1 (20 g, 48 mmol) in DCM (200 mL) at 0°C is added TFA (200 mL). The reaction mixture is stirred at room temperature for 2 hours and concentrated in vacuum. The residue is dissolved in DCM and saturated aqueous NaHCO3, the organic layer is washed with saturated aqueous NaHCO3, dried over sodium sulfate and concentrated in vacuum to afford compound 2 (12 g).
1H NMR (400 MHz, CDCl3): δ [ppm] 8.40 (br s, 2H), 7.82 (s, 1 H), 7.45 (d, 1 H), 7.26 (d, 1 H), 4.66 (t, 1 H), 3.10 (m, 2H), 2.30 (m, 1 H), 2.18 (m, 1 H), 1.90 (m, 2H).
Step 2-1
To a mixture of L-valine (220 mg, 1.9 mmol) and NaHCO3 (482 mg, 5.6 mmol) in
H2O (6 mL) at 0°C is added dropwise methylchloroformate (0.25 mL, 3.25 mmol). The reaction mixture is stirred for 2 hours at 0-5°C. The mixture is diluted with water and washed with Et2O. The aqueous layer is acidified with 1 N HCl to pH 3 and the product is extracted with EtOAc. The combined organic layers are washed with brine, dried over sodium sulfate and concentrated in vacuum. The residue is triturated with hexanes-Et2O to give (R)-2-methoxycarbonylamino-3- methyl-butyric acid (248 mg, 75%).
1H NMR (400 MHz, CDCl3): δ [ppm] 5.12 (m, 1 H), 4.30 (m, 1 H), 3.70 (s, 3H), 2.22 (m, 1 H), 1.00 (d, 3H), 0.93 (d, 3H). Step 2-2
To a mixture of (R)-2-methoxycarbonylamino-3-methyl-butyric acid (68 mg, 0.39 mmol) and compound 2 (100 mg, 0.32 mmol) in anhydrous DMF (2 mL) is added DIPEA (0.25 mL, 1.43 mmol) followed by HATU (142 mg, 0.37 mmol) The reaction mixture is stirred for 4 hours at room temperature. Ice is added and the product is extracted with EtOAc. The combined organic layers are washed with brine, dried over sodium sulfate and concentrated in vacuum. The residue is purified by flash column chromatography on silica gel (EtOAc/MeOH 0% to 10%) to give compound 3 (150 mg).
1H NMR (400 MHz, DMSO) 12.25 (d, 1H), 7.8 (d, 1H), 7.45-7.33 (m, 1H), 7.33-7.15 (m, 2), 5.1-5.2 (m, 1H), 3.9-3.7 (m, 2H), 3.5 (s, 3H), 2.25-2.05 (m, 2H), 2.05-1.8 (m, 3H), 0.8 (m, 7H)
LC/MS: m/z = 470.90 (M + H+).
HPLC (Method C): tR = 7.78 min.
Intermediate 7
{(S)-1-[(S)-4,4-Difluoro-2-(5-iodo-1 H-benzoimidazol-2-yl)-pyrrolidine-1- carbonyl]-2-methyl-propyl}-carbamic acid methyl ester 1 . DMF
MeO
Figure imgf000350_0001
Step 1
Compound 4 (0.493 mg, 1.96 mmol), 4-lodo-benzene-1 ,2-diamine (677 mg, 2.94 mmol), HATU (1.12 g, 2.9 mmol) and DIPEA (1.02 ml_, 5.88 mmol) are added to 5 mL of DMF. The mixture is stirred overnight at rt and concentrated under reduced pressure. The residue is diluted in 5 mL of AcOH, stirred overnight at 50 °C, and concentrated to dryness. The resulting residue is purified by flash chromatography on silica gel (MeOH/DCM, O to 5%) to give compound 5 (800 mg).
Step 2
Compound 5 (160 mg) is dissolved in 5 mL of MeOH and the solution is added in 4M HCI/dioxane (1 mL). The mixture is stirred overnight at rt and concentrated under vacuum to dryness to give compound 6.
Step 3
Compound 6 (132 mg, 0.31 mmol), valine (71 mg, 0.41 mmol), HATU (154 mg, 0.41 mmol) and DIPEA (0.22 mL, 1.25 mmol) are added to 5 mL of DMF. The mixture is stirred overnight at rt. The solvent is removed reduced pressure, and the residue is purified by flash chromatography on silica gel (methanol/DCM, 0 to 5%) to give compound 7 (155 mg). 1H NMR (400 MHz, CDCl3): δ [ppm] 10.65 (bs, 1 H), 7.30-7.85 (m, 3H), 5.53 (m, 2H), 3.55-4.41 (m, 6H), 2.85 (m, 2H), 1.90 (m, 1 H), 0.83-1.42 (m, 6H).
LC/MS : m/z 507.06 (M + H+). Intermediate 12
(S)-2-Ethyl-5-(5-iodo-1H-benzoimidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester
H2O
M>
Figure imgf000351_0001
11 Step I
Compound 8 (500 mg, 2.91 mmol) and (Boc)2O (709 mg, 3.2 mmol) are added to 10 mL of DCM. The mixture is stirred overnight at rt. The mixture is concentrated under reduced pressure and the residue is purified by flash chromatography on silica gel (ethyl acetate/hexane, 0 to 15%) to give compound 9 (650 mg).
Step 2
To a mixture of compound 9 in 10 mL of MeOH is added 10% Pd-C (50 mg). The reaction mixture is stirred 1 hour under hydrogen atmosphere. The mixture is filtered and concentrated to dryness to give compound 10 (650 mg).
Step 3
Compound 10 (650 mg, 2.4 mmol) and LiOH-H2O (302 mg, 7.2 mmol) are added to a solution of 10 mL of MeOH and 2 mL of water. The reaction mixture is stirred overnight at rt and acidified with 2N HCl to pH 2. The mixture is extracted with DCM (3x10 mL), dried over sodium sulfate, and concentrated to dryness to give compound 1 1.
Step 4
Compound 1 1 (593 mg, 2 mmol), 4-lodo-benzene-1 ,2-diamine (685 mg, 2.4 mmol), HATU (1.12 g, 2.4 mmol) and DIPEA (0.85 mL, 4 mmol) are added to 10 mL of DMF. The mixture is stirred overnight at rt and solvent is removed under reduced pressure. The residue is dissolved in 10 mL of AcOH and stirred overnight at 50 °C. The mixture is concentrated under vacuum and the residue is purified by flash chromatography on silica gel (MeOH/DCM, 0 to 5%) to give compound 12 (600 mg).
1H NMR (400 MHz, CD3OD): δ [ppm] 7.30-7.85 (m, 3H), 5.00 (m, 1 H), 4.10 (m, 1 H), 2.45 (m, 1 H), 2.19(m, 1 H), 1.89(m, 3H), 0.83-1.42 (m, 13H).
LC/MS : m/z 441.85 (M + H+). Intermediate 13:
(S)-tert-Butyl-2-(5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H- benzo[d]imidazol-2-yl)pyrrolidine- 1 -carboxylate
Figure imgf000352_0001
13
To a stirred solution of tert-butyl (2S)-2-(5-iodo-1 H-benzimidazol-2-yl)pyrrolidine- 1 -carboxylate (2.64 g, 6.388 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3,2-dioxaborolane (2.433 g, 9.582 mmol) in DMSO (5 mL) is added potassium acetate (1.880 g, 19.16 mmol) and 1 - cyclopenta-1 ,4-dienyl-diphenyl-phosphane dichloropalladium iron (467.4 mg, 0.6388 mmol). The reaction mixture is stirred 12 hours at 100°C. The reaction is cooled to rt and poured into EtOAc and water (20ml/20ml). The organic layer is washed with water (20ml), brine (20ml) and dried over Na2SO4. The solvent is removed and the residue is purified by flash chromatography on silica gel (EtOAc /hexane, 10%-90%) to give compound 13 (1.67 g) as a white solid.
LC/MS: 10-90%MeOH 3/5min(grad/run): R.T.= 3.30 min, m/z = 414.24(M + H+). Intermediate 14:
{(S)-1-[(S)-2-(6-Ethynyl-1 H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-2- methyl-propyl}-carbamic acid methyl ester
Figure imgf000353_0001
Step 1 -1
To a solution of compound 3 (100 mg, 0.213 mmol), Bis(triphenylphosphine)palladium (II) (7.5 mg, 0.011 mmol) and copper(l) iodide (4.0 mg, 0.021 mmol) in 1.0 mL of anhydrous acetonitrile are added Ethynyltrimethylsilane (60 μl_, 0.42 mmol), and triethylamine (74 μl_, 0.53 mmol). The reaction mixture is stirred for 18 hours at room temperature and 3 hours at 36°C. The mixture is filtrated through a pad of celite using about 50 mL of EtOAc and the filtrate is concentrated under vacuum.
Step 1 -2
The crude brown material is diluted in 1.0 mL of MeOH and Potassium carbonate
(58 mg, 0.42 mmol) is added. The mixture is stirred at rt for 18 hours. The mixture is diluted with 15 mL of dichloromethane, washed with 10 mL of water, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue is purified by flash chromatography on silica gel (MeOH/EtOAc, 0% to 6%) to give compound 14 (38 mg) as a pale yellow solid.
1H NMR (400 MHz, CDCl3): δ [ppm] 10.69 (br s, 0.65H), 7.88 (br s, 0.35H), 7.64-
7.70 (m, 1 H), 7.39-7.57 (m, 1 H), 7.34 (d, 1 H), 5.60 (d, 1 H), 5.40 (br d, 1 H), 4.33 (dd, 1 H), 3.87 (q, 1 H), 3.63-3.76 (m, 1 H), 3.69 (s, 3H), 3.02-3.04 (br m, 2H), 2.34-
2.41 (m, 1 H), 2.11 -2.28 (m, 2H), 1.92-2.04 (m, 1 H), 0.84-0.93 (m, 6H).
LC/MS: m/z = 368.97 (M+H+). Intermediate 15:
Figure imgf000354_0001
Step I
To a cold (0-4 ° C) solution of 4-bromo-5-fluoro-benzene-1 ,2-diamine (1 g, 4.877 mmol) and (2S)-1 -tert-butoxycarbonylpyrrolidine-2-carboxylic acid (Boc-Pro-OH) (1.050 g, 4.877 mmol) in DMF (9.754 mL) are sequentially added HATU (2.040 g, 5.365 mmol) and 2,4,6-collidine (886.5 mg, 966.7 μl_, 7.316 mmol). The reaction mixture is slowly warmed up to rt, stirred overnight, and diluted with water (20 mL). The resulting suspension is extracted with EtOAc(3 x 25 mL), and the combined extracts are washed with saturated bicarbonate solution, and brine. The organic phase is dried over sodium sulfate, and concentrated under vacuum to give crude amide (2.35 g, contaminated with 2,4,6-collidine). The residue is dissolved in acetic acid (15 mL), stirred at 50 ° C for 8 h, and concentrated to dryness. The residue is diluted with ethyl acetate (25 mL), washed with aq. NaHCO3 solution, and brine. The organic phase is dried over sodium sulfate, concentrated under vacuum and the residue is purified by silica gel chromatography (ethyl acetate/hexanes,40 to 60 %) to give 15 (1.74 g) as light brown solid.
1 H NMR spectra in CDCl 3 and CD 3 OD showed 1.2:1 and 2:1 ratio of isomeric mixture (exchange of imidazole nitrogen) .19F spectra also showed mixture of two isomers.
1H NMR (400 MHz, CDCl3, 1.2:1 ratio of isomers): Peaks for the major isomer, δ [ppm] 7.86 (d, J = 6.2, 1 H), 7.45 (d, J = 9.2, 1 H), 6.77(s, 0.35 H), 5.02 (m, 1 H), 3.41 (m, 2 H), 2.2-1.9 (m, 2 H), 1.49 (s, 3 H). LC/MS: m/z = 303.78 (M-100+H+). 19F NMR (400 MHz, CDC13), δ [ppm] -113.4 (t), -115.7 (t). Intermediate 16:
Figure imgf000355_0001
Step 2
To a solution of intermediate 15 (1 g, 2.442 mmol) in DCM (10 ml.) at rt is added TFA (5 ml_, 64.90 mmol). The reaction mixture is stirred 45 minutes and solvent is removed under vacuum. The residue is neutralized with saturated bicarbonate solution, and the resulting solid is extracted with ethyl acetate (3 x 15 ml_). The combined organic phases are washed with brine, dried over sodium sulfate, and concentrated under vacuum to give 16 (292 mg, 1.028 mmol) as a brown gum. Intermediate 17:
Figure imgf000355_0002
To a cold (0-4 ° C) solution of intermediate 16 (298 mg, 1.049 mmol) and (2S)-2- (methoxycarbonylamino)-3-methyl-butanoic acid (202.2 mg, 1.154 mmol) in DMF (5.0 mL) are sequentially added HATU (438.8 mg, 1.154 mmol) and 2,4,6-collidine (279.7 mg, 305.0 μl_, 2.308 mmol). The reaction mixture is slowly warmed up to rt during 4.5 hours, diluted with water (10 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic phases are washed with aq. 1 N HCl, saturated bicarbonate solution, and brine. The organice phase is dried over sodium sulfate, concentrated under vacuum, and purified by silica gel chromatography (MeOH/ethyl acetate, 0 to 10%) to give intermediate 17 (130 mg) as light yellow solid.
1H NMR (400 MHz, CD3OD, 5:1 ratio of rotamers): Peaks for the major isomer, δ [ppm] 7.7 (brs, 1 H), 7.33 (d, J = 8.4, 1 H), 7.0 (d, J = 8.4, 0.5 H), 5.19 (dd, J = 7.8, 5.1 , 1 H), 4.24-4.18 (m, 1 H), 4.06-3.8 (m, 2 H), 3.63 (s, 3 H), 2.45-1.9 (m, 5 H), 0.895 (d, J = 6.8, 3 H), 0.85 (d, J = 6.6, 3 H).
LC/MS: m/z = 442.87 (M+H+). Intermediate 19
Figure imgf000356_0001
Compound 3 (2.23 g, 4.74 mmol), 4,4,4',4\ 5,5,5', 5'-octamethyl-2,2';bi(1 , 3,2- dioxaborolane (3.61 g, 14.22 mmol), PdCl2dppf (193 mg), and potassium acetate (1.53g, 15.64 mmol) are added to 40 mL of dry DMF. The mixture is purged twice with nitrogen and is stirred overnight at 85 °C. After removal of the solvent under reduced pressure, the residue is purified on flash chromatography on silica gel (methanol/DCM, 0 to 5%) to give 1.5 g of Intermediate 19.
1H NMR (400 MHz, CDCl3): δ [ppm] 7.60-7.95 (m, 3H), 5.82 (m, 1 H), 5.42 (m, 1 H), 4.29 (m, 1 H), 3.63-3.75 (m, 6H), 3.04 (m, 1 H), 1.91 -2.40 (m, 5H), 1.26-1.34 (m, 12H), 0.79-1.03 (m, 6H).
LC/MS : m/z 471.19 (M + H+).
Intermediate 20
{(S)-1-[(S)-2-(6-Azido-1H-benzoimidazol-2-yl)-pyrrolidine-1-carbonyl]-2- methyl-propyl}-carbamic acid methyl ester te, CuI
Figure imgf000356_0002
Step Compound 3 (100 mg, 0.213 mmol), sodium azide (21 mg, 0.32 mmol), sodium L- ascorbate (4.2 mg, 0.021 mmol) and copper(l) iodide (8.1 mg, 0.042 mmol) are dissolved in a mixture of 1.0 mL of DMSO and 0.2 mL of water. N, N'- dimethylethane-1 ,2-diamine is added and the reaction mixture is stirred for one hour at room temperature. A portion of 50 mL of EtOAc is added and the mixture is washed with three portions of 40 m L of water. The organic portion is dried over anhydrous sodium sulfate, concentrated and purified by flash ichromatography on silica gel (MeOH/EtOAc 0% to 10%) to give (50 mg) of intermediate 20 as a yellow gum.
1H NMR (400 MHz, CDCl3): δ [ppm] 10.68 (s, 1 H), 7.66 (d, 0.55H), 7.41 (s, 0.55H), 7.21 (d, 0.45H), 6.84-6.90 (m, 1.45H), 5.59 (br d, 1 H), 5.38-5.40 (m, 1 H), 4.35 (dd, 1 H), 3.89 (q, 1 H), 3.65-3.78 (m, 1 H), 3.70 (s, 3H), 2.99 (br s, 1 H), 2.33-2.44 (m, 1 H), 2.22-2.28 (m, 1 H), 2.07-2.20 (m, 1 H), 1.96-2.04 (m, 1 H), 0.86-0.93 (m, 6H).
LC/MS: m/z = 385.94 (M+H+).
Intermediate 21
Figure imgf000357_0001
Step 1 -1
To a stirring solution of 4-iodobenzene-1 ,2-diamine (570mg, 2.43mmol) and (2S,4R)-4-tert-butoxy-1 -(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid (998 mg, 2.437 mmol) in DMF (7ml_) are added HATU (1.01 g, 2.68mmol), and DIPEA (0.85mL, 4.87mmol) at 0°C. The reaction mixture is stirred for 3 hours, diluted with water (10OmL) with fast stirring, and a beige solid crashed out in the mixture. The suspension is filtered to give 1.59 g of solid.
Step 1 -2
The solid is dissolved in acetic acid, stirred overnight at 50°C, and concentrated to dryness under vacuum. The residue is purified by flash chromatography on silica gel (EtOAc/Hexanes, 30% to 100%) to give intermediate 21 (1.31 g). Intermediate 22
piperidine
Figure imgf000358_0001
22
To a solution of intermediate 21 (1.31 g, 2.15 mmol) in DMF (4.75 ml.) is added piperidine (1 ml.) at 0°C. The reaction mixture is stirred for 30 minutes at rt and is concentrated to dryness. The residue is purified by flash chromatography on silica gel (MeOH/CH2Cl2, 1% to 10%) to give intermediate 22 (701 mg). Intermediate 23
Figure imgf000358_0002
To a solution of intermediate 22 (691 mg, 1.79mmol) and Moc-Valine (384mg, 1.97mmol) in DMF (5 mL) are added HATU (750mg, 1.97mmol) and DIPEA (62OuL, 3.58mmol) at 0°C. The reaction mixture is stirred overnight at rt, diluted with water (10OmL) with fast stirring, and a white solid crashed out from the solution. The solid is filtered to give intermediate 23 (947mg). Intermediate 24
(S)-2-(5-lodo-1 H-benzoimidazol-2-yl)-piperidine-1 -carboxylic acid benzyl ester
Figure imgf000358_0003
To a mixture of 4-iodo-benzene-1 ,2-diamine (1.5 g, 6.4 mmol) and (S)-N-Cbz-2- piperidine-carboxylic acid (available commercially at Aldrich) (1.7 g, 6.4 mmol) in DMF (20 ml.) at 0°C is added DIPEA (3.3 ml_, 19.2 mmol) followed by HATU (3.0 g, 7.69 mmol). The reaction mixture is stirred at 0°C, brought to room temperature and stirred overnight. The reaction mixture is than concentrated in vacuum and the residue is dissolved in AcOH (15 mL) and stirred at 60°C for 4 hours. The mixture is concentrated in vacuum and the residue is dissolved in EtOAc and washed with water, 1 N HCl and brine, dried over sodium sulfate and concentrated in vacuum. The residue is purified by flash column chromatography on silica gel (MeOH/DCM 0% to 20%) to give the title compound (1.4 g, 47%).
1H NMR (400 MHz, CD3OD): δ [ppm] 7.98 (s, 1 H), 7.71 (d, 1 H), 7.43 (d, 1 H), 7.30 (br m, 5H), 5.76 (br s, 1 H), 5.20 (m, 2H), 4.18 (br d, 1 H), 3.00 (m, 1 H), 2.43 (br d, 1 H), 2.05 (m, 1 H), 1.78 (m, 1 H), 1.56 (m, 3H).
LC/MS: m/z = 462.00 (M+H+).
Intermediate 25
(S)-2-(5-lodo-1 H-benzoimidazol-2-yl)-piperazine-1 ,4-dicarboxylic acid 1- benzyl ester 4-tert-butyl ester
Figure imgf000359_0001
This intermediate is synthesized as described for Intermediate 24
The (S)-piperazine-1 ,2,4-tricarboxylic acid 4-tert-butyl ester 1 -benzyl ester is commercially available at Astatech.
LC/MS: m/z = 563.15 (M+H+). Intermediate 26
(S)-2-(5-lodo- 1 H-benzoimidazol-2-yl)-pyrrolidine- 1 -carboxylic acid benzyl ester
Figure imgf000360_0001
This intermediate is synthesized as described for Intermediate 24
1H NMR (400 MHz, CDCl3): δ [ppm] 7.48 (d, 1 H), 7.40-7.16 (m, 7H), 5.20 (m, 3H), 3.50 (m, 3H), 3.03 (m, 1 H), 2.19 (m, 1 H), 2.00 (m, 1 H).
Intermediate 27
(S)-2-(5-lodo-1 H-benzoimidazol-2-yl)-pyrrolidine-1 -carboxylic acid tert-butyl ester
Figure imgf000360_0002
This intermediate is synthesized as described for Intermediate 24 LC/MS: m/z = 413.95 (M +).
General procedure for Intermediate 28
Figure imgf000360_0003
Step 1 : The acetylene group is introduced by Sonogoshira coupling using copper and palladium catalysts in solvants such as DMF in presence of base such as TEA or DIPEA.
Step 2: The removal of the si LyI group is obtained by a base such as potassium carbonate in MeOH or by using TBAF conditions. Intermediate 28
(S)-2-(5-Ethynyl- 1 H-benzoimidazol-2-yl)-piperidine- 1 -carboxylic acid benzyl ester
Figure imgf000361_0001
Step 1
To a stirring solution of (S)-2-(5-iodo-1 H-benzoimidazol-2-yl)-piperidine-1 - carboxylic acid benzyl ester (524 mg, 1.135 mmol), CuI (22 mg, 0.114 mmol) and bis(triphenylphosphine)palladium (II) dichloride (40 mg, 0.056 mmol) in DMF (4 ml.) is added TEA (0.47 ml_, 3.4 mmol) followed by ethynyl-trimethylsilane (0.17 ml_, 1.25 mmol). The reaction mixture is stirred at room temperature overnight and concentrated in vacuum to dryness. The residue is purified by flash column chromatography on silica gel (EtOAc/hexanes 5% to 100%) to give a yellow residue which is triturated twice with DCM to afford the title compound (S)-2-(5- trimethylsilanylethynyl-1 H-benzoimidazol-2-yl)-piperidine-1 -carboxylic acid benzyl ester (340 mg, 70%).
1H NMR (400 MHz, CD3OD): δ [ppm] 7.50-7.00 (m, 8H), 5.42 (d, 1 H), 4.94 (m, 2H), 3.98 (br d, 1 H), 2.75 (m, 1 H), 2.30 (m, 1 H), 1.70 (m, 1 H), 1.55-1.20 (m, 4H), 0.02 (s, 9H).
LC/MS: m/z = 432.18 (M+H+).
Step 2
To a stirring solution of compound (S)-2-(5-trimethylsilanylethynyl-1 H- benzoimidazol-2-yl)-piperidine-1 -carboxylic acid benzyl ester (85.3 mg, 0.197 mmol) in MeOH (2 mL) is added potassium carbonate (27.3 mg, 0.197 mmol). The reaction mixture is stirred at room temperature for 3 hours and concentrated in vacuum to dryness. The residue obtained is used directly in the next step.
LC/MS: m/z = 359.87 (M +). Intermediate 29
(S)-2-(5-Ethynyl-1 H-benzoimidazol-2-yl)-piperazine-1 ,4-dicarboxylic acid 1- benzyl ester 4-tert-butyl ester
Figure imgf000362_0001
This intermediate is synthesized as described for Intermediate 28
LC/MS: m/z = 461.05 (M +H +).
Intermediate 30
(S)-2-(5-Ethynyl-1 H-benzoimidazol-2-yl)-pyrrolidine-1-carboxylic acid benzyl ester
Figure imgf000362_0002
This intermediate is synthesized as described for Intermediate 28
1H NMR (400 MHz, CDCl3) mixture of rotamers: δ [ppm] 7.90 (m, 1 H), 7.74 (m, 1 H), 7.45 (m, 1 H), 7.38-7.18 (m, 3H), 7.10-6.86 (m, 2H), 5.50 (m, 1 H), 5.20-4.90 (m, 2H), 4.00-3.50 (m, 2H), 3.10 (m, 1 H), 2.58 (m, 1 H), 2.32-1.92 (m, 2H), 1.65 (m, 1 H).
Intermediate 31
(S)-2-(5-Ethynyl-1 H-benzoimidazol-2-yl)-pyrrolidine-1-carboxylic acid tert- butyl ester
Figure imgf000362_0003
This intermediate is synthesized as described for Intermediate 28
1H NMR (400 MHz, CDCl3): δ [ppm] 7.78 (m, 1 H), 7.59 (m, 1 H), 7.40 (d, 1 H), 5.18 (d, 1 H), 3.48 (m, 2H), 3.08 (m, 2H), 2.24 (m, 2H), 2.03 (m, 1 H), 1.50 (s, 9H). Intermediate 32
{(R)-2-[ (S)-2-(5-Ethynyl- 1 H-benzoimidazol-2-yl)-pyrrolidin- 1 -yl]-2-oxo- 1 - phenyl-ethyl}-carbamic acid methyl ester
Figure imgf000363_0001
This intermediate is synthesized as described for Intermediate 28
Intermediate 33
[(S)-2-(5-Ethynyl-1 H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(R)-tetrahydro-furan- 2-yl-methanone
Figure imgf000363_0002
This intermediate is synthesized as described for Intermediate 28
1H NMR (400 MHz, CDCl3): δ [ppm] 7.62 (s, 1 H), 7.49 (d, 1 H), 7.29 (d, 1 H), 5.52 (br m, 1 H), 4.75 (br m, 1 H), 3.90 (m, 3H), 3.58 (m, 1 H), 3.10 (s, 1 H), 2.78 (br m, 1 H), 2.30 (m, 3H), 2.20-1.80 (m, 4H).
Example 1
((S)-1-{(S)-2-[5-(4-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-phenyl)-1 H-benzoimidazol-2-yl]- pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
C
Figure imgf000364_0001
Compound 3 (216 mg, 0.46 mmol), (4-boronophenyl)boronic acid (33 mg, 0.2 mmol), PdCl2dppf (16 mg, 10 mol%), and Na2CO3 (IM, 1 ml.) are added to 5 mL of acetonitrile. The mixture is purged with nitrogen and stirred overnight at 85 °C. After removal of the solvent under reduced pressure, the residue is purified by flash chromatography on silica gel (methanol/DCM, O to 5%). The resulting compound is further purified by reverse phase HPLC to obtain 34 mg of title compound.
1H NMR (400 MHz, CDCl3): δ [ppm] 7.40-7.90 (m, 1 OH), 5.5 (bs, 2H), 5.42 (m, 2H), 4.34 (m, 2H), 3.63-3.75 (m, 1 OH), 2.95 (bs, 2H), 2.00-2.45 (m, 1 OH), 0.90-1.06 (m, 12H).
LC/MS : m/z 763.58 (M + H+). The following compounds are synthesized as described in Example 1
Example 2
((S)-1-{(S)-2-[5-(3-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-phenyl)-1 H-benzoimidazol-2-yl]- pyrrolidine- 1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Figure imgf000364_0002
1H NMR (400 MHz, CD3OD): δ [ppm] 7.50-7.90 (m, 10H), 5.26 (m, 2H), 4.20 (d,
2H), 4.01 (m, 2H), 3.91 (m, 2H), 3.63(s, 6H), 2.01 -2.41 (m, 10H), 0.85-0.97 (m,
12H).
LC/MS : m/z 763.58 (M + H+).
Example 3
((S)-1-{(S)-2-[5-(4-{2-[(S)-4,4-Difluoro-1-((S)-2-methoxycarbonylamino-3- methyl-butyryl)-pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-phenyl)-1 H- benzoimidazol-2-yl]-4,4-difluoro-pyrrolidine-1-carbonyl}-2-methyl-prop yl)- carbamic acid methyl ester
Figure imgf000365_0001
1H NMR (400 MHz, CD3OD): δ [ppm] 7.59-7.90 (m, 10H), 5.48 (m, 2H), 4.58 (m, 2H), 4.09-4.28 (m, 4H), 3.91 (m, 2H), 3.64(s, 6H), 2.80-3.05(m, 4H), 1.99 (m, 2H), 0.84-0.99 (m, 12H).
LC/MS : m/z 835.56 (M + H+).
Example 4
[(S)-1-((S)-2-{5-[4-(2-{(S)-1-[(S)-2-(Methoxycarbonyl-methyl-amino)-3-methyl- butyryl]-pyrrolidin-2-yl}-1 H-benzoimidazol-5-yl)-phenyl]-1 H-benzoimidazol-2- yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-methyl-carbamic acid methyl ester
Figure imgf000365_0002
δ (400 MHz, CD3OD)δ [ppm] 7.56-7.90 (m, 10H), 5.25-5.55 (m, 2H), 4.45-4.67 (m, 2H), 4.34 (m, 2H), 3.63-3.95 (m, 10H), 2.85 (m, 6H), 1.90-2.45(m, 10H), 0.73-0.96 (m, 12H).
LC/MS : m/z 791.65 (M + H+). Example 5
((S)-1-{(S)-2-[5-(2-Cyano-4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl- butyryl)-pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-phenyl)-1 H-benzoimidazol-2- yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Figure imgf000366_0001
Intermediate 19 (103 mg, 0.22 mmol), 5-bromo-2-iodo-benzonitrile (0.1 mmol, 0.1 mmol), 1M aq NaHCO3 solution (0.5 ml_, 0.5 mmol), and Pd(PPh3J4 (11.5 mg, 10 mol %) are suspended into 2.5 mL of isopropanol in a microwave vial. The mixture is purged with nitrogen, heated to 85 °C, and stirred overnight. The mixture is concentrated under vacuum and the residue is purified by flash chromatography on silica gel (methanol/DCM, 0 to 6%) to give a white solid. This solid is further purified on reverse phase HPLC to give title compound (9.3 mg).
1H NMR (400 MHz, CD3OD): δ [ppm] 7.45-8.09 (m, 9H), 5.30 (m, 2H), 4.34 (d, 2H), 3.91 -4.02 (m, 4H), 3.64 (s, 6H), 2.03-2.40 (m, 10H), 0.86-0.98 (m, 12H).
LC/MS : m/z 788.64 (M + H+).
The following compounds are synthesized as described in Example 5 Example 6
((S)-1-{(S)-2-[5-(5-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-pyridin-2-yl)-1 H-benzoimidazol-2-yl]- pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Figure imgf000366_0002
1H NMR (400 MHz, CD3OD): δ [ppm] 7.57-8.87 (m, 9H), 5.27 (m, 2H), 4.25 (d, 2H), 3.91 -4.02 (m, 4H), 3.64 (s, 6H), 2.03-2.40 (m, 10H), 0.86-0.98 (m, 12H).
LC/MS : m/z 764.65 (M + H+). Example 7
((S)-1-{(S)-2-[5-(4-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-2-methyl-phenyl)-1H-benzoimidazol- 2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Figure imgf000367_0001
1H NMR (400 MHz, CD3OD): δ [ppm] 7.21 -7.54 (m, 9H), 5.27 (m, 2H), 4.25 (d, 2H), 3.91 -4.02 (m, 4H), 3.64 (s, 6H), 2.03-2.40 (m, 10H), 0.86-0.98 (m, 12H).
LC/MS : m/z 777.60 (M + H+). Example 8
((S)-1-{(S)-2-[5-(2-Methoxy-4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl- butyryl)-pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-phenyl)-1 H-benzoimidazol-2- yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic aci d methyl ester
Figure imgf000367_0002
1H NMR (400 MHz, CD3OD): δ [ppm] 7.28-7.80 (m, 9H), 5.27 (m, 2H), 4.25 (d, 2H), 3.86-4.10 (m, 7H), 3.64 (s, 6H), 2.03-2.40 (m, 10H), 0.86-0.98 (m, 12H).
LC/MS : m/z 793.58 (M + H+). Example 9
((S)-1-{(S)-2-[5-(2-Fluoro-4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl- butyryl)-pyrrolidin-2-yl]- 1 H-benzoimidazol-5-yl}-phenyl)- 1 H-benzoimidazol-2- yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Figure imgf000367_0003
1H NMR (400 MHz, CD3OD): δ [ppm] 7.46-7.80 (m, 9H), 5.27 (m, 2H), 4.25 (d, 2H), 3.90-4.10 (m, 4H), 3.64 (s, 6H), 2.03-2.40 (m, 10H), 0.86-0.98 (m, 12H).
LC/MS : m/z 781.56 (M + H+). Example 10
((S)-1-{(S)-2-[5-(2-Chloro-4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl- butyryl)-pyrrolidin-2-yl]- 1 H-benzoimidazol-5-yl}-phenyl)- 1 H-benzoimidazol-2- yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Figure imgf000368_0001
To a mixture of Intermediate 19 (135mg, 0.24 mmol), 2,5-diiodo- chlorobenzene(39mg, 0.10 mmol) and Pd(PPh3)4 (12.4mg, O.OI Ommol) in 2.5ml of isopropanol is added 0.53ml of 1M aq NaHCO3 solution. This mixture is heated under microwave at 150°C for 300 seconds and concentrated under vacuum. The residue is purified by flash chromatography on silica gel (MeOH/CH2Cl2, 0% to 6%), and further purified by reverse phase HPLC using a gradient of acetonitrile/water to give title compound(18.3mg)
1H NMR (400 MHz, CD3OD): δ [ppm] 7.80-7.30 (m, 9H), 5.28 (dd, 2H), 4.24 (d, 2H), 4.1 -3.85 (m, 4H), 3.64(s, 6H), 2.46-2.00 (m, 10H), 0.90 (d, 6H), 0.88 (d, 6H). LC/MS: m/z = 797.5(M+H+).
The following compounds are synthesized as described in Example 10
Example 1 1
((S)-1-{(S)-2-[5-(2-Cyano-6-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl- butyryl)-pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-pyridin-3-yl)-1 H- benzoimidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamicacid methyl ester
Figure imgf000368_0002
1H NMR (400 MHz, CD3OD): δ [ppm] 8.62 (d, 2H), 7.64(d, 2H), 7.45-6.94 (m, 4H), 5.10 (m, 2H), 4.18 (d, 2H), 3.90-3.75 (m, 8H), 3.58(s, 6H), 2.40-1.80 (m, 10H), 1.80-1.60(m, 12H).
LC/MS: m/z = 789.6(M+H+).
Example 12
(S)-1-{(S)-2-[5-(2,5-Dimethoxy-4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3- methyl-butyryl)-pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-phenyl)-1 H- benzoimidazol-2-yl]-pyrrolidine- 1 -carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Figure imgf000369_0001
1H NMR (400 MHz, CD3OD): δ [ppm] 8.75-7.30 (m, 6H), 6.96(s, 2H), 5.20 (dd, 2H), 4.16 (d, 2H), 4.00-3.80 (m, 4H), 3.68(s, 6H), 3.56 (s, 6H), 2.40-1.90 (m, 10H), 0.84 (d, 6H), 0.80(d, 6H).
LC/MS: m/z = 823.6 (M+H+).
10
Example 13
((S)-1-{(S)-2-[5-(4-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]- 1 H-benzoimidazol-5-yl}-2, 3-dimethyl-phenyl)- 1 H- benzoimidazol-2-yl]-pyrrolidine- 1 -carbonyl}-2-methyl-propyl)-carbamic acid 15 methyl ester
Figure imgf000369_0002
To a mixture of Intermediate 19( 60mg, 0.12 mmol), 1 ,4-dibromo-2,3-dimethyl- benzene(14.6mg, 0.055 mmol) and PdCl2dppf-DCM (4.5mg, 0.0055mmol) in
20 0.5ml of 1 ,2-dimethoxyethane is added 0.25ml of a 2M aq Na2CO3 solution. This mixture is heated under microwave at 150°C for 20 minutes. The brown biphasic solution is diluted with EtOAc, washed by H2O and brine. The organic phase is dried over sodium sulfate, filtered and concentrated under vacuum. The residue is purified by flash chromatography on silica gel (MeOH/DCM, 2% to
25 30%) to give title compound(19 mg) of a beige powder.
1H NMR (400 MHz, CD3OD): δ [ppm] 7.57-7.36 (m, 4H), 7.17-7.15 (d, 2H), 7.08 (s, 2H), 5.27 ( m, 2H), 4.24 (d, 2H), 4.1 -3.99 (m, 2H), 3.93-3.91 (m, 2H), 3.64(s, 6H), 2.46-2.23 (m, 5H), 2.19 (s, 6H), 2.13-2.028 (m, 5H), 0.96-0.92 (d, 6H), 0.88-0.86 30 (d, 6H).
LC/MS: m/z = 791.6(M+H+). The following compounds are synthesized as described in Example 13
Example 14
((S)-1-{(S)-2-[5-(4-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]- 1 H-benzoimidazol-5-yl}-2, 5-dimethyl-phenyl)- 1 H- benzoimidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamicacid methyl ester
Figure imgf000370_0001
1H NMR (400 MHz, CD3OD): δ [ppm] 7.65-7.39 (m, 6H), 7.19 (d, 1 H), 7.12 (s, 1 H), 5.27 ( m, 2H), 4.24 (d, 2H), 4.1 -3.9 (m, 2H), 3.93-3.89 (m, 2H), 3.64(s, 6H), 2.46- 2.25 (m, 5H), 2.22 (s, 6H), 2.15-2.011 (m, 5H), 0.96-0.92 (d, 6H), 0.88-0.86 (d, 6H).
LC/MS: m/z = 791.6(M+H+).
Example 15
((S)-1-{(S)-2-[5-(5-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-pyrimidin-2-yl)-1 H-benzoimidazol-2- yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Figure imgf000370_0002
1H NMR (400 MHz, CD3OD): δ [ppm] 9.10 (d, 2H), 8.71 -8.38 (m, 3H), 7.91 -7.60 (m, 3H), 5.25 ( m, 2H), 4.25 (dd, 2H), 4.04-4.02 (m, 2H), 3.93-3.88 (m, 2H), 3.64(s, 6H), 2.68-1.99 (m, 10H), 0.92 (d, 6H), 0.87 (d, 6H).
LC/MS: m/z = 765.6(M+H+).
Example 16
(2S,2'S)-tert-butyl-2,2l-(5,5l-(thiophene-2,5-diyl)bis(1H-benzo[d]imidazole- 5,2-diyl))dipyrrolidine-1-carboxylate
Figure imgf000371_0001
To a solution of (S)-tert-Butyl-2-(5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)- 1 H-benzo[d]imidazol-2-yl)pyrrolidine-1 -carboxylate (322 mg, 0.7791 mmol) in DME (6 ml) is added 2,5-dibromothiophene (94.26 mg, 43.90 μl_, 0.3896 mmol), Tetrakis(triphenylphosphane) palladium (0) (180.0 mg, 0.1558 mmol) and 2M aq Na2CO3 (1.168 ml_, 2.337 mmol). The reaction is purged with nitrogen for several minutes and sealed in a reaction tube. The reaction is stirred overnight at 90°C. The reaction is cooled to room temperature and the mixture is extracted with EtOAc (5 ml x 3). The combined organic layer is dried over sodium sulfate and concentrated. The crude is purified over silica gel to afford 325 mg of desired title product.
LC/MS: 10-90%MeOH 3/5min(grad/run): R.T.= 3.16 min, M+1 =655.63 Example 17
Dimethyl-(2S,2'S)-1, 1 l-((2S,2lS)-2,2l-(5,5l-(thiophene-2,5-diyl)bis(1H- benzo[of]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1- oxobutane-2, 1 -diyl)dicarbamate
\
Figure imgf000371_0002
tert-butyl-(2S)-2-[5-[5-[2-[(2S)-1 -tert-butoxycarbonylpyrrolidin-2-yl]-1 H- benzimidazol-5-yl]-2-thienyl]-1 H-benzimidazol-2-yl]pyrrolidine-1 -carboxylate (205 mg, 0.3131 mmol) is dissolved in DCM (10 mL) and HCl 4 M in dioxane (2.348 ml_, 9.393 mmol) is added into the solution. The reaction is stirred at room temperature for 30 minutes and the solvent is removed to afforded 185 mg of desired tetra HCl salt. This salt (57 mg, 0.09493 mmol) is dissolved in DMF (2 ml) and 4-methylmorpholine (76.81 mg, 83.49 μl_, 0.7594 mmol), (2R)-2- (methoxycarbonylamino)-3-methyl-butanoic acid (83.14 mg, 0.4746 mmol) are added into this solution. The mixture is stirred at room temperature for 30 minutes. Propylphosphonic anhydride (302.0 mg, 0.4746 mmol) is added into the reaction and the reaction is stirred at room temperature for 3 hours. The reaction is diluted with 20 ml EtOAc and washed with water (5 ml x 2), saturated aq NaHCO3 and brine. The organic layer is concentrated under vacuum and purified by reverse phase HPLC to give 28.6 mg of bis HCl salt of title compound. LC/MS: 10-90%MeOH 3/5min(grad/run): R.T.= 3.09 min, M+1 =769.85
DMSO-d6: 7.92 (bs, 2H); 7.77 (m, 4H); 7.66 (s, 2H); 7.30 (m, 2H); 5.20 (m, 2H); 4.10 (m, 2H); 3.83 (m, 4H); 2.20-1.88 (m, 6H); 1.70-1.40 (m, 4H); 1.00-0.80 (m, 12H)
Example 18
methyl N-[(1S)-1-[(2S)-2-[5-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]pyrrolidin-2-yl]-1H-benzimidazol-5-yl]-2-thienyl]-1 H- benzimidazol-2-yl]pyrrolidine- 1 -carbonyl]-2-methyl-propyl]carbamate
Figure imgf000372_0001
Step I:
Intermediate 19 (236 mg, 0.454 mmol), 2,4-dibromothiophene (50 mg, 0.2067 mmol) and Pd(PPh3)4 (23.89 mg, 0.02067 mmol) are added in isopropanol (2.000 ml.) and 1M aq NaHCO3 (0.5 mL). Then, the mixture is purged with nitrogen and stirred for 5 minutes at 15O°C in the microwave. The reaction mixture is diluted with water (5 mL) and EtOAc (15 mL) and filtered off insoluble materials. Then, the filtrate is washed with water, dried over sodium sulfate, and concentrated under vacuum. The residue is purified by silica gel thin layer chromatography plate (methanol-EtOAc, 1 to 10%) to give title compound (6.0 mg).
1H NMR (400 MHz, DMSO): δ [ppm] 12.5 (s, 1 H), 9.44 (s, 1 H), 8.25 (d, 1 H), 7.80- 7.40 ( m, 2H), 7.27 (br s, 1 H), 7.14 (d, 1 H), 6.86 (s, 1 H), 4.96 (s, 1 H), 3.92 (s, 3H), 3.48 (m, 1 H), 2.95-2.61 (m, 3H), 2.04-1.38 (m, 14H), 1.09 (d, 3H), 0.99 (d, 3H) LC/MS: m/z = 769.59 (M+H+).
Example 19
((S)-1-{(S)-2-[5-(4-Benzyloxy-5-{2-[(S)-1-((S)-2-methoxycarbonylamino-3- methyl-butyryl)-pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-pyrimidin-2-yl)-1 H- benzoimidazol-2-yl]-pyrrolidine- 1 -carbonyl}-2-methyl-propyl)-ca rbamic acid methyl ester
Figure imgf000373_0001
10
Step I
Title compound is prepared using a similar procedure as described in Example 5. 1H NMR (400 MHz, CD3OD): δ [ppm] 8.35-8.65 (m, 3H), 7.27-7.90 (m, 9H), 5.69 (s, 2H), 5.27 (m, 2H), 4.25 (m, 2H), 3.90-4.10 (m, 4H), 3.64 (s, 6H), 2.03-2.40 (m, 15 10H), 0.86-0.98 (m, 12H).
LC/MS : m/z 871.56 (M + H+).
Example 20
((S)-1-{(S)-2-[5-(4-Hydroxy-5-{2-[(S)-1-((S)-2-methoxycarbonylamino-3- 20 methyl-butyryl)-pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-pyrimidin-2-yl)-1 H- benzoimidazol-2-yl]-pyrrolidine- 1 -carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
Figure imgf000373_0002
25 Step 1
To a solution of compound from example 19(15mg) in 3 mL of methanol is added Pd-C 10% (5 mg). The reaction is stirred for 30 minutes under hydrogen atmosphere. The reaction mixture is filtered, concentrated to dryness and the residue is purified by reverse phase HPLC to give title compound as a white solid (8 mg).
1H NMR (400 MHz, CD3OD): δ [ppm] 8.24 (s, 2H), 7.95 (s, 2H), 7.54 (m, 3H), 5.27 (m, 2H), 4.25 (d, 2H), 3.90-4.10 (m, 4H), 3.64 (s, 6H), 2.03-2.40 (m, 10H), 0.86- 0.98 (m, 12H).
LC/MS : m/z 781.60 (M + H+).
Example 21
((S)-1-{(S)-2-[6-(1-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]-3H-benzoimidazol-5-yl}-1 H-[1 ,2,3]triazol-4-yl)-1 H- benzoimidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbam ic acid methyl ester
Figure imgf000374_0001
DBU (154 μl_, 1.03 mmol) is diluted in 0.5 mL of anhydrous toluene. Copper(l) iodide (5.9 mg, 0.031 mmol) is added followed by a solution of {(S)-1 -[(S)-2-(6-
Ethynyl-1 H-benzoimidazol-2-yl)-pyrrolidine-1 -carbonyl]-2-methyl-propyl}- carbamic acid methyl ester intermediated (38 mg, 0.10 mmol) in 0.5 mL of toluene and a solution of {(S)-1 -[(S)-2-(6-Azido-1 H-benzoimidazol-2-yl)- pyrrolidine-1 -carbonyl]-2-methyl-propyl}-carbamic acid methyl ester intermediate 20 (50 mg, 0.13 mmol) in 1.0 mL of toluene. The resulting mixture is submitted to microwave for 30 minutes at normal power. The final mixture is filtrated through a pad of celite using DCM. The filtrate is concentrated and purified by flash chromatography on silica gel (MeOH/CH2Cl2, 0% to 15%) The compound is further purified by reverse phase HPLC to give titlecompound (6.5 mg) as a white solid. 1H NMR (400 MHz, dmso-d6): δ [ppm] 12.56 (br s, 1 H), 12.32 (br s, 1 H), 9.23 (br s, 1 H), 8.05 (br d, 2H), 7.54-7.78 (br m, 4H), 7.34 (dd, 2H), 5.18-5.23 (m, 2H), 4.09 (t, 2H), 3.86 (br s, 4H), 3.54 (s, 6H), 2.24-2.30 (br m, 4H), 1.92-2.04 (br m, 6H), 0.82-0.91 (m, 12H).
LC/MS: m/z = 754.57 (M+H+).
Example 22
(2R,2'R,5S,5lS)-tert-butyl 5,5l-(6,6l-(1 ,4-phenylene)bis(1H-benzo[d]imidazole- 6,2-diyl))bis(2-ethylpyrrolidine-1-carboxylate)
Figure imgf000375_0001
Step I
To a mixture of compound 12( 61 mg, 0.14 mmol), (4-boronophenyl)boronic acid (9.9mg, 0.06 mmol) and pd(DPPF)CL2- DCM (4.9mg, O.OOόmmol) in 0.5ml of acetonitrile is added 0.3ml of a 2M aq Na2CO3. This mixture is stirred at 85°C for 20 hours and diluted with EtOAc. The organic phase is washed with H2O, brine, dried over sodium sulfate, and concentrated under vacuum. The residue is purified by flash chromatography by silica gel (MeOH/CH2Cl2, 1% to 30%) to give title compound (13.7 mg).
LC/MS: m/z = 705.6(M+H+).
Example 23
1 ,4-bis(2-((2S,5R)-5-ethylpyrrolidin-2-yl)-1 H-benzo[d]imidazol-6-yl)benzene
Figure imgf000375_0002
Step 2
To a solution of compound from Example 22 (13mg, 0.018mmol) in CH2Cl2 (0.1 ml) is added TFA (50μl). The reaction mixture is stirred at rt for 3 hours and concentrated to dryness. The residue is diluted with a solution of 2% MeOH in CH2Cl2, and washed by an aqueous saturated NaHCO3 solution. The aqueous phase is extracted twice by CH2Cl2 and the combined organic phases are dried over Na2SO4, filtered and concentrated under vacuum to give title compound (8 mg). LC/MS: m/z = 505.3(M+H+).
Example 24
((S)-1-{(2R,5S)-2-Ethyl-5-[5-(4-{2-[(2S,5R)-5-ethyl-1-((S)-2- methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1 H-benzoimidazol- 5-yl}-phenyl)- 1 H-benzoimidazol-2-yl]-pyrrolidine- 1 -carbonyl}-2-methyl- propyl)-carbamic acid methyl ester
Figure imgf000376_0001
To a solution compound from Example 23 (8mg, 0.015mmol), Moc-Valine (4.16mg, 0.023mmol), and 2,4,6-collidine (6.2ul, 0.047mmol) in DMF (5 mL) is added HATU (9mg, 0.023mmol) at OC. The reaction mixture is stirred at rt overnight, diluted with EtOAc, and washed with brine. The organic phase is dried over Na2SO4, filtered and concentrated. The residue is purified by reverse phase HPLC to give title compound(4.3mg).
1H NMR (400 MHz, CD3OD): δ [ppm] 7.71 -7.54 (m, 12H), 5.44 (d, 1 H), 5.26 (d, 1 H), 4.4 ( m, 1 H), 4.36 (d, 1 H), 4.13 (m, 1 H), 3.93 (m, 1 H), 3.63(s, 3H), 3.059 (s, 3H), 2.61 -1.26 ( m, 10H), 0.52-0.75(m, 22H).
LC/MS: m/z = 820.6(M+H+).
Exemple 25
((S)-1-{(2S,4R)-4-tert-butoxy-2-[5-(4-{2-[(2S,4R)-4-tert-butoxy-1-((S)-2- methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1 H-benzoimidazol- 5-yl}-phenyl)- 1 H-benzoimidazol-2-yl]-pyrrolidine- 1 -carbonyl}-2-methyl- propyl)-carbamic acid methyl ester
Figure imgf000376_0002
To a mixture of Intermediate 23 (447mg, 0.82 mmol), (4-boronophenyl)boronic acid(59 mg, 0.35 mmol) and pd(DPPF)CL2- DCM (29mg, 0.035mmol) in 3ml of acetonitrile is added 1.8ml of a 2M aq Na2CO3. This mixture is stirred 20 hours at 85° C. The resulted solution is diluted with EtOAc, washed by H2O and brine. The organic phase is dried over sodium sulfate, filtered and concentrated. The residue is purified by flash chromatography on silica gel (MeOH/CH2Cl2, 1% to 10%) and further purified by reverse phase HPLC to give title compound (47.5 mg). 1H NMR (400 MHz, CD3OD): δ [ppm] 7.90-7.50 (m, 10H), 5.32 ( t, 2H), 4.66 (m, 2H), 4.20 (d, 2H), 4.22 (dd, 2H), 3.88 (dd, 2H), 3.66(s, 6H), 2.56-2.28 (m, 4H), 2.00 (m, 2H), 1.26 (s, 18H), 0.88(d, 6H), 0.86 (d, 6H).
LC/MS: m/z = 907.6(M+H+).
Example 26
((S)-1-{(2S,4R)-4-Hydroxy-2-[5-(4-{2-[(2S,4R)-4-hydroxy-1-((S)-2- methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1 H-benzoimidazol- 5-yl}-phenyl)- 1 H-benzoimidazol-2-yl]-pyrrolidine- 1 -carbonyl}-2-methyl- propyl)-carbamic acid methyl ester
Figure imgf000377_0001
To a solution of compound from example 25 (15mg, 0.015mmol) is added TFA (0.3ml_) at 0°C. The reaction mixture is stirred 1 hour at rt, concentrated to dryness, and triturated with DCM (3X) to give title compound(16mg).
1H NMR (400 MHz, CD3OD): δ [ppm] 7.92 (d, 2H), 7.84 (m, 2H), 7.78 (m, 6H), 5.38 ( m, 2H), 4.60 (m, 2H), 4.18 (d, 2H), 3.98 (m, 4H), 3.58(s, 6H), 2.50 (m, 2H), 2.30 (m, 2H), 1.96 (m, 2H), 0.80(d, 6H), 0.78 (d, 6H).
LC/MS: m/z = 795.6(M+H+).
Example 27
Dimethyl (2S,2'S)-1 , 11-((2S,2'S)-2,21-(5,51-(1 ,4-phenylene)bis(6-fluoro-1 H- benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1- oxobutane-2, 1 -diyl)dicarbamate
Figure imgf000377_0002
To a solution intermediate 17 (117.2 mg, 0.2655 mmol) and (A- boronophenyl)boronic acid (20 mg, 0.1207 mmol) in acetonitrile (2.5 mL) under nitrogen atmosphere are sequentially added Pd(dppf)Cl2-DCM (9.857 mg, 0.01207 mmol) and sodium bicarbonate (603.5 μl_ of 1 M, 0.6035 mmol) . The resultant suspension is heated in microwave at 150 ° C for 6 minutes, concentrated under vacuum, and dissolved in a solution of 10% MeOH in CH 2 Cl 2. The suspension is filtered and the filtrate concentrated under vacuum. The residue is purified by silica gel chromatography (MeOH/ethyl acetate, 0 to 10 %) and further purified by reverse phase HPLC to give title compound (48 mg) as white solid.
1H NMR (400 MHz, CD3OD, 5:1 ratio of rotamers): Peaks for the major isomer, δ [ppm] 7.6-7.2(m, 4 H), 5.25 (dd, J = 7.8, 5.1 , 1 H), 4.24 (d, J = 7.4, 1 H), 4.1 -3.8 (m, 2 H), 3.64 (s, 3 H), 2.5-1.9 (m, 5 H), 0.92 (d, J = 6.6, 3 H), 0.87 (d, J = 6.6, 3 H).
LC/MS: m/z = 799.6 (M+H+).
General procedure for Example 28:
Intermediate 1
Figure imgf000378_0001
The dimer is formed by Sonogoshira coupling using copper and palladium catalysts in solvants such as DMF in presence of base such as TEA or DIPEA.
Example 28
(S)-2-{5-[2-((S)-1-Benzyloxycarbonyl-piperidin-2-yl)-1 H-benzoimidazol-5- ylethynyl]-1H-benzoimidazol-2-yl}-piperazine-1 ,4-dicarboxylic acid 1 -benzyl ester 4-tert-butyl ester
Figure imgf000378_0002
To a stirring solution of (S)-2-(5-ethynyl-1 H-benzoimidazol-2-yl)-piperazine-1 ,4- dicarboxylic acid 1 -benzyl ester 4-tert-butyl ester (77 mg, 0.16 mmol), (S)-2-(5- iodo-1 H-benzoimidazol-2-yl)-piperidine-1 -carboxylic acid benzyl ester (70 mg, 0.15 mmol), CuI (3 mg, 0.015 mmol) and bis(triphenylphosphine)palladium (II) dichloride (10.6 mg, 0.015 mmol) in DMF (2 mL) is added TEA (0.1 ml_, 0.76 mmol). The reaction mixture is stirred at room temperature for 2 hours, diluted with EtOAc and water. The mixture is filtered to remove insoluble material and the layers of the filtrate are separated. The organic layer is dried over sodium sulfate and concentrated in vacuum to dryness. The residue is purified by flash column chromatography on silica gel (MeOH/DCM 0% to 20%) and repurified by reverse phase HPLC using a gradient of CH3CN/water to give the title compound (9.4 g, 7%).
LC/MS: m/z = 795.27 (M +H +).
HPLC (Method A): tR = 10.48 min.
Example 29
(S)-2-{5-[2-((S)-1-Benzyloxycarbonyl-4-tert-butyloxycarbonyl-piperazin-2-yl)- 1 H-benzoimidazol-5-ylethynyl]-1 H-benzoimidazol-2-yl}-piperazine-1 ,4- dicarboxylic acid 1 -benzyl ester 4-tert-butyl ester
Figure imgf000379_0001
This compound is prepared as described in example 28
LC/MS: m/z = 896.74 (M +H +).
HPLC (Method A): tR = 11.95 min.
Example 30
(S)-2-{5-[2-((S)-1-Benzyloxycarbonyl-piperidin-2-yl)-1 H-benzoimidazol-5- ylethynyl]-1H-benzoimidazol-2-yl}-piperidine-1-carboxylic acid benzyl ester
Figure imgf000379_0002
This compound is prepared as described in example 28 LC/MS: m/z = 693.82 (M +H +).
HPLC (Method A): tR = 8.85 min.
Example 31
(S)-2-{5-[2-((S)-1-Benzyloxycarbonyl-pyrrolidin-2-yl)-1 H-benzoimidazol-5- ylethynyl]-1H-benzoimidazol-2-yl}-pyrrolidine-1-carboxylic acid benzyl ester
Figure imgf000380_0001
This compound is prepared as described in example 28
1H NMR (400 MHz, DMSO-d6): δ [ppm] 7.85 (d, 2H), 7.67 (d x d, 2H), 7.56 (br s, 2H), 7.40-7.27 (m, 4H), 7.10 (t, 2H), 6.97 (t, 2H), 6.82 (t, 2H), 5.19 (m, 2H), 5.08 (m, 2H), 4.85 (m, 2H), 3.68 (m, 2H), 2.54 (m, 2H), 2.40 (m, 2H), 2.10 (m, 2H), 1.95 (m, 4H).
LC/MS: m/z = 665.52 (M+H+). Example 32
[(S)-5-(5-{2-[(S)-1-((R)-tetrahydro-furan-2-carbonyl)-pyrrolidin-2-yl]-1 H- benzoimidazol-5-ylethynyl}-1 H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-(R)- tetrahydro-furan-2-yl-methanone
Figure imgf000380_0002
This compound is prepared as described in example 28
1H NMR (400 MHz, DMSO-d6) mixture of rotamers: δ [ppm] 7.91 (br m, 1.52H), 7.81 (br m, 0.48H), 7.72 (m, 1.52H), 7.59 (m, 2H), 7.47 (br m, 0.48H), 5.57 (m, 0.48H), 5.20 (m, 1.52H), 4.62 (br m, 1.52H), 4.25 (m, 0.48H), 3.88 (m, 2H), 3.80- 3.30 (m, 8H), 2.33 (m, 2H), 2.10 (m, 6H), 1.97-1.70 (m, 6H).
LC/MS: m/z = 593.24 (M+H+). Example 33
{(R)-2-[(S)-2-(5-{2-[(S)-1-((R)-2-Methoxycarbonylamino-2-phenyl-acetyl)- pyrrolidin-2-yl]- 1 H-benzoimidazol-5-ylethynyl}- 1 H-benzoimidazol-2-yl)- pyrrolidin- 1 -yl]-2-oxo- 1 -phenyl-ethyl}-carbamic acid methylester
Figure imgf000381_0001
This compound is prepared as described in example 28
1H NMR (400 MHz, DMSO-d6): δ [ppm] 7.87 (br s, 2H), 7.70 (d, 4H), 7.56 (m, 2H), 7.47-7.28 (m, 8H), 6.82 (m, 2H), 5.50 (d, 2H), 5.22 (d, 2H), 3.92 (m, 2H), 3.50 (s, 6H), 3.18 (m, 2H), 2.22 (m, 2H), 2.05 (m, 4H), 1.88 (m, 2H).
LC/MS: m/z = 779.38 (M+H+).
Example 34
(S)-2-(5-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin- 2-yl]- 1 H-benzoimidazol-5-ylethynyl}- 1 H-benzoimidazol-2-yl)-pyrrolidine- 1 - carboxylic acid tert-butyl ester
Figure imgf000381_0002
This compound is prepared as described in example 28
LC/MS: m/z = 654.31 (M+H+).
HPLC (Method B): tR = 13.94 mm.
General procedure for Example 35 and 36
Figure imgf000381_0003
Example 35
((S)-2-Methyl-1-{(S)-2-[5-((S)-2-pyrrolidin-2-yl-1 H-benzoimidazol-5-ylethynyl)- 1 H-benzoimidazol-2-yl]-pyrrolidine- 1 -carbonyl}-propyl)-carbamic acid methyl ester
Figure imgf000382_0001
This compound is prepared as described in example 34
1H NMR (400 MHz, CD3OD): δ [ppm] 7.69 (m, 2H), 7.52 (m, 2H), 7.38 (m, 2H), 7.15 (m, 2H), 5.22 (m, 1 H), 4.58 (m, 2H), 4.23 (m, 2H), 4.02 (m, 1 H), 3.90 (m, 1 H), 3.63 (s, 3H), 2.48-1.90 (m, 9H), 0.95 (m, 6H).
Example 36
{(S)-1-[(S)-2-(5-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]- 1 H-benzoimidazol-5-ylethynyl}- 1 H-benzoimidazol-2-yl)- pyrrolidine- 1-carbonyl]-2,2-dimethyl-propyl}-carbamic acid methyl ester
Figure imgf000382_0002
Step 2
This compound is prepared as described in example 34
1H NMR (400 MHz, DMSO-d6): δ [ppm] 12.30 (m, 2H), 7.65 (m, 1 H), 7.60 (m, 1 H),
7.49 (m, 1 H), 7.44 (m, 1 H), 7.30-7.22 (m, 3H), 7.13 (m, 1 H), 5.12 (m, 2H), 4.20
(m, 1 H), 4.03 (m, 1 H), 3.80 (m, 2H), 3.51 (s, 3H), 3.49 (s, 3H), 2.20 (m, 4H),
2.10-1.80 (m, 5H), 1.21 (m, 2H), 0.86 (s, 9H), 0.80 (m, 6H).
LC/MS: m/z = 725.47 (M+H+).
HPLC (Method B): tR = 15.45 min.
Example 37
{(S)-1-[(S)-2-(5-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]- 1 H-benzoimidazol-5-ylethynyl}- 1 H-benzoimidazol-2-yl)- pyrrolidine- 1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester
Figure imgf000382_0003
This compound is prepared as described in example 34
1H NMR (400 MHz, DMSO-d6): δ [ppm] 12.30 (d, 2H), 7.62 (m, 2H), 7.46 (m, 2H), 7.30 (m, 4H), 5.12 (m, 2H), 4.03 (m, 2H), 3.80 (m, 4H), 3.52 (s, 6H), 2.20 (m, 4H), 2.06-1.80 (m, 6H), 1.80 (m, 12H).
LC/MS: m/z = 711.44 (M+H+).
HPLC (Method D): tR = 22.88 min.
Example 38
{(S)-2-Methyl-1-[(S)-2-(5-{2-[(S)-1-((R)-tetrahydro-furan-2-carbonyl)- pyrrolidin-2-yl]- 1 H-benzoimidazol-5-ylethynyl}- 1 H-benzoimidazol-2-yl)- pyrrolidine-1-carbonyl]-propyl}-carbamic acid methyl ester
Figure imgf000383_0001
This compound is prepared as described in example 34.
1H NMR (400 MHz, DMSO-d6): δ [ppm] 12.30 (m, 2H), 7.68 (m, 1 H), 7.62-7.40 (m, 3H), 7.30 (m, 3H), 5.47 (d, 1 H), 5.10 (m, 2H), 4.59 (t, 1 H), 4.23 (m, 1 H), 4.03 (t, 1 H), 3.77 (m, 3H), 3.60 (m, 1 H), 3.50 (s, 3H), 2.30-1.70 (m, 11 H), 1.20 (m, 2H), 0.90 (m, 6H).
LC/MS: m/z = 652.41 (M+H+). Example 39
{(S)-1-[(S)-2-(5-{2-[(S)-1-((R)-2-Methoxycarbonylamino-2-phenyl-acetyl)- pyrrolidin-2-yl]- 1 H-benzoimidazol-5-ylethynyl}- 1 H-benzoimidazol-2-yl)- pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester
Figure imgf000383_0002
This compound is prepared as described in example 34
1H NMR (400 MHz, DMSO-d6): δ [ppm] 7.87 (d, 2H), 7.69 (m, 3H), 7.55 (m, 2H), 7.34 (m, 5H), 6.82 (m, 1 H), 5.50 (d, 1 H), 5.20 (m, 2H), 4.10 (t, 1 H), 3.93 (m, 1 H), 3.85 (m, 1 H), 3.51 (s, 3H), 3.49 (s, 3H), 3.19 (m, 1 H), 2.32 (m, 2H) 2.20 (m, 2H), 2.16-1.80 (m, 6H), 0.92 (d, 3H), 0.88 (d, 3H).
LC/MS: m/z = 745.46 (M+H+).
HPLC (Method E): tR = 8.48 min. General procedure for Synthesis of compounds for Example 40:
Interm
Figure imgf000384_0001
Example 40
(S)-2-(5-{(E)-4-[2-((S)-1-Benzyloxycarbonyl-piperidin-2-yl)-1 H-benzoimidazol- 5-yl]-but-1-en-3-ynyl}-1 H-benzoimidazol-2-yl)-piperidine-1-carboxylic acid benzyl ester
Figure imgf000384_0002
A mixture of (S)-2-(5-ethynyl-1 H-benzoimidazol-2-yl)-piperidine-1 -carboxylic acid benzyl ester (41 mg, 0.115 mmol) and dichloro(p-cymene) ruthenium (II) dimer (5 mg) is purged with N2. AcOH (1 mL) is added and the mixture is stirred at room temperature overnight and concentrated in vacuum to dryness. The residue is purified by flash column chromatography on silica gel (EtOAc/hexanes 5% to 100%) and repurified by reverse phase HPLC using a gradient of CH3CN/water to afford the title compound (5.9 mg, 7%).
1H NMR (400 MHz, CD3OD): δ [ppm] 7.77 (m, 3H), 7.72-7.50 (m, 4H), 7.34 (m, 9H), 7.25 (d, 1 H), 6.66 (d, 1 H), 5.85 (m, 2H), 5.20 (m, 4H), 4.18 (m, 2H), 3.04 (m, 2H), 2.45 (m, 2H), 2.10 (m, 2H), 1.83 (m, 2H), 1.70-1.44 (m, 6H).
LC/MS: m/z = 719.96 (M+H+).
General procedure for Example 42 I
Figure imgf000385_0001
Example 41
(S)-2-(5-{4-[2-((S)-1-Benzyloxycarbonyl-piperidin-2-yl)-1H-benzoimidazol-5- yl]-buta- 1 , 3-diynyl}- 1 H-benzoimidazol-2-yl)-piperidine- 1 -carboxylic acid benzyl ester
Figure imgf000385_0002
To a stirring solution of (S)-2-(5-ethynyl-1 H-benzoimidazol-2-yl)-piperidine-1 - carboxylic acid benzyl ester (26 mg, 0.0723 mmol), CuI (3 mg) and bis(triphenylphosphine)palladium (II) dichloride (8 mg) in THF (1.5 mL) is added TEA (30 μl_, 3.4 mmol). The reaction mixture is stirred at room temperature for 12 hours and filtered through celite and the filtrate is concentrated in vacuum to dryness. The residue is purified by flash column chromatography on silica gel (EtOAc/hexanes 0% to 100%) to give the title compound (S)-2-(5-{4-[2-((S)-1 - benzyloxycarbonyl-piperidin-2-yl)-1 H-benzoimidazol-5-yl]-buta-1 ,3-diynyl}-1 H- benzoimidazol-2-yl)-piperidine-1 -carboxylic acid benzyl ester (10 mg, 39%).
1H NMR (400 MHz, DMSO-d6): δ [ppm] 12.59 (d, 2H), 7.84 (s, 2H), 7.66 (s, 2H), 7.60 (d, 2H), 7.46 (d, 2H), 7.40-7.10 (m, 10H), 5.54 (m, 2H), 5.08 (m, 4H), 4.01 (m, 2H), 3.05 (m, 2H), 2.38 (m, 2H), 1.80 (m, 2H), 1.59 (m, 4H), 1.38 (m, 4H).
LC/MS: m/z = 717.96 (M+H+).
Example 42
((S)-1-{(S)-2-[5-(4-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)- pyrrolidin-2-yl]-1 H-benzoimidazol-5-yl}-2,5-difluoro-phenyl)-1 H- benzoimidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamicacid methyl ester
Figure imgf000386_0001
This compound is prepared as described in example 13
1H NMR (400 MHz, CD3OD): δ [ppm] 7.80-7.52 (m, 6H), 7.42 (d, 1 H), 7.38 (m, 1 H), 5.25 ( m, 2H), 4.24 (d, 2H), 4.1 -3.9 (m, 2H), 3.95-3.90 (m, 2H), 3.64(s, 6H), 2.50- 2.00 (m, 10H), 0.98(d, 6H), 0.90 (d, 6H).
LC/MS: m/z = 799.6(M+H+).
Example 43
Methyl N-[(1S)-1-[(2S)-2-[5-[5-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3- methyl-butanoyl]pyrrolidin-2-yl]-1 H-benzimidazol-5-yl]-3-methyl-2-pyridyl]- 1 H-benzimidazol-2-yl]pyrrolidine- 1 -carbonyl]-2-methyl-propyl]carbamate
Figure imgf000386_0002
Suzuki coupling of solution of methyl N-[(1 S)-2-methyl-1 -[(2S)-2-[6-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H-benzimidazol-2-yl]pyrrolidine-1 - carbonyl]propyl]carbamate (139.0 mg, 0.2955 mmol) and 5-bromo-2-1odo-3- methyl-pyπdine (40.00 mg, 0.1343 mmol) in acetonitπle (2.5 mL) is carried out using Pd(dppf)Cl2-DCM (16 mg, 0.01959 mmol) and sodium bicarbonate (671.5 μl_ of 1 M, 0.6715 mmol) as described for Example 28 to methyl N-[(1 S)-1 -[(2S)-2-[5- [5-[2-[(2S)-1 -[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]- 1 H-benzimidazol-5-yl]-3-methyl-2-pyπdyl]-1 H-benzimidazol-2-yl]pyrrolidine-1 - carbonyl]-2-methyl-propyl]carbamate (47.7 mg, 0.06018 mmol, 44.80%) as white solid.
Rf = 0.24 (1 :5; MeOH:Ethyl acetate). 1 H NMR (400 MHz, CD3OD, 5:1 mixture of rotamers): Peaks for the major isomer, 8.66 (brd, 1 H), 8.02 (br s, 1 H), 7.9-7.5 (m, 5 H), 7.37 (dd, 1 H), 5.3-5.25 (m, 2 H), 4.25 (d, 2 H), 4.1 -3.7 (m, 4 H), 3.64 (s, 6 H), 2.5-1.9 (m, 13 H), 0.923 (d, 6 H), 0.867 (d, 6 H). LC/MS: m/z = 778.63 (M+H+).
Example 44
Dimethyl-(2S,2'S)-1 , 1 l-((2S,2lS)-2,2l-(5,5l-(thiophene-3,4-diyl)bis(1 H- benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1- oxobutane-2, 1 -diyl)dicarbamate
Figure imgf000387_0001
This compound is made using the procedure described for example 17.
LC/MS: 10-90%MeOH 3/5min(grad/run): R.T.= 2.63 min, M+1 =769.60
DMSO-d6:7.70-7.00 (m, 10H); 5.20 (m, 2H); 4.20 (m, 2H); 3.70 (m, 4H); 3.55 (m, 6H); 2.40-1.80(m, 10H); 1.70-1.30 (m, 6H); 1 .00-0.65 (m, 12H)
Example 45
bis((S)-tetrahydrofuran-3-yl)-(2S,2'S)-1 , 1 l-((2S,2lS)-2,2l-(5,5l-(thiophene-3,4- diyl)bis(1 H-benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2, 1-diyl))bis(3-methyl- 1 -oxobutane-2, 1 -diyl)dicarbamate
Figure imgf000388_0001
This compound is made using the procedure described for example 17.
LC/MS: 10-90%MeOH 3/5min(grad/run): R.T.= 2.55 min, M+1 =881 .60
DMSO-d6:7.70-6.95 (m, 10H); 5.10 (m, 2H); 4.10-3.00 (m, 14H); 2.70 (m, 2H); 2.40-1.30 (m, 16H); 1 .00-0.65 (m, 12H)
Example 46
Dimethyl-(2S,2lS)-1,1'-((2S,2lS)-2,2l-(5,5l-(thiophene-2,3-diyl)bis(1H- benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1- oxobutane-2, 1 -diyl)dicarbamate
Figure imgf000388_0002
This compound is made using the procedure described for example 17.
LC/MS: 10-90%MeOH 3/5min(grad/run): R.T.= 2.99 min, M+1 =769.57
DMSO-d6: 7.70-7.20 (m, 10H); 5.20 (m, 2H); 4.15 (m, 2H); 3.85 (m, 4H); 3.60 (m, 6H); 2.40-1.40 (m, 16H); 1.00-0.65 (m, 12H) Example 47
bis((S)-tetrahydrofuran-3-yl)-(2S,2'S)-1 , 1 l-((2S,2lS)-2,2l-(5,5l-(thiophene-2,3- diyl)bis(1 H-benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2, 1-diyl))bis(3-methyl- 1 -oxobutane-2, 1 -diyl)dicarbamate
Figure imgf000389_0001
This compound is made using the procedure described for example 17.
LC/MS: 10-90%MeOH 3/5min(grad/run): R.T.= 3.03 min, M+1 =881.5
DMSO-d6: 7.70-7.20 (m, 10H); 5.20-5.10 (m, 4H); 415-3.5-(m, 14H); 2.40-1 .30 (m, 16H); 1.00-0.65 (m, 12H)
Example 48. Synthesis of 4-methyl-N-(t-butoxycarbonyl)-(2S)-prolinol compound
The process for synthesizing compounds of the invention uses 4-methyl-N- (t-butoxycarbonyl)-(2S)-prolinol as a starting material. Scheme 1 illustrates the process of this invention as employed to synthesize 4-methyl-N-(t- butoxycarbonyl)-(2S)-prolinol 7. As shown in Scheme 1 , the process includes multiple steps in converting the preferred starting material L-pyroglutamic acid 1 , to the enantiomerically and diastereomerically pure 4-methyl-N-(t- butoxycarbonyl)-(2S)-prolinol. The process includes first protecting the carboxylic acid as an ester (e.g. ethyl ester), followed by protection of the nitrogen with a protecting group (e.g. t-butoxylcarbonyl (BOC)). The protected pyroglutamate 3 is then converted to an enaminone 4, preferably by reacting with a nitrogen containing acetal or orthoester (e.g. 1 -t-butoxy-N,N,N',N'- tetramethylmethanediamine (Bredereck's reagent)). This conversion is carried out at elevated temperatures between 60-150°C either neat or with a solvent, preferably an ethereal solvent such as 1 ,2-dimethoxyethane. Enaminone 4 is hydrolyzed, preferably with a strong acid then reacted with a source of formaldehyde (e.g. 37 wt. % formaldehyde in water) to afford the desired A- methylene pyroglutamate 5. The 4-methylene glutamate 5 is stereospecifically reduced to the 4-methyl pyroglutamate 6 using and of the standard conditions for hydrogenation (e.g. hydrogen/10% palladium on carbon) known to those in the art. The amide carbonyl and the carboxylic acid ester of 4-methyl pyroglutamate 6 are reduced either sequentially or simultaneously with reducing agents commonly used by those familiar with the art (e.g. sodium borohydride-boron trifluoride etherate) to produce the desired 4-methyl-N-(t-butoxycarbonyl)-(2S)- prolinol 7.
Figure imgf000390_0001
Similar synthetic procedures are described in Katoh, M. et at. , Tetrahedron Letters, 46 (2005), p5161 -5163, the entire teachings of which are incorporated herein by reference. Example 49. Synthesis of 4(S)-methyl-L-BOC-proline (2)
Figure imgf000391_0001
2
A solution of 1 (100Og, 3.32mol) in water (10L) was charged to a 2OL hydrogenator along with 5% Palladium on Carbon (56% wet, 12Og, JM-JR537). The resulting mixture was hydrogenated for 8hrs with rapid agitation under a 3.0 bar hydrogen pressure. The catalyst was removed by filtration through Celite and the resulting light yellow solution was acidified to pH 1.5 with 3N HCl in the presence of isopropyl acetate (16L). The layers were separated and the aqueous layer was re-extracted with isopropyl acetate (8L). The combined organic layers were then washed with water (16L), followed by brine (8L) and then distilled under reduced pressure to dryness. The crude product (695g) was obtained as an off-white solid. Analysis by 1H-NMR indicated that the solid was a diastereomeric mixture of 9:1 cis/trans isomers (ratio of the methine proton alpha to the carbonyl). This mixture was upgraded to 20:1 cis/trans isomers by re-crystallizing twice from a 2:1 isopropyl acetate/heptane solvent mixture to obtain 459g of solid (60% yield). 1H-NMR(dmsod6): 12.45(s,1 H); 4.03(t,1 H, J=10.5Hz); 3.54(m, 1 H); 2.77(m, 1 H); 2.37(m, 1 H); 2.17(m, 1 H); 1.41 (m, 1 H); 1.38(m, 9H); 0.97(t, 3H, J=8.0Hz).
Example A. Cell-Based Luciferase Reporter HCV (Ib) RNA Replication Assay Cell Culture Replicon cell lines Huh-7, 5.2 and ET which are derived from the Huh-7 hepatocarcinoma cell line are maintained in culture as generally described in Krieger, N; Lohmann, V; Bartenschlager, R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 2001 , 75, 4614- 4624 . The Huh-7, 5.2 cells contain the highly cell culture-adapted replicon l389luc-ubi-neo/NS3-375.1 construct that carries, in addition to the neomycin gene, an integrated copy to the firefly luciferase gene (Krieger, N; Lohmann, V; 5 Bartenschlager, R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 2001 , 75, 4614-4624). This cell line allows measurement of HCV RNA replication and translation by measuring luciferase activity. It has been previously shown that the luciferase activity tightly follows the replicon RNA level in these cells (Krieger, N; Lohmann, V; Bartenschlager, R.
10 Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 2001 , 75, 4614-4624). The Huh-7, ET cell line has the same features as those mentioned for Huh-7, 5.2 cell line, except that ET cells are more robust and contain an adaptative mutation in the HCV NS4B gene instead of NS5A. Both cell lines are maintained in cultures at a sub-confluent level (<85%)
15 as the level of replicon RNA is highest in actively proliferating cells. The culture media used for cell passaging consist of DMEM (Gibco BRL Laboratories, Mississauga, ON, Canada) supplemented with 10% foetal bovine serum with 1% penicilin/streptomycin, 1% glutamine, 1% sodium pyruvate, 1% non-essential amino acids, and 180 ug/ml of G418 final concentration. Cells are incubated at
20 37°C, in an atmosphere of 5% CO2 and passaged twice a week to maintain sub- confluence.
Approximately 3000 viable Huh-7, 5.2 or ET cells (100 μl) are plated per well in a white opaque 96-well microtiter plate. The cell culture media used for
25 the assay is the same as described above except that it contains no G418 and no phenol red. After an incubation period of 3-4 hours at 37° C in a 5% CO2 incubator, compounds (100 μl) are added at various concentrations. Cells are then further incubated for 4 days at 37° C in a 5% CO2 incubator. Thereafter, the culture media is removed and cells are lysed by the addition of 95 μL of the
30 luciferase buffer (luciferin substrate in buffered detergent). Cell lysates are incubated at room temperature and protected from direct light for at least 10 minutes. Plates are read for luciferase counts using a luminometer (Wallac MicroBeta Trilux, Perkin Elmer™, MA, USA). The 50% inhibitory concentrations (IC50S) for inhibitory effect are determined from dose response curves using eleven concentrations per compound in duplicate. Curves are fitted to data points using nonlinear regression analysis, and IC50S are interpolated from the resulting curve using GraphPad Prism software, version 2.0 (GraphPad Software Inc., San Diego, CA, USA).
Table 2 show compounds reresentative of the present invention and the EC50 values against the HCV 1 b genotype.
Figure imgf000393_0001
Figure imgf000394_0001
Figure imgf000395_0001
Figure imgf000396_0001
Figure imgf000397_0001
Figure imgf000398_0001
Figure imgf000399_0001
Figure imgf000400_0001
Figure imgf000401_0001
Figure imgf000402_0001
The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

We claim:
1. A compound of formula (NIA):
Figure imgf000403_0001
(NIA)
or pharmaceutically acceptable salts thereof, wherein
each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl;
B and B' are each independently absent, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
R1 is halogen, -0Ra, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)0R3, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, - SO2NRaRb, -NRbS02R3, -NRbS02NR3Rb, -P(=0)0R30Rb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
R3-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2' and R2 are each independently halogen, C1-1O alkyl, C1-6 halogenated alkyl, -(CHz)1-6OH, -OR3, -C(=0)0R3, NRaRb, -NRbC(=O)Ra,-C(O)NRaRb, -S(O)0-3Ra, C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, C1-1S alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
X and Y are each independently
, or a bond;
Figure imgf000404_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R4 is H, C1-6 alkyl, or halogenated C|-6 alkyl;
R5 and R5' are each independently halogen, -C(O)NRaRb> -(CH2)i-6OH, C1-6 alkyl, C1-6 halogenated alkyl, or C6-14 aryl; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R6 and R6' are each independently H, C1-6 alkyl, -(CH2)i-6OH, C2-6 alkenyl, or C2-6 alkynyl;
m and n, combined are 1 , 2, 3 or 4;
p is O, 1 , 2, 3 or 4;
q' is 0, 1 or 2;
q and r are each independently 0, 1 , 2, 3 or 4;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, - C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)0R3, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, - S(O)0-3Ra, -SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, or -P(=O)ORaORb,;
R11 is halogen, -OR3, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb,
NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)0R3, -OC(=O)NRaRb, - 0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, - SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -0Ra, oxo, -NRaRb, =NO-RC , -C(=O)ORa, - C(O)NR3Rb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, - S(O)0-3R3, -SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
2. A compound of formula (NIA'):
Figure imgf000406_0001
(NlA')
or pharmaceutically acceptable salts thereof, wherein
each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl;
B and B' are each independently absent or -(C≡C)-;
R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -
C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, - NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)0R3, -OC(=O)NRaRb, - 0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, - SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, -P(=0)0R30Rb, C1 6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
R3-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2' and R2 are each independently halogen, CMO alkyl, C1-6 halogenated alkyl, -(CHz)1-6OH, -OR3, -C(=0)0R3,
NR3Rb, -NRbC(=0)R3,-C(0)NR3Rb, -S(O)0-3Ra, C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, CMS alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
X and Y are each independently
, - ' or a bond ;
Figure imgf000407_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R4 is H, C1-6 alkyl, or halogenated C|-6alkyl;
R5 and R5' are each independently halogen, -C(O)NRaRb> -(CH2)i-6OH, d_6 alkyl, C1-6 halogenated alkyl, C6. -u aryl, or C1-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; R6 and R6' are each independently H, C1-6 alkyl, -(CH2)i-6OH, C2-6 alkenyl, or
C2-6 alkynyl;
m and n, combined are 1 , 2, 3 or 4;
p is O, 1 , 2, 3 or 4;
q' is 0, 1 or 2;
q and r are each independently 0, 1 , 2, 3 or 4;
10 is halogen, -ORa, oxo, -NRaRb, =NO-RC -C(=O)ORa,
C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb,
NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -
OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -
S(0)o-3Ra, -SO2NRaRb, -NRbSO2Ra, -NRbS02NR3Rb, or -P(=0)0R30Rb,;
R11 is halogen, -OR3, -NR3Rb, -C(=0)0R3, -C(0)NR3Rb, -C(=O)OH, -C(=0)R3, - C(=N0Rc)R3, -C(=NRc)NR3Rb, -NRdC(=0)NR3Rb,
NRbC(=0)R3, -NRdC(=NRc)NR3Rb, -NRbC(=0)0R3, -0C(=0)NR3Rb, - 0C(=0)R3, -0C(=0)0R3, hydroxyl, nitro, azido, cyano, -S(O)0 3R3, - SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -OR3, oxo, -NR3Rb, =NO-RC , -C(=0)0R3, - C(O)NR3Rb, -C(=O)OH, -C(=0)R3, -C(=N0Rc)R3, -C(=NRc)NR3Rb, - NRdC(=0)NR3Rb, -NRbC(=0)R3, -NRdC(=NRc)NR3Rb, -NRbC(=0)0R3, - 0C(=0)NR3Rb, -0C(=0)R3, -0C(=0)0R3, hydroxyl, nitro, azido, cyano, - S(O)0-3R3, -SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
3. A compound of formula (NB):
Figure imgf000408_0001
(HB) or pharmaceutically acceptable salts thereof, wherein
each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl;
B and B' are each independently absent, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb,
C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb,
NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, - S(O)0-3R3, -SO2NRaRb, -NRbSO2Ra, -NRbS02NR3Rb, -P(=0)0R30Rb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5- 7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
R3-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2^ and R2 are each independently halogen, C1-10 alkyl, C1-6 halogenated alkyl, -(CH2)1-6OH, -OR3, -C(=O)ORa, -NR3Rb, -NRbC(=0)R3,- C(O)NR3Rb, -S(0)o-3Ra, C6-I2 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, C1-1S alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
X and Y are each independently
, or a bond;
Figure imgf000410_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R4 is H, C1-6 alkyl, or halogenated C1-6 alky;
R5 and R5' are each independently halogen, -NRaRb, -C(O)NRaRb> -(CH2)i- 6OH, C-ι-6 alkyl, C1.*, halogenated alkyl, hydroxyl, C6-14 aryl, or C1.*, alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R6 and R6' are each independently H, C1-6 alkyl, -(CH2)1-6OH, C2-6 alkenyl, or C2-6 alkynyl;
m, and n, combined are 1 , 2, 3 or 4;
p is 0, 1 , 2, 3 or 4;
q' is 0, 1 or 2;
q and r are each independently 0, 1 , 2, 3 or 4;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, - C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)0R3, - OC(=O)NRaRb, -0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, - S(O)0-3Ra, -SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, or -P(=O)ORaORb,;
R11 is halogen, -OR3, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb,
NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=0)0R3, -OC(=O)NRaRb, - 0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, - SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -0Ra, oxo, -NRaRb, =NO-RC , -C(=O)ORa, - C(O)NR3Rb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -0C(=0)R3, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, - S(OV3R3, -SO2NR3Rb, -NRbSO2R3, -NRbS02NR3Rb, or -P(=0)0R30Rb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
4. The compound according to any one of claims 1 -3, wherein each A is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or triazolyl; and wherein each A is independently substituted with (R1Jp.
5. The compound according to claim 4, wherein each A is independently cyclopropyl, cyclohexyl, phenyl, or naphthalene, wherein each A is independently substituted with (Ri)p.
6. The compound according to claim 5, wherein each A is independently selected from the group consisting of:
Figure imgf000412_0001
wherein t1 + t2 = p.
7. The compound according to claim 6, wherein A is:
Figure imgf000412_0002
The compound according to claim 4, wherein each A is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, quinolinyl, or triazolyl, each of which is substituted with
(Ri )p.
The compound according to claim 8, wherein each A is independently selected from the group consisting of:
Figure imgf000413_0001
Figure imgf000414_0001
t1 + t2 = p
10. The compound according to claim 9, wherein each A is independently selected from:
Figure imgf000414_0002
Figure imgf000415_0001
(A5a).
11. The compound according to any one of claims 1 -3, wherein each A is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (Ri)p.
12. The compound according to any one of claims 1 -11 , wherein B and B' are independently absent, C1-6 alkyl or C2-6 alkynyl.
13. The compound according to claim 12, wherein B and B' are independently absent, -(CH2)2- or -(C≡C)-.
14. The compound according to claim 13, wherein B and B' are independently absent or -(C≡C)-.
15. The compound according to any one of claims 1 -14, wherein the distance between C and C is between about 16 A to about 24 A in length.
16. The compound according to any one of claims 1 -15, wherein -
Figure imgf000415_0002
is selected from the group consisting of:
Figure imgf000415_0003
Figure imgf000416_0001
Figure imgf000417_0001
Figure imgf000418_0001
Figure imgf000418_0002
Figure imgf000419_0001
Figure imgf000419_0002
Figure imgf000419_0003
Figure imgf000420_0001
Figure imgf000420_0002
Figure imgf000420_0003
Figure imgf000421_0001
Figure imgf000421_0002
t1 + t2 = p.
17. The compound according to any one of claims 16, wherein
Figure imgf000421_0003
is selected from the group consisting of:
Figure imgf000422_0001
Figure imgf000422_0005
and
Figure imgf000422_0006
and
t1 + Xl = p.
18. The compound according to any one of claims 1 -17, wherein
Figure imgf000422_0002
is selected from the group consisting of:
and
Figure imgf000422_0004
Figure imgf000422_0003
; and t1 + t2 = p.
19. The compound according to any one of claims 1 -17, wherein
Figure imgf000423_0001
t1 + t2 = p.
20. The compound according to any one of claims 1 -17, wherein
Figure imgf000423_0002
21. The compound according to any one of claims 1 -17, wherein
Figure imgf000423_0003
t1 + t2 = p.
22. The compound according to any one of claims 1 -17, wherein
Figure imgf000424_0001
23. The compound according to any one of claims 1 -17, wherein
Figure imgf000424_0002
24. The compound according to any one of claims 1 -17, wherein
Figure imgf000424_0003
25. The compound according to any one of claims 1 -17, wherein
Figure imgf000425_0001
26. The compound according to any one of claims 1 -17, wherein
Figure imgf000425_0002
27. The compound according to any one of claims 1 to 26, wherein R1 is halogen, C^ alkyl which is unsubstituted or substituted one or more times by R10, -C(=O)ORa, -C(O)NRaRb, hydroxyl, cyano, or C1-3 alkoxy.
28. The compound according to claim 27, wherein R1 is chloro, fluoro, bromo, methyl, ethyl, propyl, butyl, -CH2OH, difluoromethyl, trifluoromethyl, hydroxyl, cyano, or methoxy.
29. The compound according to any one of claims 1 to 28, wherein each R2' are independently fluoro or methyl.
30. The compound according to any one of claims 29, wherein q is 0.
31. The compound according to any one of claims 1 to 30, wherein each R2 are independently fluoro or methyl.
32. The compound according to claim 31 , wherein r is 0.
33. The compound according any one of claims 1 -32, wherein R6 and R6' are H or methyl.
34. The compound according to any one of claims 1 -33, wherein R5 and R5' in formulas (NB), (VIII), (IX), (X) and (Xl), are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, -NRaNb, t-butoxy-, or hydroxyl; or two R5 groups together with the atoms to which they are attached form fused
cyclopropyl, spiro cyclopropyl or
Figure imgf000426_0001
, two R5' groups together with the atoms to which they are attached form fused cyclopropyl, spiro
cyclopropyl or
Figure imgf000426_0002
; and R5 and R5' in formulas (NIA), (NIA'), (IVA) and (VA), are each independently halogen, methyl, ethyl, isopropyl, di- fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, - NRaNb, or t-butoxy-; or two R5 groups together with the atoms to which
they are attached form fused cyclopropyl, spiro cyclopropyl or
Figure imgf000426_0003
, two R5' groups together with the atoms to which they are attached form
fused cyclopropyl, spiro cyclopropyl or
Figure imgf000426_0004
.
35. The compound according to claim 89, wherein R5 and R5' in formulas (NB), (VIII), (IX), (X) and (Xl) are each independently methyl, methoxy, ethyl, di- fluoromethyl, trifluoromethyl, or two R5 groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl or two R5' groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl; and R5 and R5' in formulas (NIA), (NIA'), (IVA) and (VA) are each independently methyl, ethyl, di- fluoromethyl, trifluoromethyl, or two R5 groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl or two R5' groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl.
36. The compound according to claim 89, wherein R5 and R5' are methyl.
37. The compound according to anyone of claims 1 to 36, wherein m and n are independently 1 or 2.
38. The compound according to claim 37, wherein m and n are 1.
39. The compound according to any one of claims 1 to 38, wherein X and Y are
Figure imgf000427_0001
40. The compound according to any one of claims 1 to 39, wherein R3 and R3' are each independently, C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
41. The compound according to claim 40, wherein R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
42. The compound according to claims 41 , wherein R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10.
43. The compound according to claim 42, wherein R3 and R3' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert- butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-, which are unsubstituted or substituted one or more times by R10.
44. The compound according to claim 41 , wherein R3 and R3' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
45. The compound according to claim 41 , wherein R3 and R3' are each independently benzyl which is unsubstituted or substituted one or more times by R11.
46. The compound according to any oen of claims 1 -45, wherein R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0 3R3, -SO2NRaRb, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra -Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl
47. The compound according to claim 46, wherein R10 is -NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb.
48. The compound according to claim 47, wherein R10 is -NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, or -NRbSO2Ra.
49. The compound according to any one of claim 1 to 48, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
50. The compound according to claim 49, wherein Ra and Rc are each
independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5- 6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or C1-3 alkyl.
51. The compound according to claim 50, wherein Ra-Rd are each
independently H or C1-3 alkyl.
52. The compound according to any one of claims 1 -51 , wherein the compound is of formula (IVA):
Figure imgf000429_0001
(IVA)
or pharmaceutically acceptable salts thereof, wherein
R7 and R7' are each independently C1-β alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, d_12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
m and n combined are 0, 1 , 2, 3 or 4.
53. The compound according to claim 52, wherein R8 and R8' are each
independently -NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
54. The compound according to claim 53, wherein R8 and R8' are each
independently -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, tetrahydrofuran, or benzyl.
55. The compound according to any one of claims 52 to 54, wherein R7 and R7' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
56. The compound according to any one of claims 52 to 54, wherein R7 and R7' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10.
57. The compound according to any one of claims 52 to 54, wherein R7 and R7' are each independently methyl, ethyl, propyl, isopropyl,
methoxyisopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
58. The compound according to any one of claims 52 to 54, wherein R7 and R8 or Rr and R8. together with the carbon to which they are attached are each independently:
Figure imgf000430_0001
59. The compound according to any one of claims 1 -58, wherei the compound is of formula (VA):
Figure imgf000431_0001
(VA),
or pharmaceutically acceptable salts thereof.
60. The compound of any one of Claims 1 -51 , wherein R5 and R5' are each C1-6 alkyl or C1-6 halogenated alkyl.
61. The compound of claim 60, wherein the compound is of formula (V):
Figure imgf000431_0002
(V),
or pharmaceutically acceptable salts thereof.
62. The compound according to claim 61 , wherein the compound is of formula (Vl):
Figure imgf000431_0003
(Vl), or pharmaceutically acceptable salts thereof.
63. The compound according to any one of claims 1 to 62, wherein p is 0.
64. The compound according to any one of claims 1 to 62, wherein p is 2.
65. The compound according to any one of claims 1 to 62, wherein p is 1. 66. The compound according to any one of claims 1 -65, wherein the compound is of formula (VII):
Figure imgf000432_0001
(VII)
or pharmaceutically acceptable salts thereof;
wherein
R7 and R7' are each independently C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
67. A compound of formula (VIII):
Figure imgf000433_0001
(VIM)
or pharmaceutically acceptable salts thereof, wherein
C and C are each independently a 4-7 membered heterocycle;
R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, - NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, - OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, - NRbSO2Ra, -NRbSO2NRaRb, -P(=O)ORaORb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
R2 and R2' are each independently halogen, CM0 alkyl, C1-6 halogenated alkyl, -(CH2)1-6OH, -ORa, -C(=O)ORa, -NRaRb, -NRbC(=O)Ra,- C(O)NRaRb, -S(O)0-3Ra, C6-12 aryl, or 5-12 membered heteroaryl;
Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7- 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
X and Y are each independently or a bond;
Figure imgf000434_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R3 and R3' are each independently H, C1-18 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently halogen, -NRaRb, -C(O)NRaRb> -(CH2)i-6OH, d_6 alkyl, C1-6 halogenated alkyl, hydroxyl, C6-14 aryl, or C1-6 alkoxy; wherein two occurrence of R5 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R5' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ;
R6 and R6' are each independently H, C1-6 alkyl, -(CH2)i-6OH, C2-6 alkenyl, or C2-6 alkynyl;
m, and n, are each independently 0, 1 , 2, 3 or 4;
q and r are each independently 0, 1 , 2, or 3; R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NR3Rb, or -P(=O)ORaORb,;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb,
NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(Oy3R3, - SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, or -P(=O)ORaORb, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R12 is halogen, -0Ra, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NR3Rb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
Figure imgf000435_0001
- is selected from the group consisting of:
Figure imgf000435_0002
Figure imgf000436_0001
wherein D is a 5-7 cycloalkyl which is unsubstituted or substituted by (Ri)ti, a 5-7 membered heterocycle which is unsubstituted or substituted by (R1J11 or a 5-7 membered heteroaryl which is unsubstituted or substituted by (R1^1; p is 0, 1 , 2, 3 or 4; and
t1 + t2 = p.
68. The compound according to claim 67, wherein the compound is of formula (IX):
Figure imgf000436_0002
(IX),
or pharmaceutically acceptable salts thereof.
69. The compound according to claim 67, wherein the compound is of formula (X) :
Figure imgf000437_0001
(X),
or pharmaceutically acceptable salts thereof.
70. The compound according to claim 67, wherein the compound of formula (Xl) :
Figure imgf000437_0002
(Xl)
or pharmaceutically acceptable salts thereof, wherein :
R7 and R7' are each independently C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-s alkenyl which is unsubstituted or substituted one or more times by R10, C2-s alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
71. The compound according to claim 70, wherein R8 and R8' are each independently -NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
72. The compound according to claim 71 , wherein R8 and R8' are each independently -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, tetrahydrofuran, or benzyl.
73. The compound according to any one of claims 70 or 72, wherein R7 and R7' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
74. The compound according to any one of claims 70 or 72, R7 and R7' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10.
75. The compound according to any one of claims 70 or 72, wherein R7 and R7' are each independently methyl, ethyl, propyl, isopropyl, methoxyisopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3- methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
76. The compound according to claim 70, wherein R7 and R8 or R7' and R8' together with the carbon to which they are attached are each independently:
Figure imgf000438_0001
77. The compound according to any one of claims 67 to 76, wherein
- (Ri )c- is selected from the group consisting of:
Figure imgf000439_0001
(A5a).
78 The compound according to any one of claims 67 to 77, wherein R1 is halogen, C1-4 alkyl which is unsubstituted or substituted one or more times by R10, -C(=O)ORa, -C(O)NRaRb, hydroxyl, cyano, or C1-3 alkoxy.
79. The compound according to any one of claims 67 to 77, wherein R1 is chloro, fluoro, bromo, methyl, ethyl, propyl, butyl, -CH2OH, difluoromethyl, trifluoromethyl, hydroxyl, cyano, or methoxy.
80. The compound according to any one of claims 67 to 79, wherein each R2' are fluoro or methyl.
81. The compound according to any one of claims 80, wherein q is 0.
82. The compound according to any one of claims 67 to 81 , wherein each R2 are independently fluoro or methyl.
83. The compound according to claim 82, wherein r is 0.
84. The compound according any one of claims 67 to 83, wherein R6 and R6' are H or methyl.
85. The compound according to any one of claims 67 to 84, wherein R5 and R5' are each independently halogen, methyl, ethyl, isopropyl, di- fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, - NRaNb, t-butoxy-, or hydroxyl; or two R5 groups together with the atoms to which they are attached form fused cyclopropyl, spiro cyclopropyl or
Figure imgf000440_0001
, two R5' groups together with the atoms to which they are
H attached form fused cyclopropyl, spiro cyclopropyl or H .
86. The compound according to claim 85, wherein R5 and R5' are each
independently methyl, ethyl, methoxy, di-fluoromethyl, trifluoromethyl, or two R5 groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl or two R5' groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl
87. The compound according to claim 86, wherein R5 and R5' are methyl.
88. The compound according to anyone of claims 67 to 88, wherein m and n are independently 1 or 2.
89. The compound according to claim 88, wherein m and n are 1.
90. The compound according to any one of claims 67 to 89, wherein X and Y are
O
91. The compound according to any one of claims 67 to 90, wherein R3 and R3' are each independently, C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-s alkenyl which is unsubstituted or substituted one or more times by R10, C2-s alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
92. The compound according to claim 91 , wherein R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
93. The compound according to claims 92, wherein R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10.
94. The compound according to claim 93, wherein R3 and R3' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert- butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-, which are unsubstituted or substituted one or more times by R10.
95. The compound according to claim 91 , wherein R3 and R3' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
96. The compound according to claim 91 , wherein R3 and R3' are each independently benzyl which is unsubstituted or substituted one or more times by R11.
97. The compound according to any one of claims 67 to 96, wherein R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra -Rd are each independently H, d.^ alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl
98. The compound according to claim 97, wherein R10 is -NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb.
99. The compound according to claim 98, wherein R10 is -NRaRb, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, or -NRbSO2Ra.
100. The compound according to any one of claims 67 to 99, wherein Ra-Rd are each independently H, d-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
101. The compound according to claim 100, wherein Ra and Rc are each
independently H, C1-6 alkyl, C2-6 alkenyl, C^ alkynyl, phenyl, C7-8 aralkyl, 5- 6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or d_3 alkyl.
102. The compound according to claim 101 , wherein Ra-Rd are each
independently H or C1-3 alkyl.
103. The compound according to any one of claims 67 to 102, wherein p is 0. 104. The compound according to any one of claims 67 to 102, wherein p is 2. 105. The compound according to any one of claims 67 to 102, wherein p is1. 106. A compound of formula (I):
Figure imgf000442_0001
(I)
or pharmaceutically acceptable salts thereof, wherein,
A' is C2-A alkenyl, C2-5 alkynyl, C3.i0 cycloalkyl, C6-14 aryl, 4-12 membered heterocycle or 5-12 membered heteroaryl; C and C are each independently a 4-7 membered heterocycle;
R1 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb,
C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb,
NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0- 3Ra, -SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, -P(=O)ORaORb, C1 6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7- 16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2' and R2 are each independently halogen, C1-10 alkyl, C1-6 halogenated alkyl, -(CH2)1-6OH, -ORa, -C(=O)ORa, -NRaRb, -NRbC(=O)Ra,- C(O)NRaRb, -S(O)0-3Ra, C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3' are each independently H, C1-18 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R5 and R5' are each independently H, halogen, -NRaRb, -C(O)NRaRb, -(CH2V6OH, C1.
6 alkyl, C1-6 halogenated alkyl, hydroxyl, C6-14 aryl, or C1-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein two occurrence of R4' can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 ; wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R6 and R6' are each independently H, C1-6 alkyl, -(CH2V6OH, C2-6 alkenyl, or C2-6 alkynyl;
X and Y are each independently
or a bond;
Figure imgf000444_0001
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C;
R4 is H, d_6 alkyl, or halogenated C1-6 alky;
m, and n, combined are 1 , 2, 3 or 4;
p is O, 1 , 2, 3 or 4;
q and r are each independently 0, 1 , 2, 3 or 4;
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb,;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb,
NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, - OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, - SO2NR3Rb, -NRbSO2R3, -NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, -0Ra, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-i6 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
wherein
Figure imgf000445_0001
is not,
Figure imgf000445_0004
or
Figure imgf000445_0003
optionally substituted ethyl, phenyl, oxazolyl, furanyl, pyridyl, bicycle[2,2,2]octanyl, isoquinolinyl, and naphthyl.
107. The compound according to claim 106, wherein said compound is of formula (II):
Figure imgf000445_0002
or pharmaceutically acceptable salts thereof.
108. The compound according to claim 106 or 107, wherein A' is cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxadiazolyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or triazolyl; each of which is substituted with (R1^
109. The compound according to claim 108, wherein A' thienyl, pyrimidyl, pyridazinyl, thiazolyl, N-methylimidazolyl, piperazinyl, thiadiazolyl, 1 ,4- diazepanyl or triazole.
110. The compound according to claim 109, wherein A' thienyl.
111. A compound of formula
Figure imgf000446_0001
or pharmaceutically acceptable salts thereof, wherein
two of R1 on adjacent carbons can be taken together with the carbons to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R10 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12 , wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2 and R2' are each independently H, halogen, C1-6 alkyl, or C^ alkoxy;
X and Y are each independently , or a bond;
Figure imgf000446_0002
R3 and R3' are each independently H, C1-12 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R4 is H, C1-6 alkyl, or halogenated d-6 alkyl, or can be merged with R3 or R3' to form a 3-12 membered heterocycle;
R5 and R5' are each independently H, halogen, C1-4 alkyl, hydroxyl, C1-4alkoxy, or C1-4 halogenated alkyl;
R6 and R6' are each independently H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
m, n, and p are each independently 0, 1 , 2, 3 or 4;
q and r are each independently 0, 1 , 2, or 3.
R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra-Rd are each independently H, C1-i2 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R12 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6- 18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
112. The compound according to any one of claims 106 to 111 , wherein X and Y are
Figure imgf000448_0001
113. The compound according to any one of claims 106 to 112, wherein R5 and R5' are each independently H, halogen, methyl, ethyl, t-butoxy-, or hydroxy I.
114. The compound according to claim 113, wherein R5 and R5' are fluoro.
115. The compound according to claim 113, wherein R5 and R5' are H.
116. The compound according to any one of claims 106 to 112, wherein R5 and R5' are each independently halogen, methyl, ethyl, isopropyl, di- fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, -CH2OH, - NRaNb, t-butoxy-, or hydroxyl; or two R5 groups together with the atoms to which they are attached form fused cyclopropyl, spiro cyclopropyl or
Figure imgf000448_0002
and /or two R5' groups with the atoms to which they are attached
form fused cyclopropyl, spiro cyclopropyl or
Figure imgf000448_0003
.
117. The compound according to claim 116, wherein R5 and R5' are each independently methyl, ethyl, methoxy, difluromethyl, trifluoromethyl, or two R5 groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl and/or two R5' groups together with the atoms to which they are attached form fused cyclopropyl or spiro cyclopropyl.
118. The compound according to claim 90, wherein R5 and R5' are methyl.
119. The compound according to any one of claims 106 to 118, wherein m and n are each independently 0, 1 , or 2.
120. The compound according to claim 119, wherein m and n are 2.
121. The compound according to claim 119, wherein m and n are 1.
122. The compound according to any one of claims 106 to 121 , wherein R6 are R6' are H.
123. The compound according to any one of claims 106 to 121 , wherein R6 are R6' are H or methyl.
124. The compound according to any one of claims 106 to 123, wherein R1 is halogen, C1-3 alkyl, hydroxyl, cyano, benzyloxy, or C1-3 alkoxy.
125. The compound according to claim 124, wherein R1 is chloro, fluoro, methyl, hydroxyl, benzyloxy, cyano, or methoxy.
126. The compound according to any one of claims 106 to 123, p is 0.
127. The compound according to any one of claims 106 to 123, p is 2.
128. The compound according to any one of claims 106 to 123, p is 1.
129. The compound according to any one of claims 106 to 128, wherein R2 and R2' are fluoro.
130. The compound according to any one of claims 106 to 128, wherein R2 and R2' are H.
131. The compound according to any one of claims 106 to 130, wherein q and r are 1.
132. The compound according to any one of claims 106 to 131 , wherein R3 and R3' are each independently, C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
133. The compound according to claim 132, wherein R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 6-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.
134. The compound according to claims 132, wherein R3 and R3' are each independently, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10.
135. The compound according to claim 132, wherein R3 and R3' are each independently phenyl which is unsubstituted or substituted one or more times by R11.
136. The compound according to claim 132, wherein R3 and R3' are each independently benzyl which is unsubstituted or substituted one or more times by R11.
137. The compound according to any one of claims 106 to 131 , wherein R3 and R3' are each independently, C1-12 alkyl which is unsubstituted or substituted one or more times by R10.
138. The compound according to claim 137, wherein R3 and R3' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert- butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclohexyl(CH2)-, which are unsubstituted or substituted one or more times by R10.
139. A compound according to claim 111 , wherein wherein said compound is of formula (IV):
Figure imgf000451_0001
(IV)
or pharmaceutically acceptable salts thereof; wherein
R7 and R7' are each independently C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, d-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
140. The compound according to claim 139, wherein
R7 and R7' are each independently C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-7 membered heteroaralkyl, 3-6 membered heterocycle, or 4-7 membered heterocycle-alkyl; and
R8 and R8' are each independently -NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -NRbSO2Ra, -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3- 12 membered heterocycle, or 4-18 membered heterocycle-alkyl.
141. The compound according to claim 139 or 140, wherein R8 and R8' are each independently -NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
142. The compound according to claim 141 , wherein R8 and R8' are each independently -NRbC(=O)ORa, wherein Ra-Rb are each independently H, C1-6 alkyl, phenyl, tetrahydrofuran, or benzyl.
143. The compound according to any one of claims 139 to 142, wherein R7 and R7' are each independently phenyl.
144. The compound according to any one of claims 139 to 142, wherein R7 and R7' are each independently, C1-6 alkyl.
145. The compound according to any one of claims 139 to 142, wherein R7 and R7' are each independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, 2-methylbutane, 3-methylbutane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
146. The compound according to claim 139 or 140, R7 and R8 or R7' and R8' together with the carbon to which they are attached are each independently:
Figure imgf000452_0001
147. The compound according to any one of claims 1 to 146, wherein R10 is halogen, -ORa, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, wherein Ra and Rc are each independtly H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-n aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl.
148. The compound according to any one of claims 1 to 146, wherein R10 is - NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, - NRbSO2Ra, or -NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6- 8 membered heterocycle-alkyl.
149. The compound according to any one of claims 1 to 146, wherein R10 is - NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, or -NRbSO2Ra, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl.
150. The compound according to any one of claims 1 to 146, wherein R10 is halogen, -ORa, oxo, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, cyano, wherein Ra-Rb are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl
151. The compound according to any one of claims 1 to 150, wherein R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3Ra, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra and Rc are each independtly H, C1-12 alkyl, C2. 12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl.
152. The compound according to any one of claims 1 to 150, wherein R11 is halogen, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, - OC(=O)ORa, hydroxyl, cyano, -SO2NRaRb, -NRbSO2Ra, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
153. The compound according to claim 152, wherein R11 is halogen, -ORa, - NRaRb, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRbC(=O)ORa, -OC(=O)NRaRb, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
154. The compound according to claim 153, wherein R11 is halogen, -0Ra, - NRaRb, hydroxyl, cyano, C1-6 alkyl, wherein Ra-Rb are each independently H, C1-3 alkyl.
155. The compound according to any one of claims 1 to 154, wherein R12 is halogen, -0Ra, oxo, -NRaRb, =NO-RC , -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, - C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, - NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hydroxyl, nitro, azido, cyano, -S(O)0-3R3, -SO2NRaRb, -NRbSO2Ra, - NRbSO2NRaRb, or -P(=O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, wherein Ra and Rc are each independtly H, C1-12 alkyl, C2. 12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or methyl.
156. The compound according to any one of claims 1 to 154, wherein R12 is halogen, -ORa, oxo, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, - NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, - OC(=O)ORa, hydroxyl, cyano, -SO2NRaRb, -NRbSO2Ra, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle- alkyl, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
157. The compound according to claim 156, wherein R12 is halogen, -ORa, oxo, -NRaRb, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -NRdC(=O)NRaRb, - NRbC(=O)Ra, -NRbC(=O)ORa, -OC(=O)NRaRb, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, wherein Ra,Rb, and Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6- 8 membered heterocycle-alkyl.
158. The compound according to claim 159, wherein R12 is halogen, -0Ra, oxo, - NRaRb, hydroxyl, cyano, C1-6 alkyl, wherein Ra-Rb are each independently H, C1-3 alkyl.
159. The compound according to any one of claims 1 to 158, wherein Ra-Rd are each independently H, C1 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.
160. The compound according to claim 159, wherein Ra and Rc are each
independently H, C1 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5- 6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl, and Rb, and Rd.are each independently H or C1-3 alkyl.
161. The compound according to claim 160, wherein Ra-Rd are each
independently H or C1-3 alkyl.
162. The compound according to any one of claims 1 to 161 , for treating or preventing a Hepatitis C viral infection in a human.
163. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 161 and at least one pharmaceutically acceptable carrier or excipient.
164. A pharmaceutical combination comprising at least one compound according to any one of claims 1 to 161 and at least one additional agent and at least one pharmaceutically acceptable carrier or excipient.
165. The pharmaceutical combination according to claim 164, wherein said at least one additional agent is selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomudulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).
166. The pharmaceutical combination according to claim 164, wherein said at least one additional agent is selected from ribavirin and interferon-α.
167. The pharmaceutical combination according to any one of claims 164 to 166, wherein said compound and said additional agent are in dosage unit forms suitable for sequential administration.
168. The pharmaceutical combination according to any one of claims 164 to 166, wherein said compound and said additional agent are in dosage unit forms suitable for simultaneous administration.
PCT/US2010/042340 2009-07-16 2010-07-16 Benzimidazole analogues for the treatment or prevention of flavivirus infections WO2011009084A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2767887A CA2767887A1 (en) 2009-07-16 2010-07-16 Benzimidazole analogues for the treatment or prevention of flavivirus infections
JP2012520823A JP2012533569A (en) 2009-07-16 2010-07-16 Benzimidazole analogues for treating or preventing flavivirus infections
CN2010800415480A CN102656160A (en) 2009-07-16 2010-07-16 Benzimidazole analogues for the treatment or prevention of flavivirus infections
EP10734877A EP2454254A2 (en) 2009-07-16 2010-07-16 Benzimidazole analogues for the treatment or prevention of flavivirus infections
MX2012000695A MX2012000695A (en) 2009-07-16 2010-07-16 Benzimidazole analogues for the treatment or prevention of flavivirus infections.
AU2010274001A AU2010274001A1 (en) 2009-07-16 2010-07-16 Benzimidazole analogues for the treatment or prevention of Flavivirus infections
IN999DEN2012 IN2012DN00999A (en) 2009-07-16 2010-07-16
IL217503A IL217503A0 (en) 2009-07-16 2012-01-12 Benzimidazole analogues for the treatment or prevention of flavivirus infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22615209P 2009-07-16 2009-07-16
US61/226,152 2009-07-16
US31701710P 2010-03-24 2010-03-24
US61/317,017 2010-03-24

Publications (2)

Publication Number Publication Date
WO2011009084A2 true WO2011009084A2 (en) 2011-01-20
WO2011009084A3 WO2011009084A3 (en) 2011-04-28

Family

ID=43385139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/042340 WO2011009084A2 (en) 2009-07-16 2010-07-16 Benzimidazole analogues for the treatment or prevention of flavivirus infections

Country Status (10)

Country Link
US (3) US8354419B2 (en)
EP (1) EP2454254A2 (en)
JP (1) JP2012533569A (en)
CN (1) CN102656160A (en)
AU (1) AU2010274001A1 (en)
CA (1) CA2767887A1 (en)
IL (1) IL217503A0 (en)
IN (1) IN2012DN00999A (en)
MX (1) MX2012000695A (en)
WO (1) WO2011009084A2 (en)

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088368B2 (en) 2009-05-13 2012-01-03 Gilead Sciences, Inc. Antiviral compounds
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143301B2 (en) 2009-04-09 2012-03-27 Bristol Myers Squibb Company Hepatitis C virus inhibitors
EP2435421A1 (en) * 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120172368A1 (en) * 2009-09-03 2012-07-05 Koen Vandyck Bis-Benzimidazole Derivatives
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2012154777A1 (en) * 2011-05-12 2012-11-15 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8344155B2 (en) 2009-09-04 2013-01-01 Glaxosmith Kline Llc Chemical compounds
EP2542074A1 (en) * 2010-03-04 2013-01-09 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of hcv replication
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012162578A3 (en) * 2011-05-26 2013-03-21 Abbvie Inc. Anti-viral compounds
WO2012162580A3 (en) * 2011-05-26 2013-03-28 Abbvie Inc Anti-viral compounds
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2651920A2 (en) * 2010-12-15 2013-10-23 Abbvie Inc. Anti-viral compounds
US8618153B2 (en) 2009-11-12 2013-12-31 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8785487B2 (en) 2010-01-25 2014-07-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2014520822A (en) * 2011-07-09 2014-08-25 スンシネ ルアケ プハルマ カンパニー リミテッド Spiro compounds as hepatitis C virus inhibitors
JP2014527978A (en) * 2011-09-26 2014-10-23 カトリック ユニヴェルシテット ルーヴェン Viral replication inhibitor
US8927739B2 (en) 2011-05-18 2015-01-06 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9006455B2 (en) 2009-11-11 2015-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9126986B2 (en) 2011-12-28 2015-09-08 Janssen Sciences Ireland Uc Hetero-bicyclic derivatives as HCV inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9187496B2 (en) 2009-12-18 2015-11-17 Idenix Pharmaceuticals Llc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9770439B2 (en) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US9776981B2 (en) 2009-11-11 2017-10-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10039779B2 (en) 2013-01-31 2018-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10086011B2 (en) 2013-08-27 2018-10-02 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10233156B2 (en) 2015-03-30 2019-03-19 Shionogi & Co., Ltd. 9-membered fused ring derivative
EP2712655B1 (en) * 2011-04-28 2019-12-18 The Broad Institute, Inc. Inhibitors of histone deacetylase
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10793538B2 (en) 2012-12-20 2020-10-06 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
US11377423B2 (en) 2012-07-27 2022-07-05 The Broad Institute, Inc. Inhibitors of histone deacetylase
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP4129402A4 (en) * 2020-03-31 2024-06-12 Mitsubishi Tanabe Pharma Corporation Hydroxypyrrolidine derivative and medicinal application thereof
US12037340B2 (en) 2022-05-19 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012533569A (en) * 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド Benzimidazole analogues for treating or preventing flavivirus infections
MX2012010918A (en) 2010-03-24 2013-01-18 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections.
WO2011119858A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
MX2013006828A (en) * 2010-12-16 2014-10-14 Abbvie Inc Anti-viral compounds.
TWI610916B (en) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceuticals applications thereof
CN103848821B (en) 2012-11-29 2016-10-12 广东东阳光药业有限公司 Spiro-compound, pharmaceutical composition and their purposes as hepatitis c inhibitor
WO2014082380A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
US9738629B2 (en) 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
WO2020132278A1 (en) 2018-12-19 2020-06-25 Florida State University Research Foundation, Inc. Anti-flavivirus compounds and methods of use

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
ES2431314T3 (en) * 2004-02-20 2013-11-26 Boehringer Ingelheim International Gmbh Viral Polymerase Inhibitors
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
ES2383388T3 (en) 2008-02-12 2012-06-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ587557A (en) 2008-02-13 2012-04-27 Bristol Myers Squibb Co Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5100595B2 (en) 2008-09-30 2012-12-19 シャープ株式会社 AV equipment, server, AV equipment operating system, and AV equipment operating program
JP5268532B2 (en) 2008-09-30 2013-08-21 株式会社日立ハイテクノロジーズ Sample measuring method and measuring apparatus
JP5225240B2 (en) 2008-10-01 2013-07-03 住友ゴム工業株式会社 Rubber composition for tire and tire
CN104163816A (en) 2008-12-03 2014-11-26 普雷西迪奥制药公司 Inhibitors of HCV NS5A
CA2750577A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
TWI438200B (en) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Hepatitis c virus inhibitors
CA2753313A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
MY160130A (en) 2009-02-27 2017-02-28 Enanta Pharm Inc Hepatitis c virus inhibitors
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
ME02418B (en) 2009-03-27 2016-09-20 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
CA2756255A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
TWI476190B (en) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Hepatitis c virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (en) 2009-04-15 2015-02-20 Эббви Инк. Antiviral compounds
BRPI1016172A2 (en) 2009-04-24 2016-04-19 Tibotec Pharm Ltd diaryl ethers
CA2760205A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
AP3622A (en) 2009-05-13 2016-03-02 Gilead Sciences Inc Antiviral compounds
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
SG171708A1 (en) 2009-06-11 2011-07-28 Abbott Lab Anti-viral compounds to treat hcv infection
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
JP2012533569A (en) * 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド Benzimidazole analogues for treating or preventing flavivirus infections
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc Chemical compounds
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2554087C2 (en) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-condensed arylene or heteroarylene hepatitis c virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
CA2787309A1 (en) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
KR20120124495A (en) 2010-03-04 2012-11-13 이난타 파마슈티칼스, 인코포레이티드 Combination pharmaceutical agents as inhibitors of hcv replication
BR112012022125A2 (en) 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp compound, dihydrochloride salt, pharmaceutical composition, use of the compound, and method for treating a patient
WO2011119858A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011150243A1 (en) 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011153396A1 (en) 2010-06-04 2011-12-08 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
WO2011156543A2 (en) 2010-06-09 2011-12-15 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
BR112013002729A2 (en) 2010-08-04 2016-05-31 Bristol Myers Squibb Co hepatitis c virus inhibitors
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2012021704A1 (en) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
CN103249730A (en) 2010-09-24 2013-08-14 百时美施贵宝公司 Hepatitis c virus inhibitors
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
CA2811662A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives for treating hepatitis c virus infection
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
EP2621932A4 (en) 2010-09-29 2014-03-26 Merck Sharp & Dohme Tetracyclic heterocycle compounds for treating hepatitis c viral infection
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
MX2013004655A (en) 2010-10-26 2013-08-27 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus.
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
AP2013007263A0 (en) 2011-05-27 2013-11-30 Achillion Pharmaceuticals Inc Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenesuseful for treating HCV infections

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US9163017B2 (en) 2008-12-23 2015-10-20 Abbvie Inc. Anti-viral compounds
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US9249138B2 (en) 2008-12-23 2016-02-02 Abbvie Inc. Anti-viral compounds
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143301B2 (en) 2009-04-09 2012-03-27 Bristol Myers Squibb Company Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US9981955B2 (en) 2009-05-13 2018-05-29 Gilead Pharmasset Llc Antiviral compounds
US8669234B2 (en) 2009-05-13 2014-03-11 Gilead Sciences, Inc. Antiviral compounds
US8088368B2 (en) 2009-05-13 2012-01-03 Gilead Sciences, Inc. Antiviral compounds
US8273341B2 (en) 2009-05-13 2012-09-25 Gilead Sciences, Inc. Antiviral compounds
US8841278B2 (en) 2009-05-13 2014-09-23 Gilead Pharmasset Llc Antiviral compounds
US8822430B2 (en) 2009-05-13 2014-09-02 Gilead Pharmasset Llc Antiviral compounds
US9511056B2 (en) 2009-05-13 2016-12-06 Gilead Pharmasset Llc Antiviral compounds
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2435421A1 (en) * 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8921514B2 (en) 2009-06-11 2014-12-30 Abbvie Inc. Anti-viral compounds
US10028937B2 (en) 2009-06-11 2018-07-24 Abbvie Inc. Anti-viral compounds
US10039754B2 (en) 2009-06-11 2018-08-07 Abbvie Inc. Anti-viral compounds
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US9586978B2 (en) 2009-06-11 2017-03-07 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120172368A1 (en) * 2009-09-03 2012-07-05 Koen Vandyck Bis-Benzimidazole Derivatives
US9814699B2 (en) 2009-09-04 2017-11-14 Janssen Pharmaceuticals, Inc. Chemical compounds
US8853416B2 (en) 2009-09-04 2014-10-07 Janssen Pharmaceuticals, Inc. Chemical compounds
US9150587B2 (en) 2009-09-04 2015-10-06 Janssen Pharmaceuticals, Inc. Chemical compounds
US8492554B2 (en) 2009-09-04 2013-07-23 Glaxosmithkline Llc Chemical compounds
US8344155B2 (en) 2009-09-04 2013-01-01 Glaxosmith Kline Llc Chemical compounds
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9776981B2 (en) 2009-11-11 2017-10-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9006455B2 (en) 2009-11-11 2015-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8618153B2 (en) 2009-11-12 2013-12-31 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2513113B1 (en) * 2009-12-18 2018-08-01 Idenix Pharmaceuticals LLC 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US9187496B2 (en) 2009-12-18 2015-11-17 Idenix Pharmaceuticals Llc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US8735398B2 (en) 2009-12-30 2014-05-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8785487B2 (en) 2010-01-25 2014-07-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
EP2542074A1 (en) * 2010-03-04 2013-01-09 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of hcv replication
EP2542074A4 (en) * 2010-03-04 2014-05-14 Enanta Pharm Inc Combination pharmaceutical agents as inhibitors of hcv replication
US9060971B2 (en) 2010-03-04 2015-06-23 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of HCV replication
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2651920A4 (en) * 2010-12-15 2014-12-17 Abbvie Inc Anti-viral compounds
EP2651920A2 (en) * 2010-12-15 2013-10-23 Abbvie Inc. Anti-viral compounds
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2012087976A3 (en) * 2010-12-21 2012-11-29 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9340520B2 (en) 2011-02-07 2016-05-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2712655B1 (en) * 2011-04-28 2019-12-18 The Broad Institute, Inc. Inhibitors of histone deacetylase
US10662199B2 (en) 2011-04-28 2020-05-26 The Broad Institute, Inc. Inhibitors of histone deacetylase
US11572368B2 (en) 2011-04-28 2023-02-07 The General Hospital Corporation Inhibitors of histone deacetylase
JP2014513690A (en) * 2011-05-12 2014-06-05 ブリストル−マイヤーズ スクイブ カンパニー Hepatitis C virus inhibitor
WO2012154777A1 (en) * 2011-05-12 2012-11-15 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EA024201B1 (en) * 2011-05-12 2016-08-31 Бристол-Майерс Сквибб Компани Hepatitis c virus inhibitors
CN103827108A (en) * 2011-05-12 2014-05-28 百时美施贵宝公司 Hepatitis c virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8927739B2 (en) 2011-05-18 2015-01-06 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
WO2012162578A3 (en) * 2011-05-26 2013-03-21 Abbvie Inc. Anti-viral compounds
EP2714693A4 (en) * 2011-05-26 2014-12-10 Abbvie Inc Anti-viral compounds
WO2012162580A3 (en) * 2011-05-26 2013-03-28 Abbvie Inc Anti-viral compounds
EP2714693A2 (en) * 2011-05-26 2014-04-09 Abbvie Inc. Anti-viral compounds
JP2014520822A (en) * 2011-07-09 2014-08-25 スンシネ ルアケ プハルマ カンパニー リミテッド Spiro compounds as hepatitis C virus inhibitors
US10456414B2 (en) 2011-09-16 2019-10-29 Gilead Pharmasset Llc Methods for treating HCV
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
JP2014527978A (en) * 2011-09-26 2014-10-23 カトリック ユニヴェルシテット ルーヴェン Viral replication inhibitor
US9126986B2 (en) 2011-12-28 2015-09-08 Janssen Sciences Ireland Uc Hetero-bicyclic derivatives as HCV inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11377423B2 (en) 2012-07-27 2022-07-05 The Broad Institute, Inc. Inhibitors of histone deacetylase
US10793538B2 (en) 2012-12-20 2020-10-06 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
US10039779B2 (en) 2013-01-31 2018-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9770439B2 (en) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US11116783B2 (en) 2013-08-27 2021-09-14 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10086011B2 (en) 2013-08-27 2018-10-02 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11707479B2 (en) 2013-08-27 2023-07-25 Gilead Sciences, Inc. Combination formulation of two antiviral compounds
US9744170B2 (en) 2014-01-03 2017-08-29 Abbvie Inc. Solid antiviral dosage forms
US10105365B2 (en) 2014-01-03 2018-10-23 Abbvie Inc. Solid antiviral dosage forms
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
RU2702637C2 (en) * 2015-03-30 2019-10-09 Сионоги Энд Ко., Лтд. Benzimidazole or imidazopyridine derivatives useful for treating or preventing diseases associated with acc2
US10233156B2 (en) 2015-03-30 2019-03-19 Shionogi & Co., Ltd. 9-membered fused ring derivative
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP4129402A4 (en) * 2020-03-31 2024-06-12 Mitsubishi Tanabe Pharma Corporation Hydroxypyrrolidine derivative and medicinal application thereof
US12037340B2 (en) 2022-05-19 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors

Also Published As

Publication number Publication date
WO2011009084A3 (en) 2011-04-28
AU2010274001A1 (en) 2012-02-23
EP2454254A2 (en) 2012-05-23
US20110172238A1 (en) 2011-07-14
IN2012DN00999A (en) 2015-04-10
US20130157997A1 (en) 2013-06-20
US8765731B2 (en) 2014-07-01
IL217503A0 (en) 2012-03-01
US20140243257A1 (en) 2014-08-28
US8354419B2 (en) 2013-01-15
CN102656160A (en) 2012-09-05
MX2012000695A (en) 2012-06-12
CA2767887A1 (en) 2011-01-20
JP2012533569A (en) 2012-12-27

Similar Documents

Publication Publication Date Title
US8354419B2 (en) Benzimidazole analogues for the treatment or prevention of flavivirus infections
US8779156B2 (en) Analogues for the treatment or prevention of flavivirus infections
US20130072523A1 (en) Analogues for the treatment or prevention of flavivirus infections
US20130090364A1 (en) Analogues for the treatment or prevention of flavivirus infections
US20130085150A1 (en) Analogues for the treatment or prevention of flavivirus infections
US20130102629A1 (en) Analogues for the treatment or prevention of flavivirus infections
JP5612612B2 (en) Hepatitis C virus inhibitor
ES2646131T3 (en) Antiviral compounds
MX2013006951A (en) Anti-viral compounds.
WO2013095275A1 (en) Novel hepatitis c virus inhibitors
ES2560842T3 (en) An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative
TW201238961A (en) Analogues for the treatment or prevention of flavivirus infections

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080041548.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10734877

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2767887

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 217503

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/000695

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012520823

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010274001

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 999/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010734877

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010274001

Country of ref document: AU

Date of ref document: 20100716

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10734877

Country of ref document: EP

Kind code of ref document: A2